"REDUCTION OF PTERIDINES"

a Thesis

submitted for the

Degree of Doctor of Philosophy

in the

Australian National University

by

Sadao Matsuura

Department of Medical Chemistry
John Curtin School of Medical Research
Institute of Advanced Studies
Australian National University.

January, 1961.

The work described in this Thesis was carried out by the candidate at the Australian National University. In the few instances where the work of others has been used, proper acknowledgment is made.

S. Matsuura

ACKNOWLEDGMENTS.

Numbering of the Pteridine Ring.

The numbering of the pteridine ring in this thesis
accords with the international rules of nomenclature.

(I)

Recent studies, using physical methods, indicate that
hydroxypteridines exist (in the cases studied) in the lactam
form, for example (II).

(II)   (III)

However, for ease in reference, in this thesis
hydroxypteridines are named, in accordance with tradition,
i.e. as if they have the lactim form (III). Thus (III) is
named 2,4,7-trihydroxypteridine, and not 1,2,3,4,7,8-
hexahydro-2,4,7-trioxopteridine.

Summary

Reduction: The fifteen possible hydroxy- and polyhydroxy-
pteridines were reduced, chemically and catalytically.
Potassium borohydride, sodium dithionite, and potassium (or
sodium) amalgam were used as the chemical reducing agents.
Hydrogenation over palladium, platinum, and Raney-nickel were
used for catalytic reductions.   Except 2,4,7-trihydroxy-
pteridine all these were successfully reduced by at least one
of the above methods.   Hydroxypteridines lacking a hydroxy
group in the pyrazine ring gave tetrahydropteridines and, in
some cases, a dihydro-compound as well.   Thus 2-hydroxy-
pteridine gave 5,6,7,8-tetrahydro-2-hydroxypteridine and also
3,4-dihydro-2-hydroxypteridine.   The latter is the first
example of the reduction of a pteridine in the pyrimidine
ring.

On the other hand, hydroxypteridines having a hydroxy
group in the pyrazine ring gave only dihydro-compounds on
reduction.   Thus 6-hydroxypteridines gave 7,8-dihydro-6-
hydroxypteridines, and 7-hydroxypteridines gave their 5,6-
dihydro-derivatives.

Synthesis: The structures of the products, often indicated
by ionization constants and ultraviolet spectra, were
confirmed by synthesis in most cases.

A synthetic route to the hitherto inaccessible 5,6-
dihydropteridines was discovered.   This involved reduction

of the Schiff's base of a 4,5-diaminopyrimidine. In addition a method was devised for preparing 5,6,7,8-tetrahydro--4-hydroxypteridine which could not be synthesized by Lister and Ramage's method (cyclization of a 5-amino-4-(benzyl-β-hydroxyethylamino)-pyrimidine). It is a well-known defect of this method that it cannot be used to make tetrahydro-hydroxypteridines. For, if a hydroxy-group is present in the pyrimidine ring before the cyclization, an alternative reaction occurs and gives a glyoxalinopyrimidine in place of the desired tetrahydropteridine. The alternative reaction succeeds because of the tautomeric possibilities of the hydroxy-group. Hence the problem was solved by introducing an ethoxy group at the pyrimidine stage. The ethoxy-group, under the conditions of cyclization, was hydrolysed to a hydroxy-group and gave the desired tetrahydro-hydroxypteridine.

Some 7,8-dihydropteridines were required lacking a substituent in the 6-position. But no method for producing such substances has been recorded. However it seemed that 7,8-dihydropteridines, lacking a substituent in the 6-position, could be prepared by condensing aminoacetal and a 4-chloro-5-nitropyrimidine. In practice, a difficulty arose in the last step (cyclization), but this was solved by hydrolysis of the acetal group before the reduction of the

nitro-group.   7,8-Dihydro-2-hydroxypteridine was prepared in this way.

In all thirty six new compounds were prepared and are listed at the end of this summary.

Ionization constants: Ionization constants were measured in order to record precise spectra of single ionic species. Sometimes these constants gave useful clues to structure, e.g. the significant rise of basic strength in 7,8-dihydro-pteridines compared to the parent pteridines. This rise is undoubtedly caused by extra resonance in the cation exactly as in simple nitrogen heterocyclic compounds having an amino-group in the γ-position (e.g. 4-aminopyridine).

Spectra: Close similarity of the ultraviolet spectra of 5,6,7,8-tetrahydropteridines and of the corresponding 4,5-diaminopyrimidines furnished a convenient confirmation of the structure of tetrahydro-2-hydroxypteridine. A similar relationship confirmed the structure of the alkaline hydrolysis product of dihydro-7-hydroxypteridine, as 4-amino-5-carboxymethylaminopyrimidine. The similarity in ultraviolet spectra of x,y-dihydro-2-hydroxypteridine and of 2-hydroxypteridine (known to be covalently hydrated across the 3,4-bond) confirmed the structure of the former as 3,4-dihydro-2-hydroxypteridine.

New Substances (All analysed)

Pteridine

2-Hydroxy-6-methylpteridine

Dihydropteridines

7,8-Dihydro-4,6-dimethylpteridine
3,4-Dihydro-2-hydroxypteridine
7,8-Dihydro-2-hydroxypteridine
3,4-Dihydro-2-hydroxy-6-methylpteridine
7,8-Dihydro-2-hydroxy-6-methylpteridine
x,y-Dihydro-4-hydroxypteridine
5,6-Dihydro-4-hydroxypteridine
x,y-Dihydro-2,7-dihydroxypteridine
5,6-Dihydro-4,7-dihydroxypteridine

Tetrahydropteridines

8-Benzyl-4-chloro-5,6,7,8-tetrahydropteridine
8-Benzyl-5,6,7,8-tetrahydro-4-hydroxypteridine
5,6,7,8-Tetrahydro-2-hydroxypteridine
5,6,7,8-Tetrahydro-4-hydroxypteridine
5,6,7,8-Tetrahydro-2,4-dihydroxypteridine
Formyltetrahydro-2,4-dihydroxypteridine

Sulphur Containing Products

Sodium tetrahydro-2,4-dihydroxypteridine sulphonate
Sodium tetrahydro-2,7-dihydropteridine sulphonate
Sodium dihydro-2,7-dihydroxypteridine sulphonate
Sodium dihydro-2-hydroxypteridine sulphonate

Pyrimidines

4-Acetonylamino-2-hydroxy-5-nitropyrimidine

4-Acetonylamino-6-hydroxy-5-nitropyrimidine

5-Amino-4-(benzyl-β-hydroxyethylamino)-6-benzyloxypyrimidine hydrochloride

5-Amino-4-(benzyl-β-hydroxyethylamino)-6-chloropyrimidine hydrochloride

5-Amino-4-(benzyl-β-hydroxyethylamino)-6-hydroxypyrimidine

4-Amino-5-cyanomethylaminopyrimidine

4-Amino-5-ethoxycarbonylmethylamino-6-hydroxypyrimidine

4-Amino-5-β-diethoxyethylamino-2-hydroxypyrimidine

4-Amino-5-β-diethoxyethylamino-6-hydroxypyrimidine

5-Amino-4-β-diethoxyethylamino-2-hydroxypyrimidine

5-Bromo-4-phthaloylglycylaminopyrimidine

4-β-Diethoxyethylamino-2-hydroxy-5-nitropyrimidine

4-β-Diethoxyethylamino-6-hydroxy-5-nitropyrimidine

2,4-Bis-β-diethoxyethylamino-5-nitropyrimidine

4-Formylmethylamino-2-hydroxy-5-nitropyrimidine

Pyrazine

2-Amino-3-hydroxymethylpyrazine.

CONTENTS

SECTION 1.

INTRODUCTION.

a. Opening Remarks.

Many pteridine derivatives such as xanthopterin, leucopterin, isoxanthopterin, erythropterin, chrysopterin, ichthyopterin, biopterin, drosopterin and the folic acid group have been found in nature and their structures have been investigated. In the course of those studies it was found that some of these derivatives have relatively low oxidation reduction potentials and a number of reversible reductions were demonstrated. Some of the reductions are now known to be of great importance for the reproduction of living cells.

The biologically active substance "folic acid" was isolated from liver and yeast (Pfiffner et al., 1943, 1947; Stokstad 1943; Stokstad, Hutchings and Subba Row, 1948) and its structure was shown to be that of a pteridine derivative (la-I) (Angier et al., 1945, 1946).

COOH
|
CH-NH-CO ─ [benzene ring] ─ NH-CH$_2$ [pteridine ring system with OH, N atoms, NH$_2$]
|
CH$_2$
|
CH$_2$
|
COOH

(1a-I)

The biological function of folic acid was then investigated,
and it was eventually found that it acted as a coenzyme after
reduction to 5,6,7,8-tetrahydrofolic acid. In some enzyme
systems this functioned in loose combination with formaldehyde
giving the so-called "active formaldehyde". In other
enzymes it is combined with formic acid ("active formate").
These pteridine coenzymes bring about the transfer of single
carbon atom fragments in the biosynthesis of purines,
pyrimidines and some amino acids. Careful work has
established the metabolic route from folic acid to the
5,6,7,8-tetrahydrofolic acid via a dihydro derivative.
The same dihydrofolic acid was also prepared by chemical
reduction (O'Dell, Vandenbelt, Bloom and Pfiffner, 1947;
Futtermann, 1957) and it is now considered to be the
7,8-dihydro derivative from somewhat indirect chemical
analogies (O'Dell et al., 1947) and by enzymic evidence

based on lack of a new centre of asymmetry (Osborn and
Huennekens, 1958).

Simpler pteridines have been little invesitgated
from the viewpoint of reduction. By studying the reduction
of hydroxypteridines, the present work seeks partly to remedy
this state of affairs.

b. Historical Outline.

The earliest work on the reduction of the pteridine
ring arose during structural investigations of the natural
pigments; xanthopterin (1b-I), isoxanthopterin (1b-II), and
leucopterin (1b-III), folic acid (1a-I), and other naturally
occuring pteridines.

(1b-I)

(1b-II)

(1b-III)

Although the structure of xanthopterin was not known until 1940, it was found to be reduced with zinc dust in acidic or in alkaline solution in 1927 (Wieland and Schöpf, 1925). Fuming hydriodic acid (Wieland, Tartter and Purrmann, 1940), hydrogen sulphide, sodium dithionite and sodium sulphite (Koschara, 1936, 1937) were all found to reduce xanthopterin to a leuco-compound, which was reoxidized to the starting material by shaking in the air. Xanthopterin was also reduced catalytically, and it was reported that three moles of hydrogen were taken up if the formula was $C_{10}H_{18}N_{16}O_6$ and two moles if the formula was $C_{13}H_{11}N_{11}O_4$ (Koschara, 1937). (The uncertainty arose from difficulties in micro-combustion, and the formula was proved later to be $C_6H_5N_5O_2$). Isoxanthopterin (1b-II) was reduced with hydriodic acid (Wieland, Tartter and Purrmann, 1940), but reduction was assumed only on the evidence of liberated iodine and no reduced product was isolated. Leucopterin could not be reduced by these reagents. During 1940-1, the structures of xanthopterin (Purrmann, 1940a), isoxanthopterin (Purrmann, 1941), and leucopterin (Purrmann, 1940b) were finally established. In 1944, leucopterin was reduced with sodium amalgam to a dihydroxanthopterin which was identical with the

product obtained by the reduction of xanthopterin with zinc, fuming hydreiodic acid etc., (Totter, 1944).

About 1943, a biologically active substance, "folic acid", was isolated, and research was concentrated on the determination of its structure. In 1947, O'Dell et al., hydrogenated folic acid in acidic and in alkaline solution over palladium or Adams' catalyst. They found that folic acid absorbed two atoms of hydrogen in alkaline solution using a palladium catalyst, but four atoms of hydrogen in acidic solution over Adams' catalyst. The reduction of folic acid has since been carried out with sodium dithionite, and dihydrofolic acid was obtained (Futtermann, 1957; Blakley, 1960).

Some other hydrogenated pteridines were made by reduction, and some synthetic work was attempted (as in Pesson's synthesis, described below). However, it was not until 1950 that any method was discovered which gave hydropteridines in which the positions of the hydrogen atoms were known beyond doubt. Pesson (1948) condensed 4,5-diamino-2-ethylthio-6-hydroxypyrimidine (1b-IV) with benzoin and obtained two isomeric dihydro compounds (X and Y), which were oxidized to the same pteridine (1b-V).

OH   OH

H_2N N   Ph   N   N

H_2N N   SEt   Ph   N   N   SEt

$\xrightarrow{\text{Benzoin}} \left\{ \begin{array}{c} X \\ + \\ Y \end{array} \right\} \xrightarrow{\text{FeCl}_3}$

(1b-IV)   (1b-V)

A general synthetic route from chloropyrimidines to 7,8-dihydropteridines was developed by Boon, Ramage and their collaborators and independently by Polonovski and his collaborators. This was a notable advance because it gave rise to dihydropteridines which were indubitably 7,8-dihydro-derivatives. Up to the inception of the work described in the present thesis, no similar method for producing dihydropteridines with the hydrogen atoms in other positionshad been found.

Thus 7,8-dihydro-6-hydroxypteridines (1b-VIIIa) (Boon, Jones and Ramage, 1951.; Polonovski and Jerome, 1950) and 7,8-dihydro-6-alkylpteridines (1b-VIIIb) (Boon and Jones, 1951; Polonovski, Pesson and Puister, 1950) were unambiguously synthesized by the route (1b-VI ⟶ 1b-VIII).

| (1b-VI) | (1b-VII) | (1b-VIII) |

a, R_3 = OH	a, R_3 = OH
b, R_3 = alkyl	b, R_3 = alkyl
or aryl	or aryl

A number of 7,8-dihydro-hydroxypteridines were synthesized by this method. For example, 7,8-dihydro-6-hydroxypteridine (1b-XIb) was synthesized from 2,4-dichloro-5-nitropyrimidine (1b-IXa) (Boon, Jones and Ramage, 1951). Condensation of glycine ethyl ester with 2,4-dichloro-5-nitropyrimidine (1b-IXa) gave 2-chloro-4-ethoxycarbonylmethylamino-5-nitropyrimidine (1b-Xa) which, on hydrogenation over Raney nickel, gave 2-chloro-7,8-dihydro-6-hydroxypteridine (1b-XIa). 7,8-Dihydro-6-hydroxypteridine (1b-XIb) was obtained by reductive removal of the 2-chloro-group of (1b-XIa) with hydriodic acid.

(1b-IX) (1b-X) (1b-XI)

	R_1	R_2
a,	Cl	H
b,	H	Cl

	R_1	R_2
a,	Cl	H
b,	OH	H
c,	H	OH

	R_1	R_2
a,	Cl	H
b,	H	H
c,	OH	H
d,	H	OH

7,8-Dihydro-2,6-dihydroxypteridine (1b-XIc) was synthesized
from the same pyrimidine (1b-IXa) *via* (1b-Xa) and (1b-Xb)
(Boon, Jones and Ramage, 1951).   7,8-Dihydro-4,6-
dihydroxypteridine (1b-XId) was synthesized from 4,6-dichloro-
5-nitropyrimidine (1b-IXb) (Boon, Jones and Ramage, 1951) by
a similar synthesis to that used for 7,8-dihydro-2,6-
dihydroxypteridine.

7,8-Dihydro-2,4,6-trihydroxypteridine (1b-XV)

was synthesized as shown (Boon and Leigh, 1952):

(1b-XII)   (1b-XIII)   (1b-XIV)

(1b-XV)

4-Chloro-2,6-dihydroxypyrimidine (1b-XII) was condensed with
p-toluenediazonium salt to give (1b-XIII), and this was then
condensed with glycine methyl ester to give (1b-XIV) which,
on reduction, gave 7,8-dihydro-2,4,6-trihydroxypteridine
(1b-XV).

The structure of dihydroxanthopterin was finally

established as 2-amino-7,8-dihydro-4,6-dihydroxypteridine
(1b-XVI) by a slight and obvious modification of this
synthesis (Boon and Leigh, 1951, 1952).

(1b-XVI)

7,8-Dihydro-2-hydroxy-4,6-dimethylpteridine (1b-XX) was
synthesized from 2,4-dichloro-6-methyl-5-nitropyrimidine
(1b-XVII) by the following route (Lister and Ramage, 1953):

(1b-XVII)   (1b-XVIII)   (1b-XIX)

(1b-XX)   (1b-XXI)

However, before the present work was undertaken, no
method existed for preparing 7,8-dihydropteridines lacking
a hydroxy- or alkyl-group in the 6-position.

7,8-Dihydropteridines, which have no hydroxy group in
the 6-position, were found to be readily hydrogenated to the
corresponding tetrahydropteridines (Polonovski, Pesson and
Puister, 1950; Lister and Ramage, 1953; Lister, Ramage and
Coates, 1954). (All of these had an alkyl-group in the
6-position). Because these tetrahydropteridines had
ultraviolet absorption spectra similar to the corresponding
4,5-diaminopyrimidines, the 5,6,7,8-tetrahydro structure was
assigned to them. For example the 7,8-dihydro-2-hydroxy-4,6-
dimethylpteridine (1b-XX) was reduced to a tetrahydro compound
which had (similar) ultraviolet absorption spectra to those of
4,5-diamino-2-hydroxy-6-methylpyrimidine and it was therefore
assigned the structure 5,6,7,8-tetrahydro-2-hydroxy-4,6-
dimethylpteridine (1b-XXI) (Lister and Ramage, 1953).

Another unambiguous synthetic route to 5,6,7,8-
tetrahydropteridines had been worked out (Brook and Ramage,
1955, 1957), and 5,6,7,8-tetrahydropteridines with no other
substituent in the 6-positions are also available by this
method. However the synthesis of 5,6,7,8-tetrahydro-
hydroxypteridines with no substituent in the 8-position could

not be accomplished. 8-Benzyl-5,6,7,8-tetrahydro-2-
hydroxy-4-methylpteridine (1b-XXVI) was prepared
unambiguously as follows, but unfortunately it resisted
debenzylation (Brook and Ramage, 1955).

(1b-XXII)

a, R = CH$_3$

b, R = H

(1b-XXIII)

a, R = CH$_3$

b, R = H

(1b-XXIV)

a, R = CH$_3$

b, R = H

(1b-XXV)

(1b-XXVI)

R = CH$_3$

Condensation of 2,4-dichloro-6-methyl-5-nitropyrimidine
(1b-XXII) with benzyl-β-hydroxyethylamine gave (1b-XXIII).
8-Benzyl-2-chloro-5,6,7,8-tetrahydro-4-methylpteridine
(1b-XXIV) was obtained from (1b-XXIII) by reduction and then
by treatment with phosphorus trichloride.   Hydrolysis of
(1b-XXIV) with 5N-hydrochloric acid gave 8-benzyl-5,6,7,8-
tetrahydro-2-hydroxy-4-methylpteridine (1b-XXVI) but attempt
at replacement of the 8-benzyl-group with hydrogen by
treatment with sodium in liquid ammonia gave an unstable
product.   5,6,7,8-Tetrahydropteridine (1b-XXV) was
synthesized from (1b-XXIV) by reduction with sodium in liquid
ammonia, a process which achieved both debenzylation and
dechlorination simultaneously (Brook and Ramage, 1957). The
disadvantage of this method for preparing tetrahydro-
pteridines is that an alternative cyclization to glyoxalino-
pyrimidines occurs if a tautomerizable group (e.g. -OH or
-NH$_2$) is present at stage (1b-XXIII) (Ramage and Trappe,
1952).

A little work has been done on the reduction of amino-
and ethoxy-pteridines. However, as the present research
work is concerned with hydroxypteridines, the rest of this
historical outline will be confined to an account of work on
the reduction of pteridine and hydroxypteridines, and will
include proofs of structures.

Pteridine was first prepared by the condensation of
4,5-diaminopyrimidine with glyoxal (Jones, 1948) and was

14

later reduced to the tetrahydro derivative with lithium aluminium hydride (Taylor and Sherman, 1959). The same tetrahydropteridine was also prepared by catalytic hydrogenation of 2,4-dichloro-5,6,7,8-tetrahydropteridine (Taylor and Sherman, 1959) and was identified as 5,6,7,8-tetrahydropteridine by comparison with a sample which was unambiguously prepared by Brook and Ramage (1957), as described above.

All the possible mono- and poly- hydroxypteridines are known (Table 1, see p. 17) but, prior to the present work few had been reduced. Reduction of 6-hydroxy-, and 6,7-dihydroxy-, pteridines with sodium amalgam always gave the corresponding 7,8-dihydro-6-hydroxy derivatives. Thus for example, both 6-hydroxy-, and 6,7-dihydroxy-, pteridine gave 7,8-dihydro-6-hydroxypteridine (1b-XIb) identical with that obtained by Boon's synthesis (Albert, Brown and Cheeseman, 1952). Similarly, 4,6,7-trihydroxypteridine gave the known 7,8-dihydro-4,6-dihydroxypteridine (1b-XId) (Albert and Brown, 1953). 2,4,6,7-Tetrahydroxypteridine was reduced with sodium amalgam to what was apparently 7,8-dihydro-2,4,6-trihydroxy-pteridine (Albert, Lister and Pedersen, 1956) because it was oxidized to 2,4,6-trihydroxypteridine. The same dihydro-compound was obtained by the reduction of 2,4-dichloro-6,7-dihydroxypteridine with sodium amalgam (Taylor and Sherman, 1959). Similarly sodium amalgam reduction of 4,6,7-trihydroxy-$N_{(1)}$-methyl-2-oxopteridine produced 7,8-dihydro-4,6-dihydroxy-$N_{(1)}$-methyl-2-oxopteridine (Pfleiderer, 1957).

The use of two other reducing agents is exemplified in the
reduction of 4-hydroxy-6-methylpteridine by sodium
borohydride to a tetrahydro-4-hydroxy-6-methylpteridine
(Blakley, 1959), and in the reductive cleavage of 7-hydroxy-
pteridine (1b-XXVII) by sodium dithionite to give 4-amino-5-
carboxymethylaminopyrimidine (1b-XXVIII) (Albert, Brown and
Cheeseman, 1952). The same compound (1b-XXVIII) was also
obtained by a catalytic hydrogenation over Adams' catalyst
in 0.1 N-sodium hydroxide solution (Albert, Brown and
Cheeseman, 1952).

(1b-XXVII)   (1b-XXVIII)   (1b-XXIX)

Evidence for the ring opening structure (1b-XXVIII) was
obtained from analytical figures and from the presence of a
carboxyl group. This compound gave an ester hydrochloride,
as do amino acids, by treatment with hydrogen chloride in
methanol, but conclusive evidence for the position of the
introduced hydrogen was not presented.   The compound

(1b-XXVIII) easily cyclized to a dihydro-7-
hydroxypteridine, believed to be (1b-XXIX), by refluxing
in N-hydrochloric acid and it was regenerated by boiling
in N-sodium hydroxide (Albert, Brown and Cheeseman, 1952,).

All hydroxypteridines which had been reduced to
products of confirmed orientation, prior to the present work
are shown in Table 2 (see p. 18).

Table 1

List of known hydroxypteridines

Reference

(Pteridine	Jones	1948)
2-Hydroxypteridine	Albert, Brown and Cheeseman	1951
4-Hydroxypteridine	Albert, Brown and Cheeseman	1951
6-Hydroxypteridine	Albert, Brown and Cheeseman	1952
7-Hydroxypteridine	Albert, Brown and Cheeseman	1952
2,4-Dihydroxypteridine	Kuhn and Cook	1937
2,6-Dihydroxypteridine	Albert, Lister and Pedersen	1956
2,7-Dihydroxypteridine	Albert, Lister and Pedersen	1956
4,6-Dihydroxypteridine	Albert and Brown	1953
4,7-Dihydroxypteridine	Albert and Brown	1953
6,7-Dihydroxypteridine	Albert, Brown and Cheeseman	1952
2,4,6-Trihydroxypteridine	Wieland and Liebig	1944
2,4,7-Trihydroxypteridine	Tschesche and Korte	1951
2,6,7-Trihydroxypteridine	Albert, Lister and Pedersen	1956
4,6,7-Trihydroxypteridine	Albert and Brown	1953
2,4,6,7-Tetrahydroxypteridine	Schöpf, Reichert and Riefstahl	1941

Table 2.

Hydroxypteridines where the positions of the hydrogen atoms are unambiguously known.

Pteridines which have been reduced and the product unambiguously identified	Reducing agent	Reference (Reduction)	Product	Reference (Unambiguous synthesis)
6-Hydroxypteridine	Na-Hg	1)		
6,7-Dihydroxypteridine	Na-Hg	1)		2)
4,6,7-Trihydroxypteridine	Na-Hg	3)		2)
2,4,6,7-Tetrahydroxypteridine	Na-Hg	4)		5)
This substance has been synthesized, but not obtained by reduction.				2)

1) Albert, Brown and Cheeseman,   1952

2) Boon, Jones and Ramage,   1951

3) Albert and Brown,   1953

4) Albert, Lister and Pedersen,   1956

5) Boon and Leigh,   1952

The structures of the reduction products were mainly confirmed by comparison with samples prepared unambiguously. The first synthetic routes to 7,8-dihydro-, 5,6-dihydro-, and 5,6,7,8-tetrahydro-, hydroxypteridines having no substituent in the 6-, and 7-positions, were worked out.

Ionization constants of the hydrogenated pteridines were determined by potentiometric titration or by spectroscopic methods.

The ultraviolet absorption spectra, and the infrared absorption spectra of the reduced pteridines were also determined for comparison of structure.

SECTION 2.

METHODS.

a. Methods Available for Reduction.

As indicated in the historical outline, many methods have been used for the reduction of pteridine derivatives. They include physical, chemical and biochemical procedures. For systematic investigation of the reduction of the pteridine ring, it is important to select a proper combination of reducing agent and the substance to be reduced. Many such combinations are possible, but for simplicity and in order to achieve practical result, attention has been confined to selected variations in (a) the reducing agent and (b) the ionic species of the substance to be reduced.

As all hydroxypteridines have acidic and basic functions, the pH of the solution determines the ionic species of the hydroxypteridine in the reaction mixture. It is clearly desirable, therefore to restrict each reduction of a hydroxypteridine to one ionic species in any one experiment. For example, 7-hydroxypteridine has three pKa values of 6.41 (acidic), 1.2 (basic) and -2.0 (basic). Hence, if the 7-hydroxypteridine is reduced in a solution of pH 9, the reaction occurs almost entirely between the 7-hydroxypteridine anion and the reducing agent, but at pH 4 the reaction occurs almost entirely between the neutral molecule and the reducing agent. The pKa values of hydroxypteridines are shown in Table 3, p. 25. In some

cases the number of ionic species available for the reduction was limited on account of insolubility of one or other of the species.

The most important variable in the reduction of pteridines is the choice of a reducing agent. Classical theory suggests that reduction using chemical reagents is initiated by the attack of a proton to give an intermediate cation. The cation then takes up two electrons from the reducing agent which converts it into an anion, and the reduction is then completed by abstraction of a second proton from the surrounding medium. However, it is now commonly accepted that other mechanisms of reduction are evoked by particular classes of reagents. For example, dissolving metals reduce the substance by a hydrogen anion $(2 e + H^+)$ mechanism. (Baker, 1952; Ingold, 1953). Complex metal hydrides also reduce a substance by a hydrogen anion mechanism, in some cases with the formation of a transient addition complex. The reduction of pyridinenucleotides by sodium dithionite, also proceeds through an addition complex, but it is of another type (Yarmolinsky and Colowick, 1956). Finally hydrogenations using metal catalysts are considered to be reductions by free hydrogen atoms (Conant and Cutter, 1922; Laidler, 1951).

The following reagents were selected for the present work: potassium borohydride (hydrogen anion type), sodium

amalgam (dissolving metal type), sodium dithionite
(reduction through an addition compound), hydrogenation over
platinum, palladium and Raney nickel (free hydrogen atoms).

Potassium borohydride is one of the best of the
complex hydride[s] because it can be used in aqueous solution.
This is a great advantage for the reduction of hydroxy-
pteridines because most hydroxypteridines are quite
insoluble in organic solvents. For this reason lithium
aluminium hydride (a more active complex metal hydride than
potassium borohydride) has been used only for the reduction
of lipo-soluble pteridines, e.g. pteridine, a chloropteridine
(Taylor and Sherman, 1959) and an alkylpteridine (Brook and
Ramage, 1957). All hydroxypteridines in the present work,
were treated with potassium borohydride.

Because potassium (or sodium) amalgam is used in
alkaline conditions, all hydroxypteridines can be treated
with this reagent. (Some hydroxypteridines, for example 7-
hydroxypteridine, give an insoluble sodium salt and in such
cases potassium amalgam is superior to sodium amalgam).
Reduction of some 6,7-dihydroxypteridines by this reagent is
unusual in that elimination of the 7-hydroxy group occurs,
giving the corresponding 7,8-dihydro-6-hydroxypteridines.
Some reductions of hydroxypteridines by this reagent have
been described in the historical outline (p.14).

Sodium dithionite was chosen as an example of the type

of reducing agent which makes an addition compound with the substance to be reduced. This compound is usually hydrolysed below pH 8. This reagent is used in an alkaline solution and when this is made less alkaline to decompose the addition complex, sulphur dioxide is produced. In practice, this restricts the application of the method, because sulphite ion combines with some reduced hydroxy-pteridines to give sulphur-containing products (as will be described later).

All catalytic hydrogenations in the present work were carried out at room temperature and atmospheric pressure. Because of the poor solubility of polyhydroxy-pteridines in alcohol only the monohydroxypteridines were available for the reduction over Raney-nickel which is deactivated if used in alcohol more dilute than 85%. The reduction over palladium catalyst in 0.1N-sodium (or potassium) hydroxide solution was employed for all hydroxy-pteridines, and in a number of cases platinum catalyst was also used. Because catalytic hydrogenation may be followed quantitatively, it can give information on the facility and the extent to which a substance is being reduced.

Biochemical and electrolytic reductions were not investigated in the present work.

Table 3.

pK$_a$ values of hydroxypteridines.

| Hydroxypteridines	pK$_a$		Reference
	basic	acidic	
2-Hydroxypteridine	2	11.13	1
4-Hydroxypteridine	−0.17	7.89	1, 2
6-Hydroxypteridine	3.67	6.7	3
7-Hydroxypteridine	−2.0, 1.2	6.41	3
2,4-Dihydroxypteridine	1.0	7.91	1
2,6-Dihydroxypteridine	2.7	6.7*	4
2,7-Dihydroxypteridine		5.83, 10.07	4
4,6-Dihydroxypteridine		6.08, 9.73	5
4,7-Dihydroxypteridine		6.08, 9.62	5
6,7-Dihydroxypteridine		6.9, 10	3
2,4,6-Trihydroxypteridine		5.73, 9.41	4
2,4,7-Trihydroxypteridine		3.61	4

*for anhydrous species.

1) Albert, Brown and Cheeseman,   1951

2) Brown and Mason   ,   1956

3) Albert, Brown and Cheeseman,   1952

4) Albert, Lister and Pedersen,   1956

5) Albert and Brown   ,   1953

b. Methods Available for Diagnosing the Positions where Hydrogen Atoms have Entered the Molecule.

Chemical, physical, biochemical methods as well as combinations of these methods have been used for determining the positions at which external hydrogens are introduced during reduction of heteroaromatic substances.

The two chemical methods for determining molecular structures consist of the synthetic and the degradative approaches. The synthetic method gives conclusive evidence as long as any shift of a double bond is avoided during the synthesis. Much use has been made, in this thesis, of the synthetic method, and this will be discussed in 3 b (p.67).

In the degradative method it is likewise important that neither the original molecule nor the resulting smaller molecules are altered by the process. An example of this method is seen in the fission of double bonds by ozonolysis. Thus, the decomposition of 3,5-diethoxycarbonyl-2,6-dimethyl-4-phenyldihydropyridine by ozonolysis yielded phenylacetic acid (2b-II). Since bond rearrangements were unlikely, this suggested the 1,4-dihydro structure (2b-I) for this pyridine (Kuss and Karrer, 1957).

$$\text{(2b-I)} \qquad\qquad \text{(2b-II)}$$

This method however can not be used to determine the structure of reduced hydroxypteridines, because the type of reduced hydroxypteridines with which this thesis is concerned have <u>two</u> hydrogen atoms on the relevant carbon atom. Such reduced pteridines are too readily oxidized to the original pteridines for the ozonolysis technique to be practicable.

Providing the introduced hydrogen atoms do not migrate from the original positions, and providing that a suitable reaction for removing hydrogen atoms from definite positions in the reduced molecule is available, a tracer method may be used for the determining where the hydrogen atoms were originally introduced. For example, the structure of reduced diphosphopyridine nucleotide was established as a 1,4-dihydro configuration by using deuterium as a tracer (Pullman, San Pietro and Colowick, 1954). The principle of the method is shown below.

(2b-III)   (2b-IV)   (2b-V)


(2b-VI) a,   b.

The details are as follows:

Diphosphopyridine nucleotide (DPN) (2b-III), when reduced in heavy water with sodium dithionite, took up one atom of deuterium to form a "dihydro"-compound (2b-IV?). This was reoxidized to DPN (2b-V) which retained half an atom of deuterium per mole of DPN. The deuterated DPN (2b-V) was hydrolysed to a nicotinamide and then methylated to $N_{(1)}$-methylnicotinamide (2b-V, R = CH_3). The nicotamide was then oxidized with alkaline ferricyanide to a mixture of the corresponding 2-, and 6-, pyridones (2b-VIa and 2b-VIb). By examining the deuterium content of (2b-V, R = CH_3),

(2b-VIa) and (2b-VIb), the position of the introduced deuterium could be established as follows. If one of the final products (2b-VIa) contained (the equivalent of) half an atom of deuterium and the other contained none, the first dihydro compound would have to be the 1,6-dihydro derivative of DPN. Conversely, if (2b-VIb) contained half an atom of deuterium and (2b-VIa) contained none, the first reduction product would have to be a 1,2-dihydro structure. If (2b-VIa) and (2b-VIb) both contained half an atom of deuterium, the first dihydro compound would have to be a 1,4-dihydro derivative of DPN. Finally if DPN was reduced to a 1,2- and a 1,6-dihydro compound in equal amount, then both (2b-VIa) and (2b-VIb) would have the same deuterium content. However, in this case the deuterium content of each compound would be reduced to half of that of (2b-V) at the stage of ferricyanide oxidation. The structure of the reduced diphosphopyridine nucleotide was in fact confirmed as the 1,4-dihydro derivative, from the deuterium contents of (2b-V), (2b-VIa) and (2b-VIb). This method can theoretically be used to distinguish the 3,4-dihydro-2-hydroxypteridine from other possible dihydro-2-hydroxypteridines if the following reactions could be done in practice.

(2b-VII)   (2b-VIII)

(2b-IX)   (2b-X)

The reduction of (2b-VII) to a dihydro derivative (as 2b-VIII) is described in the present work, and the oxidation of (2b-IX)⟶(2b-X) (non-deuterated) was described by Brown and Mason (1956). Unfortunately, a trial experiment showed that oxidation of the dihydro-2-hydroxypteridine (2b-VIII) to 2-hydroxypteridine could not be done satisfactorily, even with cold dilute potassium permanganate. Therefore, this method could not be used for determining the structure of x,y-dihydro-2-hydroxypteridine.

If a new asymmetric centre is introduced by the reduction of a molecule at a certain position, it is possible to limit the possible structures of the product. For example, dihydrofolic acid had three possible structures, (2b-XI),

(2b-XII) and (2b-XIII). Structure (2b-XIII) has an
asymmetric centre. The two dihydrofolic acids which were
prepared respectively by biological and chemical methods,
showed no difference in biological activity. This means
that the dihydrofolic acid prepared by the chemical method
had no asymmetric centre in the molecule, and the
possibility of the structure (2b-XIII) was therefore
eliminated (Osborn and Huennekens, 1958).

(2b-XI)   (2b-XII)   (2b-XIII)

However, since no asymmetric centre is introduced by
reduction of simple hydroxypteridines, the method is
inapplicable to such cases.

Physical methods are also important tools for the
structural investigation of reduced pteridines. The
identity of two specimens (of a single substance) which
have been prepared by different method can readily be
established by comparison of their physical constants.
Also, very important fundamental information about the
structure of the molecule can be obtained from such physical
constants as the pKa values, ultraviolet absorption spectra,

infrared absorption spectra and nuclear magnetic resonance
spectra.   In some cases the information obtained yields
its meaning only after comparison with results from
substances of known constitution.   In the present work
such standards were often lacking and had to be prepared.
Electronic absorption is caused by a transition of electrons
from one electronic energy level to another.   The main
factors that determine the electronic absorption are the
electronic structure and polarizability of the molecule.
Compounds which have a similar electronic structure have
similar ultraviolet spectra.

(2b-XIV)   (2b-XV)   (2b-XVI)   (2b-XVII)

Thus, there is a close similarity between the ultraviolet
absorption spectra of the neutral molecule of 4,5-
diaminopyrimidine (2b-XIV) and of the anion of 4-amino-5-
carboxymethylaminopyrimidine (2b-XV), and also between the
spectra of 4,5-diaminopyrimidine as cation (2b-XVI) and
the neutral molecule of 4-amino-5-carboxymethylamino-
pyrimidine (2b-XVII).   These facts follow from the
principle that the main factor which contributes to the

ultraviolet absorption is the nature of the conjugated system.
In the above examples, the carbonyl groups in (2b-XV) and
(2b-XVII) are separated from the conjugated system of the
pyrimidine ring by a $-CH_2-$ group and do not contribute to
the ultraviolet absorption. So, (2b-XV) has the same
conjugated system as (2b-IV), and (2b-XVII) the same
conjugated system as (2b-XVI). No conclusive evidence on
the orientation of hydrogen atoms in reduced hydroxy-
pteridines could be obtained from infrared spectra, because
the spectra of these compounds can only be measured in the
solid state, where there is intense intra-molecular hydrogen-
bonding.   Infrared spectra are, however, of immense value
in ascertaining the identity of two specimens.

Nuclear magnetic resonance (NMR) spectra give direct
information on the orientation of hydrogen atoms in a molecule.
Conclusive evidence for the location of hydrogen atoms can often
be obtained by this method because the structure of the
molecule is entirely unaltered during measurement. Thus
any possibility of misunderstanding caused by an unusual
reaction or by the shift of a proton is excluded. The
structures of dihydro-$N_{(1)}$-methylnicotinamide (Hutton and
Westheimer, 1958; Dubb, Sanders and Wang, 1958) and dihydro-
3,5-diethoxycarbonyl-1,2,6-trimethylpyridine (Smith, 1958)
were confirmed respectively as 1,4-dihydro-structures,
(2b-XVIII) and (2b-XIX). (These results are in agreement

with the results obtained by the isotope tracer method).

(2b-XVIII)   (2b-XIX)

It first seemed that the NMR method could be used for the determination of the structures of xy-dihydro-2-hydroxy-pteridine and xy-dihydro-4-hydroxypteridine. It soon appeared, however, that difficulty in the application of the method to these dihydropteridines might be encountered through the insolubility of these hydroxypteridine compounds, and in fact the nuclear magnetic resonance measurements, when made, did not give sufficiently intense spectra for this very reason (These measurements were kindly carried out at the Institute of the Atomic Power Centre of Japan by Mr. H. Hayakawa).

Biochemical methods were not used during the present work because no suitable enzymes are known.

c. Likely Positions of Hydrogen Atoms in Reduced
Hydroxypteridines.

There are many possible reduced forms of the
pteridine ring, but the reduction of pteridines should yield
the more stable isomers, that is to say the final products
will retain as much conjugation as possible. Therefore, it
is unlikely to find a reduction product with such a structure
as (2c-I), because of the greatly reduced conjugation (it
should be noted that (2c-I) does not contain even one fully-
conjugated ring).

(2c-I)

On these grounds it seems reasonable that the di- and tetra-
hydropteridines likely to be obtained by reduction will
be represented by the following formulae only (or a
selection of these):

(A)   (B)   (C)

(D)   (E)   (F)

(G)   (H)   (I)

In these structures the two pairs of compounds, (B) and (C),
and (F) and (G) each have a common cation so that interchange
to the more stable form of each pair would instantly occur on
protonation. Which is the more stable form will be decided by
substituents in the ring (an example will be discussed later in
the case of x,y-dihydro-4-hydroxypteridine, see p. 48).

This contention is supported by the fact that all attempts
to synthesise a related substance, 1,4-dihydroquinazoline (2c-II),
gave 3,4-dihydroquinazoline)2c-III) (Dr. W.L.F. Armarego,
personal communication).

(2c-II)   (2c-III)

A further exclusion of some of the remaining eight reduced
structures (A,C,D,E,F,G,H and I) can be made on the
following grounds.

Previous work had indicated that hydroxypteridines
having a hydroxy group in the 6- and 7-position were always
reduced in the pyrazine ring (no exceptions were found to
this rule in the present work). Hence, 2-hydroxy-, and
4-hydroxy-pteridine are the only hydroxypteridines likely to
give respectively a 3,4-dihydro-, and 1,2-dihydro-structure
on reduction. It has also been indicated that the only
examples of the elimination of a hydroxy group from the
pyrazine ring during reduction are losses of a 7-hydroxy-
group from 6,7-dihydroxypteridines when sodium amalgam is
used. In such cases, 7,8-dihydro-6-hydroxypteridines were
obtained (see p. 14). No elimination of a hydroxy-
group from the pyrimidine ring has been recorded, and no
1,2,3,4-tetrahydropteridines have ever been obtained by
reduction.

A,C,D,E,F,G and H are therefore the structures
most likely to be obtained by reduction of simple hydroxy-
pteridines.

d. <u>Method Available for Syntheses of Hydrogenated</u>
<u>Hydroxypteridines.</u>

Before the present work only 7,8-dihydro-, and
5,6,7,8-tetrahydro-pteridines have been made by synthesis.

The synthetic route from chloronitropyrimidines to
7,8-dihydropteridines has been well developed by Boon,
Ramage and their collaborators and by Polonovski and
collaborators (see p.6).   Unfortunately, this method is
suitable only for preparing those 7,8-dihydropteridines
which have an alkyl-, or hydroxy-group in the 6-position.
In the present work, the syntheses of 7,8-dihydropteridines
having no substituent in the 6-position was desired, and
for this purpose considerable modification of the above
method was necessary.   The other synthetic method for
7,8-dihydropteridines consists of a condensation of
4-alkylamino-5-aminopyrimidines (2d-I) with benzoin
(Forrest, Hull, Rodda and Todd, 1951; Fidler and Wood,
1957).   But all hydropteridines (2d-II) which were
prepared by this method had alkyl (or aryl) groups in 6-,
7-, and 8-positions.

(2d-I)   (2d-II)

R_3; R_4; R_5 = alkyl (or aryl) group

The essential process of this method consists of an orientation of the incoming double bond to the 5,6-position by an alkyl group attached to the 4-amino group of the pyrimidine (2d-I) ring. Therefore, no modification of this method to prepare unsubstituted dihydropteridines is possible.

5,6,7,8-Tetrahydropteridines have been prepared by two ways. The first method is a reduction of 7,8-dihydropteridines (see p.11) and the second one is an unambiguous synthesis (see p.11). These are general methods and are applicable for the present purpose after some modification.

No general method has been developed for the syntheses of 1,2-, 3,4-, 5,6-, and 5,8-dihydropteridines. However, for the present work, some syntheses of these ring systems were desired, and new methods had to be thought out.

A method for the preparation of 7-amino-5,6-
dihydro-1,3-dimethyl-2,4-dioxopteridine (2d-V) by
cyanomethylation of the corresponding 4,5-diaminopyrimidine
(2d-IV) (Blicke and Godt, 1954), is an isolated instance
of a method which is not general.

(2d-III)   (2d-IV)   (2d-V)

SECTION 3

RESULTS AND DISCUSSIONS

a. Reduction

In the present study of reduction of hydroxy-
pteridines, there are four variables:
(i) the positions of the hydroxy groups attached to the
pteridine ring, (ii) the presence of groups other than
hydroxy, (iii) the ionic species of the pteridine, and (iv)
the reducing agent.

In practice it was found that the position of the
hydroxy group was the chief controlling influence on the
position of the entering hydrogen atoms.

i) Position of the hydroxy group.

2-Hydroxypteridine was reduced in alkaline solution
with potassium borohydride to a small amount of a tetrahydro-
2-hydroxypteridine and a fairly good yield of a dihydro-2-
hydroxypteridine. Hydrogenation in alkaline solution over
Adams' platinum oxide, palladium on carbon, or Raney-nickel
catalyst, gave the same two products as above. On the other
hand, hydrogenation over Adams' catalyst in neutral solution
led to the absorption of four moles of hydrogen, indicating
that a complete hydrogenation (or hydrogenolysis) of the
pteridine ring had occurred.

Sodium dithionite reduced 2-hydroxypteridine to the same x,y-dihydro-2-hydroxypteridine and a highly insoluble product, presumably a polymerized compound. Sodium amalgam reduced 2-hydroxypteridine to an unstable compound which rapidly changed to a resin in air.

The tetrahydro-2-hydroxypteridine was shown to be 5,6,7,8-tetrahydro-2-hydroxypteridine by comparison of its ultraviolet absorption and Rf values with an authentic sample prepared by synthesis (see p. 71)

	The reduction product of 2-hydroxypteridine	5,6,7,8-tetrahydro-2-hydroxypteridine obtained by synthesis
Rf. NH_4Cl	0.74 2B/3G	0.74 2B/3G
Bu/Ac	0.22 2/3 GB	0.22 2/3 GB
UV-absorption λmax (mμ)		
pH 7	230, 305	232, 306
1.0	327	327

Although the structure of the x,y-dihydro-2-hydroxypteridine is still not beyond doubt, it seems likely from the following evidence to be 3,4-dihydro-2-hydroxypteridine.

x,y-Dihydro-2-hydroxypteridine is not identical with 7,8-dihydro-2-hydroxypteridine which was obtained by synthesis (see p. 70). Also, it is spectroscopically and chromatographically different from synthetic "5,6-dihydro-2-

hydroxypteridine", (although an analytically pure sample of this substance was not obtained) (see 3b and 3d). The remaining probable structures for this compound are 3,4-dihydro-2-hydroxypteridine (3a-I) and 5,8-dihydro-2-hydroxypteridine (3a-II).

Dihydro-2-hydroxypteridines

	x,y-dihydro-	7,8-dihydro-	"5,6-dihydro-"
Rf.(NH$_4$Cl)	0.69 2B/3V	0.61 2/3B	0.76 2B/3SB
(Bu/Ac)	0.50 2B/3V	0.32 2/3Y	
pKa basic	0	3.50 ± 0.02	0.4
acidic	13		
UV-spectra			
(λmax mμ) *			
o	248, 317	223, 298	296 (pH 7)
+	254, 337	229, 312	282 (pH 0)
−	281, 343	224, 308 (pH 12)	298 (pH 12)

(3a-I)   (3a-II)

Attempts to synthesize (3a-I) were unsuccessful (see p. 75), and no synthetic route to (3a-II) could be

---

* o: neutral molecule,   + : cation,   − : anion.

found.

Infrared spectra, and tracer methods could not be
used for reasons described earlier (see 2b).   Nuclear
magnetic resonance spectra were looked for (by kindness of
Mr. N. Hayakawa), but the insolubility of the substance
prevented strong enough signals being obtained.

The first evidence in favour of the 3,4-dihydro-
structure was obtained, however, from studying the reduction
of the x,y-dihydro-2-hydroxypteridine and 2-hydroxypteridine.
x,y-Dihydro-2-hydroxypteridine could not be further reduced
in alkaline solution; but in neutral solution it absorbed
hydrogen (eventually three moles) over Adams' catalyst, yet
no 5,6,7,8-tetrahydro-2-hydroxypteridine was detected during
any stage of the hydrogenation.   This suggests that the
3,4- is more likely than the 5,8- orientation for the
original hydrogenation.

The second piece of evidence was obtained from the
reduction of 2-hydroxypteridine.   It has been established
(Brown and Mason, 1956) that 2-hydroxypteridine exists as
an anhydrous anion (3a-III), but in neutral solution it
forms a more stable hydrated neutral molecule.   These authors
assigned the structure (3a-IV) to this hydrated molecule from
comparison of its ultraviolet spectrum with that of its 1-
methyl-, and 3-methyl-derivatives.

(3a-III)   (3a-IV)

It would be reasonable to obtain 3,4-dihydro-2-hydroxy-
pteridine from (3a-III), but not from (3a-IV).   It will
be recalled that the x,y-dihydro-2-hydroxypteridine was
the main product of the reduction of 2-hydroxypteridine
anion (3a-III) in alkaline solution with potassium
borohydride or hydrogenation over palladium but no such
dihydro structure was obtained from hydrogenation of
(3a-IV) in neutral solution.

A few 5,8-dihydropteridines are known, the best
established being 8-ethyl-2-ethylamino-5,8-dihydro-7-
hydroxypteridine-6-carboxylic acid (3a-V) (Pfleiderer and
Taylor, 1960; see also Forrest, Baalen, Viscontini and
Piraux, 1960).   The acid (3a-V) shows a strong bathochromic
shift (54 mμ) compared to its decarboxylation product, which
is apparently a 5,6-dihydropteridine (3a-VI).   Thus the 5,8-
dihydro-structure, which has diminished conjugation, is
believed (Pfleiderer and Taylor) only to be stabilized by
special groups e.g. the hydrogen bond ring of (3a-V).

(3a-V)   (3a-VI)

x,y-Dihydro-2-hydroxypteridine neutral molecule showed

only a small bathochromic shift (10 mµ) when compared to

the hydrated 2-hydroxypteridine neutral molecule (Fig. 1,

p.186). A similar small bathochromic shift (Albert, Brown

and Cheeseman, 1952) also exists between the 7,8-dihydro-6-

hydroxypteridine neutral molecule and the hydrated neutral

molecule of 6-hydroxypteridine (Fig. 2, p.186).   This

evidence strongly supports the 3,4-dihydro-structure

(3a-I) for x,y-dihydro-2-hydroxypteridine (see also p. 112).

The fact that pyrimidines are more difficult to

reduce than pyrazines suggested that pteridines should be

reduced preferentially in the pyrazine ring (Albert, 1952;

Taylor and Sherman, 1959), and no examples to the contrary

had been found prior to the present work. However it is

relevant that in the quinazoline series the pyrimidine

ring can be easily reduced.   For example the quinazoline was

reduced easily to 3,4-dihydroquinazoline by hydrogenation over

Dams' catalyst (Marr and Bogert, 1935), and 4-

chloroquinazoline gave the same 3,4-dihydroquinazoline by

catalytic hydrogenation over palladium on $CaCO_3$ (Elderfield,
Williamson, Gensler and Kremer, 1947).

All the above considerations point to 3,4-dihydro-2-
hydroxypteridine (3a-I) as the most likely structure for
x,y-dihydro-2-hydroxypteridine.

4-Hydroxypteridine was reduced with potassium borohydride to
give a tetrahydro-4-hydroxypteridine and a dihydro-4-
hydroxypteridine (roughly in a 1:1 ratio). Sodium amalgam
reduction gave a product unstable to aerial oxidation and
a small amount of the same tetrahydro-4-hydroxypteridine.
Catalytic hydrogenation over Raney-nickel in neutral
conditions gave only this tetrahydro-4-hydroxypteridine. On
the other hand, hydrogenation over palladium catalyst in
0.1N-sodium hydroxide solution absorbed 60% of the calculated
hydrogen for 4H, and gave the same tetrahydro-4-hydroxy-
pteridine along with a product unstable to aerial oxidation.

The structure of the tetrahydro-4-hydroxypteridine
was established as 5,6,7,8-tetrahydro-4-hydroxypteridine by
unambiguous synthesis (see p. 84).

	Tetrahydro-4-hydroxy-pteridine obtained by reduction		5,6,7,8-Tetrahydro-4-hydroxypteridine obtained by synthesis	
m.p.	230° (decomp.)		$230-238^{o}$ (decomp.)	
pK_a				
basic	3.86 ± 0.02		3.87 ± 0.02	
acidic	10.13 ± 0.03		10.10 ± 0.03	
UV-spectra	λ max. (mμ)	log ε	λ max. (mμ)	log ε
o	289	4.01	289	4.00
+	259	4.06	259	4.04
−	284	4.11	284	4.09

The structure of the x,y-dihydro-4-hydroxypteridine is still uncertain because it could not be synthesised (see, 3b). However, it was not identical with 5,6-dihydro-4-hydroxy-pteridine which was prepared synthetically (see, p.84), and the 1,2-dihydro structure was excluded because it was reduced further to 5,6,7,8-tetrahydro-4-hydroxypteridine both by sodium borohydride, and by hydrogenation over Raney-nickel catalyst. Three possible structures, 5,8-dihydro-, 7,8-dihydro-, and the transprotonated 3,7-dihydro-, structures (see p. 36 (G) therefore remain. The NMR method was attempted on this compound, but unfortunately no spectrum was obtained because it was not sufficiently soluble. The ultraviolet spectrum did not give conclusive information but was quite unlike that of any other 7,8-dihydropteridine of which many are known (Table 15, p.120). However, the IR-spectra of this compound has a strong C = O stretching absorption at $1675 cm^{-1}$ which precludes the possibility of a 3,7-dihydro-structure in the solid state (Fig.38 , p.206).

6-Hydroxypteridine was reduced with potassium borohydride, or with sodium dithionite to a dihydro compound. This was identical with the product obtained by the reduction of 6-hydroxypteridine with sodium amalgam (Albert, Brown and Cheeseman, 1952). Hydrogenation of 6-hydroxypteridine in 0.1N-sodium hydroxide over palladium catalyst gave the same dihydro-6-hydroxypteridine as above. The structure of this compound follows from its identity with the 7,8-dihydro-6-hydroxypteridine (3a-VII) unambiguously synthesized by Boon, Jones and Ramage (1951) (see p. 7).

(3a-VII)

		λ max. (mμ)	log ε
7,8-Dihydro-6-hydroxypteridine[*]	0.1N-HCl	293	4.02
	0.1N-NaOH	307	4.05
Dihydro-6-hydroxypteridine	0.01N-HCl	292	3.97
	0.1N-KOH	308	4.05

[*]Boon, Jones and Ramage, 1951 .

7-Hydroxypteridine was reduced with potassium borohydride
to a dihydro-7-hydroxypteridine. The same compound was
obtained by the reduction of 7-hydroxypteridine with cold
potassium amalgam.

On the other hand, catalytic hydrogenation over
palladium catalyst in 0.1N-potassium hydroxide solution gave
the same ring-opened product as that obtained by the
reduction of this pteridine with sodium dithionite or by the
hydrogenation over Adams' catalyst in 0.1N-sodium hydroxide
solution (Albert, Brown and Cheeseman, 1952). The
structure 4-amino-5-carboxymethylaminopyrimidine was
assigned to this product on its analytical figures and the
formation of the methyl ester with methanolic hydrogen
chloride (Albert, Brown and Cheeseman, 1952).

(3a-VIII)   (3a-XIX)

However, this evidence did not completely exclude the
possibility of the reduced ring structure (3a-XIX) for the
ring opened product. The spectroscopic data of the present
work do however exclude any possibility of the structure
(3a-XIX) (see p.111), and hence the structure of the product

is confirmed as 4-amino-5-carboxymethylaminopyrimidine

(3a-VIII). Since the reversible conversion between

x,y-dihydro-7-hydroxypteridine and 4-amino-5-carboxymethyl-

aminopyrimidine (3a-VIII) by heating with alkali or with

acid has been established (Albert, Brown and Cheeseman,

1952), the structure of the x,y-dihydro-7-hydroxypteridine

is confirmed as 5,6-dihydro-7-hydroxypteridine (3a-XX).

(3a-XX)

2,4-Dihydroxypteridine absorbed two moles of hydrogen over

Adams' catalyst in acidic solution and gave a product very

unstable to oxidation.   The same product was also obtained

by hydrogenation over palladium or Raney-nickel in acidic

or in alkaline solution, and by reduction with sodium

amalgam under nitrogen.   The product gave one spot on

paper chromatography (developed and dried in a nitrogen

atmosphere) and was reoxidized to 2,4-dihydroxypteridine

by absorbing one mole of oxygen in alkaline solution[*] (see

---

[*]In the reoxidation mixture a small amount of 2,4,6-
trihydroxypteridine was detected by paper chromatography.

Fig. 3). Thus this compound is a tetrahydro-2,4-dihydroxypteridine.

Fig.3.

absorption of oxygen by tetrahydro-2,4-dihydroxypteridine

Because of its instability, the correct analysis of this compound was obtained only after using a little 2,3-dimercaptopropanol as an antioxidant in the water used for its purification. Acetic formic anhydride gave the more stable formyl tetrahydro derivative. The only possible tetrahydro structure for this compound is 5,6,7,8-tetrahydro-2,4-dihydroxypteridine, and its ultraviolet spectra and ionization constant also support this structure.

	4,5-Diamino-2,6-dihydroxypyrimidine	Tetrahydro-2,4-dihydroxypteridine
pK$_a$ (approximate)	4.5	5
UV-spectra, cation λmax.	260 mμ (at pH2)	263 mμ (at pH3)

Because both substances are quite unstable to oxidation, correct log ε and pK$_a$ values were not obtained.

Although all other known hydroxypteridines are reduced similarly by either potassium borohydride or catalytic hydrogenation, 2,4-dihydroxypteridine was unaffected by potassium borohydride reduction.

Sodium dithionite reduced 2,4-dihydroxypteridine to the same tetrahydro compound as was obtained by catalytic hydrogenation, but also produced a sulphur containing product. The structure of the latter has not finally been established, but the analytical figures, $C_6H_9N_4NaO_6S$, suggest the following possible structures (or their isomers).

(3a-XXI)   (3a-XXII)

The following analogy suggests that formula (3a-XXI) is correct, *i.e.* that a sulphonic group is introduced into the 6-position of a pteridine nucleus. 2-Amino-4-hydroxypteridine (Viscontini and Weilenman, 1959; Baalen and Forrest, 1959) has been reduced to an unstable tetrahydro derivative which was easily oxidized. The reoxidation of the tetrahydro-2-amino-4-hydroxypteridine in the presence of such anions as, OH^-, SO_3H^-, or CN^-, or in ammonia leads to an introduction of various groups into the 6-position of the ring (Baalen and Forrest, 1959; Viscontini and Weilenman, 1959; Forrest, Baalen, Viscontini and Piraux, 1960).

(3a-XXIII)   (3a-XXIV)

(3a-XXV)   (3a-XXVI)

Thus they obtained 2-amino-4,6-dihydroxypteridine (xanthopterin) (3a-XXVI, R = OH), 2,6-diamino-4-hydroxypteridine (3a-XXVI, R = NH_2) and the well known 2-amino-4-hydroxypteridine-6-carboxylic acid (3a-XXVI, R = CO_2H). The same sort of reaction can be expected with the sulphite ion, and they also isolated what they believed to be (3a-XXVI, R = SO_3H). But they seem to be mistaken as to the level of oxidation because their analytical figures suggest the tetrahydro-analogue (3a-XXV .H_2O, R = SO_3H).

2-Amino-4-hydroxypteridine-6-carboxamide

Forrest, Baalen, Viscontini and Piraux.

Helv. Chim. Acta, 1960, 43, 1005.

A, $C_7H_6N_4O_2$ B, $C_7H_{10}N_4O_2$

Found:	C, 40.02	H, 4.69	N, 40.22
Calc. for $C_7H_6N_4O_2$:	C, 40.8	H, 2.9	N, 40.8
Calc. for $C_7H_{10}N_4O_2$:	C, 40.0	H, 4.8	N, 40.0

2-Amino-4-hydroxypteridine-6-sulphonic acid

C , $C_6H_5N_5O_4S$

D , $C_6H_9N_5O_4S$

Found :	C, 27.15	H, 4.54	N, 25.8	S, 11.4
Calc. for $C_6H_5N_5O_4S.H_2O$:	C, 27.6	H, 2.7	N, 26.8	S, 12.3
Calc. for $C_6H_9N_5O_4S.H_2O$:	C, 27.05	H, 4.0	N, 25.5	S, 11.65

     Regarding the mechanism of the reduction, the same authors suggest that addition of the anion occurs through a 5,8-dihydro-intermediate (3a-XXIV), but they offer no evidence for this hypothesis. It seems more likely that such an addition would take place through a 7,8-dihydro structure, because the C,N-double bond is more easily polarized than is the C,C-double bond, and would lead an attack of the anion to the positive carbon atom. Such additions of anions to carbon atoms of heterocyclic compounds are well known. For example, CN^-, SO_3H^-, OH^- or $N_2H_3^-$ groups easily attack the 4-position of quinazoline (3a-XXVII) with the formation of addition compounds (3a-XXVIII) (R = CN, SO_3H, OH, or N_2H_3) (. Higashino, 1960).

(3a-XXVII)

(3a-XXVIII)

2,6-Dihydroxypteridine and 4,6-Dihydropteridine were both
reduced with potassium borohydride to a respective 2- and
4-hydroxy-7,8-dihydro-6-hydroxypteridines.   These
structures were confirmed by comparing with the
corresponding authentic samples unambiguously synthesized
by the method of Boon and Ramage (see p. 8; 94).

	Dihydro-2,6-dihydroxy-pteridine obtained by reduction	7,8-Dihydro-2,6-dihydropteridine obtained by synthesis
Rf. (NH_4Cl)	0.52 2B/3V	0.52 2B/3V
(Bu/Ac)	0.08 2B/3X	0.08 2B/3X
pK_a (basic)	2.80 ± 0.02	2.82 ± 0.02
(acidic)	10.23 ± 0.02	10.26 ± 0.03
UV-spectra	λ max. (mμ) log ε	λ max. (mμ) log ε
o	237, 265[*] 3.95, 3.46	237, 265[*] 3.95, 3.46
+	257, 317 3.94, 3.85	257, 318 3.94, 3.85
−	279 4.01	279 4.01
IR spectra	see Fig.40, p.207	see Fig.39, p.207

[*]Shoulder

	Dihydro-4,6-dihydroxy-pteridine obtained by reduction	7,8-Dihydro-4,6-dihydroxypteridine obtained by synthesis
Rf(NH$_4$Cl)	0.47 2/3B	0.47 2/3B
(Bu/Ac)	0.15 2X/3B	0.15 2X/3B
pK$_a$ (basic)	9.07 ± 0.02	9.07 ± 0.05
UV-spectra	λ max.(mμ)　　log ε	λ max.(mμ)　　log ε
o	275, 318　3.89, 3.69	274, 318　3.90, 3.69
–	275　　　　3.80	273　　　　3.83
IR-spectra	Fig. 42, p.208	Fig.41, p.208

Catalytic hydrogenation over palladium catalyst in 0.1N-potassium hydroxide solution gave the same results as above.　Although potassium amalgam reduction of 4,6-dihydroxypteridine gave 7,8-dihydro-4,6-dihydroxypteridine, 2,6-dihydroxypteridine was not reduced successfuly with potassium amalgam and 7,8-dihydro-2,6-dihydroxypteridine could not be detected in the reaction mixture.　This is due to the instability of the product under these conditions. 7,8-Dihydro-2,6-dihydroxypteridine also decomposed with potassium amalgam treatment and the product could not be detected by paper chromatography.

2,7-Dihydroxypteridine and 4,7-dihydroxypteridine were reduced with potassium borohydride, or with potassium amalgam, to the correspondigg dihydro-compounds. Catalytic hydrogenation over palladium catalyst in 0.1N-potassium hydroxide solution gave the same results.

The structure of the dihydro-4,7-dihydroxypteridine was shown to be 5,6-dihydro-4,7-dihydroxypteridine by synthesis (see p.95).   5,6-Dihydro-2,7-dihydroxypteridine was not obtained by synthesis because of technical difficulties (see p.94), and two possible structures, 5,6-dihydro- and 3,4-dihydro-2,7-dihydroxypteridine, remain for this compound.

	Dihydro-4,7-dihydroxy-pteridine obtained by reduction	5,6-Dihydro-4,7-dihydroxypteridine obtained by synthesis
Rf. (NH$_4$Cl)	0.54 2D/3V[*]	0.54 2D/3V[*]
(Bu/Ac)	0.08 2D/3V	0.08 2D/3V
pKa (acidic	8.45 $\pm$ 0.02	8.48 $\pm$ 0.05
UV-spectra	λmax.(mμ) log ε	λmax.(mμ) log ε
o	276, 328 3.78, 3.70	276, 328 3.78, 3.71
IR-spectra	See Fig.44, p.209	See Fig.43, p.209

[*] Violet fluorescence appeared after exposure to 245 mμ lamp.

Sodium dithionite reduction of 2,7-dihydroxypteridine gave a sulphur containing product, $C_6H_7N_4NaO_5S$, whose structure was not investigated further. 2,7-Dihydroxypteridine also gave an addition compound, $C_6H_4N_4Na_2O_5S.H_2O$, with sodium hydrogen sulphite.

6,7-Dihydroxypteridine was not reduced with potassium borohydride, sodium dithionite, or by hydrogenation over platinum or palladium catalyst. The reduction of this pteridine with sodium amalgam leads to elimination of the 7-hydroxy-group, giving 7,8-dihydro-6-hydroxypteridine (Albert, Brown and Cheeseman, 1952).

2,4,6-Trihydroxypteridine was reduced with potassium borohydride to a dihydro-compound. The only possible dihydro-2,4,6-trihydroxypteridine is known to be 7,8-dihydro-2,4,6-trihydroxypteridine. Catalytic hydrogenation of 2,4,6-trihydroxypteridine over palladium on carbon gave the same dihydro-compound. 7,8-Dihydro-2,4,6-trihydroxypteridine has been synthesized before (Boon and Leigh, 1952).

2,4,7-Trihydroxypteridine was not affected by reducing agents such as potassium borohydride, potassium amalgam, or by hydrogenation over palladium catalyst in 0.1N -potassium hydroxide solution.

2,6,7-Trihydroxypteridine was not affected by potassium borohydride or by hydrogenation over palladium catalyst. This compound behaved unusually towards potassium amalgam

reduction, and 7,8-dihydro-2,6-dihydroxypteridine was not detected in the reduction mixture, presumably because 7,8-dihydro-2,6-dihydroxypteridine is unstable to potassium amalgam (for the same reason as in the case of 2,6-dihydroxypteridine, see above).

4,6,7-Trihydroxypteridine was not affected by potassium borohydride or by hydrogenation over palladium catalyst. However, this compound has been reduced by sodium amalgam with elimination of the 7-hydroxy-group, giving 7,8-dihydro-4,6-dihydroxypteridine (Albert and Brown, 1953).

2,4,6,7-Tetrahydroxypteridine was not affected by potassium borohydride or by hydrogenation over palladium catalyst. This compound has been reduced by sodium amalgam with elimination of the 7-hydroxy group to 7,8-dihydro-2,4,6-trihydroxypteridine (Albert, Lister and Pedersen, 1956).

ii) The presence of groups other than hydroxy group.

Some hydroxypteridines having other substituents were also reduced in order to examine briefly the effect of such substituents on the reduction.

2-Amino-4,6-dihydroxypteridine (xanthopterin) was reduced to the known 2-amino-7,8-dihydro-4,6-dihydroxypteridine with potassium borohydride or sodium amalgam. This indicates a parallel between the effects of a 2-hydroxy- and a 2-amino-group on the course of reduction. This is of

interest in connection with naturally-occurring pteridines, almost all of which have an amino-group in the 2-position.

2-Hydroxy-6-methylpteridine (like 2-hydroxypteridine) was reduced with potassium borohydride to two compounds, one was an x,y-dihydro-2-hydroxy-6-methylpteridine and had quite similar properties (ultraviolet spectra and pKa) to 3,4-dihydro-2-hydroxypteridine. This suggests the 3,4-dihydro-structure for this compound. [The other product also had quite similar Rf values and fluorescence to 5,6,7,8-tetrahydro-2-hydroxypteridine]. The methyl group in the 6-position has therefore no appreciable effect on the reduction. This information is relevant to the folic acid series which always has a substituted methyl group in the 6-position.

	3,4-Dihydro-2-hydroxy-pteridine	3,4-Dihydro-2-hydroxy-6-methylpteridine
Rf.(NH_4Cl)	0.60 2B/3V	0.58 2B/3V
(Bu/Ac)	0.50 2B/3V	0.50 2B/3V
pKa (basic)	0	0.20 ± 0.06
(acidic)	12.5	13.05 ± 0.02
UV-spectra	λmax.(mμ) log ε	λmax.(mμ) log ε
o	248, 317 3.96, 3.88	248, 321 3.83, 3.92
–	281, 343 3.94, 3.82	282, 350 4.01, 3.84

iii) <u>Ionic species</u>.

A clear case of ionic species affecting reduction is that of the hydrogenation of 2-hydroxypteridine (see p.44). This effect arises from the fact that the neutral molecule (unlike the anion) is hydrated across the 3,4-double bond (Brown and Mason, 1956), and is therefore already a dihydropteridine.

iv) <u>Reducing agent</u>.

Close similarity was shown by the two reducing agents, potassium borohydride and hydrogenation over palladium catalyst in alkaline solution. There was however one exception. 2,4-Dihydroxypteridine, was successfully reduced over palladium catalyst but was not affected by potassium borohydride.

Palladium on carbon catalyst was more powerful than Adams' platinum oxide catalyst in alkaline solution, and this is seen in the rate of reduction by these two catalysts (see Table 4).

Table 4.

Reduction period of hydroxypteridines in 0.1N-potassium

hydroxide solution.

Pteridines	Catalyst	
	10%-palladium on carbon	Adams' platinum oxide
2-Hydroxy- a)	20 min.	
4-Hydroxy-	30 min.	
6-Hydroxy-	20 min.	
7-Hydroxy- b)	40 min.	
2,4-Dihydroxy-	40 min.	
2,6-Dihydroxy-	10 min.	7 hr. *
2,7-Dihydroxy-	70 min.	40 hr. *
4,6-Dihydroxy-	70 min.	
4,7-Dihydroxy- c)	17 hr.	
2,4,6-Trihydroxy-	10 min.	

a) mono-hydroxypteridine (1 m mole) in 1.5 eq. 0.1N-KOH

b) di-hydroxypteridine   (1 m mole) in 2 x 1.5 eq.

c) tri-hydroxypteridine   (1 m mole) in 3 x 1.5 eq.

   were reduced over 50 mg. 10%-palladium on carbon catalyst.

 * 5 mg. Adams' catalyst.

Sodium amalgam reduced all 6-hydroxypteridines to the corresponding 7,8-dihydro-6-hydroxypteridines, even when it required the elimination of a 7-hydroxy-group as in the case of 6,7-dihydroxypteridines. Two apparent exceptions were noted (the reductions of 2,6-dihydroxy- and 2,6,7-trihydroxy-pteridines) due to the instability of the product to this reagent.

Sodium dithionite produced a sulphur containing product (see e.g. 2,4-dihydroxypteridine, p.53) in the reduction of several polyhydroxypteridines.

v) <u>Positions and numbers of hydroxy groups</u>.

A systematic correlation between the facility of hydrogenation and the number and positions of hydroxy groups can be seen in Table 4, p. 64. It can be said generally that 6-hydroxypteridines are more easily reduced than the 7-isomers, and 2-hydroxypteridines are more easily reduced than the 4-isomers.   The results which were obtained by reduction of hydroxypteridines are summarized in Table 5, p. 66.

Table 5.
Reduction products of hydroxypteridines by various reducing agents.

	Potassium borohydride	Potassium amalgam	Sodium dithionite	Pd/C	Pt (Adams')	Raney-nickel
2-Hydroxypteridine	3,4-DH-2 5,6,7,8-TH-2	UI	3,4-DH-2 UI	3,4-DH-2 5,6,7,8-TH-2	3,4-DH-2 5,6,7,8-TH-2	3,4-DH-2 5,6,7,8-TH-2
4-Hydroxypteridine	x,y-DH-4 5,6,7,8-TH-4	UI 5,6,7,8-TH-4		UI 5,6,7,8-TH-4		5,6,7,8-TH-4
6-Hydroxypteridine	7,8-DH-6	7,8-DH-6 (1)	7,8-DH-6	7,8-DH-6		
7-Hydroxypteridine	5,6-DH-7	5,6-DH-7	RO (1)	RO		
2,4-Dihydroxypteridine	No	5,6,7,8-TH-4	5,6,7,8-TH-4 S	5,6,7,8-TH-4	5,6,7,8-TH-4	
2,6-Dihydroxypteridine	7,8-DH-2,6	D		7,8-DH-2,6		
2,7-Dihydroxypteridine	x,y-DH-2,7	x,y-DH-2,7	S	x,y-DH-2,7		
4,6-Dihydroxypteridine	7,8-DH-4,6	7,8-DH-4,6 (2)		5,6-DH-4,6		
4,7-Dihydroxypteridine	5,6-DH-4,7	5,6-DH-4,7		5,6-DH-4,7		
6,7-Dihydroxypteridine	No	7,8-DH-6 (1)	No	No	No	
2,4,6-Trihydroxypteridine	7,8-DH-2,4,6	7,8-DH-2,4,6		7,8-DH-2,4,6		
2,4,7-Trihydroxypteridine	No	No		No	No	
2,6,7-Trihydroxypteridine	No	D		No		
4,6,7-Trihydroxypteridine	No	7,8-DH-4,6 (2)		No		
2,4,6,7-Trihydroxypteridine	No	7,8-DH-2,4,6-(3)				

(1) Albert, Brown and Cheeseman, 1952
(2) Albert and Brown , 1953
(3) Albert, Lister and Pedersen, 1956

Key to Symbols

x,y-DH-4 = x,y-Dihydro-4-hydroxypteridine

5,6,7,8-TH-2 = 5,6,7,8-Tetrahydro-2-hydroxypteridine

UI   Unidentified unstable product

D   Decomposition

No   No reduction

RO   Ring opened product

S   Sulphur containing product.

b. Syntheses.

Syntheses Directed Towards Hydrogenated 2-Hydroxypteridines.

7,8-Dihydro-2-hydroxypteridine (and its 6-methyl-derivative).

The syntheses of 7,8-dihydropteridines have been well developed,
and 7,8-dihydro-2-hydroxy-4,6-dimethylpteridine has been
prepared (Lister and Ramage, 1953) (see p.10).   In the
present work, 7,8-dihydro-2-hydroxy-6-methylpteridine was
synthesized by a similar method, in order to compare the
reduction behaviour of 2-hydroxypteridine and its 6-methyl
derivative.   2-Hydroxy-6-methylpteridine was prepared from
the 7,8-dihydro-derivative by oxidation with potassium
permanganate, and reduced with potassium borohydride (see
p.62).   The 6-methyl-isomers, 2-hydroxy-6-methylpteridine,
7,8-dihydro-2-hydroxy-6-methylpteridine and x,y-dihydro-2-
hydroxy-6-methylpteridine, had quite similar properties,
pKa values, ultraviolet spectra and Rf. values to the
corresponding 2-hydroxypteridines (see Table 6, p. 104 and
Table 15, p. 120).   Although no 7,8-dihydropteridines
unsubstituted in the 6-position have been prepared, it was
hoped that 7,8-dihydroxy-2-hydroxypteridine could be
synthesized by using amino acetal in place of amino acetone
in the Lister-Ramage synthesis (see p. 6, 10).   Although some
difficulties were encountered (e.g. the tendency of
aminoacetaldehydes to dimerize to pyrazines), this new
synthetic method was successful.

Condensation of 2,4-dichloro-5-nitropyrimidine (3b-I) with amino acetal has been attempted before (Boon and Jones, 1950), but no product was isolated.   In the present work, all attempts to isolate (3b-II) from its mixture with the 2,4-disubstituted analogues were unsuccessful. Accordingly, the crude condensation product was hydrolyzed directly with

sodium hydroxide to give 4-β-diethoxyethylamino-2-hydroxy-5-nitropyrimidine (3b-III). At this stage the disubstituted derivative, 2,4-bis-β-diethoxyethylamino-5-nitropyrimidine, was easily removed because of its insolubility in N-sodium hydroxide solution. Hydrogenation of (3b-III) gave the 5-amino derivative (3b-IV). Attempted brief hydrolysis of the acetal group of (3b-IV) with 0.1N-hydrochloric acid gave a product showing three spots on paper chromatography. Various conditions of pH and reaction time were examined to separate three products. The first substance corresponded to (3b-VII), and the second substance was later confirmed as 7,8-dihydro-2-hydroxypteridine (3b-VI) by the synthesis described below, but an analytically pure sample could not be isolated from this reaction. The third substance was the acid decomposition product of 7,8-dihydro-2-hydroxy-pteridine.

(3b-VII)

A successful route was found in which (3b-III) was hydrolysed by acid before the hydrogenation. Thus, 2-hydroxy-4-formylmethylamino-5-nitropyrimidine (3b-V) was obtained from (3b-III) by refluxing with N-hydrochloric acid.

The aldehyde was quite unstable in alkali, and it was
found necessary to stop the neutralization of the above
reaction mixture at pH 4; neutralization even to pH 7
caused partial decomposition of the product. The aldehyde
(3b-V) was successfully hydrogenated over Raney-nickel in
methanol (but not in ethanol) to give 7,8-dihydro-2-
hydroxypteridine (3b-VI). This 7,8-dihydro-2-hydroxy-
pteridine (see p. 43) had a high basic pKa (see Table 9, p.107)
compared to 2-hydroxypteridine.

    5,6,7,8-Tetrahydro-2-hydroxypteridine. One
attempt to synthesize 5,6,7,8-tetrahydro-2-hydroxypteridine
through 8-benzyl-5,6,7,8-tetrahydro-2-hydroxypteridine has
been reported, but it was unsuccessful because of difficulty
in the debenzylation (Brook and Ramage, 1955) (see, p. 12).
On the other hand it has been known that 7,8-dihydro-
pteridines can be hydrogenated to 5,6,7,8-tetrahydro-
pteridines (Lister and Ramage, 1953). (This method is a little
ambiguous because of the possible hydrogen migration by the
metal catalyst). 5,6,7,8-Tetrahydro-2-hydroxypteridine was
synthesized from the above 7,8-dihydro-2-hydroxypteridine by
hydrogenation over Adams' catalyst in neutral aqueous solution
(hydrogenation in water gave better results than in acidic
conditions). The structure was confirmed as 5,6,7,8-
tetrahydro-2-hydroxypteridine by comparison of its pKa values,
and ultraviolet spectra with those of 4,5-diamino-2-

hydroxypyrimidine (see Table 8 , p.106,and Table13, p118).

The structure of the minor product obtained by reduction of 2-hydroxypteridine with potassium borohydride, and by hydrogenation over palladium, Raney-nickel, or Adams' catalyst in alkaline solution, was shown to be 5,6,7,8-tetrahydro-2-hydroxypteridine by comparison of its ultra-violet spectra and Rf values with the above (see p.42).

<u>5,6-Dihydro-2-hydroxypteridine.</u>   No attempts to prepare 5,6-dihydropteridines had previously been made. The two following routes are possibilities for the preparation of 5,6-dihydropteridines (3b-X):

a) by cyclization of 4,5-diaminopyrimidines substituted on the 4-amino group (e.g. 3b-VIII)

b) by cyclization of 4,5-diaminopyrimidines substituted on the 5-amino group (e.g. 3b-IX)

(Where R_1, R_2 and Y = OH or H;

   X = halogen;

   Z = -CHO, -COOH or any groups which can be

   changed to these groups)

Method (a) could not be used for the synthesis of 5,6-dihydro-2-hydroxypteridine because of difficulties in the preparation of intermediates of the type (3b-VIII). The only difficulty in method (b) is the preparation of 5-alkylaminopyrimidines. Direct alkylation leads to quaternization. However, two methods for indirect alkylations are possible. One is reduction of 5-formylaminopyrimidines with lithium aluminium hydride (Baker, Schaub and Joseph, 1954), and the other is

reductive alkylation (or reduction of the Schiff's base)
of 5-aminopyrimidines.   It is known that 5-amino-
pyrimidines condense with benzaldehyde to give Schiff's
bases (Traube and Nithak, 1906; Shirakawa, 1953), but
with aliphatic aldehydes only resinous products are
produced (Shirakawa, 1953).   The sole example of
reductive alkylation of aminopyrimidine is the conversion
of 5-amino-4-methylpyrimidine (3b-XI) to 5-ethylamino-4-
methylpyrimidine (3b-XII) using a palladium catalyst and
an excess of acetaldehyde (Overberger, Kogon and Einstman,
1954).

(3b-XI)   (3b-XII)

In the present work the following route was used to prepare
5,6-dihydro-2-hydroxypteridine (3b-XVI)

$$\text{H}_2\text{N} \quad \text{N} \atop \text{H}_2\text{N} \quad \text{N} \quad \text{OH}$$

(3b-XIII)

$$\text{EtO} \atop \text{EtO} \text{CHCHO}$$

(glyoxal monoacetal)

$$\text{EtO} \atop \text{EtO} \text{CHCH=N} \quad \text{N} \atop \text{H}_2\text{N} \quad \text{N} \quad \text{OH}$$

(3b-XIV)

H_2/Ni

$$\text{EtO} \atop \text{EtO} \text{CHCH}_2\text{NH} \quad \text{N} \atop \text{H}_2\text{N} \quad \text{N} \quad \text{OH}$$

(3b-XV)

$$\text{H} \atop \text{H} \quad \text{H} \atop \text{N} \quad \text{N} \atop \text{N} \quad \text{N} \quad \text{OH}$$

(3b-XVI)

4,5-Diamino-2-hydroxypteridine (3b-XIII) was condensed with glyoxal monodiethyl acetal (this was prepared from acrolein, Witzemann, Evans, Hass and Schroeder, 1943 b,a,c; Fischer and Baer, 1935), and although no product could be isolated paper chromatograms showed that the reaction had taken place. The reaction mixture was then hydrogenated over Raney-nickel catalyst, and 4-amino-5-β-diethoxyethylamino-2-hydroxy-pyrimidine (3b-XV) was isolated. The structure of (3b-XV) was confirmed by its non-identity with 5-amino-4-β-diethoxyethylamino-2-hydroxypyrimidine (3b-IV), prepared by an unambiguous synthesis (see, p.68). The pyrimidine gave a yellow amorphous product on treatment with N-hydrochloric acid. This substance is believed to be 5,6-dihydro-2-hydroxypteridine because pure 5,6-dihydro-4-hydroxypteridine was made from 4,5-diamino-6-hydroxy-

pteridine in the same way (see below). Although a good analysis could not be obtained for this compound because of partial decomposition during purification, paper chromatography indicated its essential homogeneity and that it was not x,y-dihydro-2-hydroxypteridine.

3,4-Dihydro-2-hydroxypteridine. No attempts to prepare 3,4-dihydropteridines have been previously made. However, an example of the synthesis of a fused 3,4-dihydropyrimidine ring is seen in the preparation of 3,4-dihydroquinazoline (3b-XVIII)from the o-aminobenzylamine derivative (3b-XVII) Gabriel and Jansen, 1890).

(3b-XVII)   (3b-XVIII)

The following routes were considered for the synthesis of 3,4-dihydro-2-hydroxypteridine (3b-XXI):

(3b-XIX)   H₂/Pt   (3b-XX)

ClCO₂Et,

Urea △,

or NH₂CO₂Et

(3b-XXI)

2-Amino-3-formylpyrazine oxime (3b-XIX) was synthesized by
a known method (Albert, Brown and Wood, 1956). Reduction
of the oxime (3b-XIX) to 2-amino-3-aminomethylpyrazine
(3b-XX) under several sets of conditions was examined
(hydrogenation over Adams', palladium, or Raney-nickel
catalysts, and reduction with lithium aluminium hydride,
sodium amalgam (under neutral conditions) and sodium
hydrosulphite). The catalytic hydrogenation of the
corresponding nitrile was also unsuccessful.

The most promising result was the hydrogenation over Adams'
catalyst where the oxime absorbed 2.5 moles of hydrogen
(theoretical amount is 2 moles) and gave a green oil.
Chromatography showed that the product had one main spot,
but no solid material could be isolated from the reaction
mixture, and treatment of the crude product with urea, cyanic
acid, ethyl chloroformate, or with urethane gave a complex
mixture in which no product identical with the x,y-dihydro-
2-hydroxypteridine could be seen when compared on a paper
chromatogram.

Another synthetic route through 2-amino-3-carboxy-
pyrazine (3b-XXII) was examined:

(3b-XXII)   (3b-XXIII)   (3b-XXIV)

(3b-XXV)

HBr,
urea,
or KCNO

(3b-XXII) was prepared from 2,4-dihydroxypteridine (Weijlard, Tischler and Erickson, 1945), but direct reduction of the acid (3b-XXIII) with aluminium amalgam, failed. However, the methyl ester (3b-XXIII) was easily reduced with lithium aluminium hydride to 2-amino-3-hydroxymethylpyrazine (3b-XXIV). However, the attempted replacement of the hydroxy group with bromine by heating with hydrobromic acid led only to decomposition. Other attempts to utilize this intermediate (3b-XXIV), such as fusion with urea, or reaction with cyanic acid, gave no better results (such reactions had been successfully carried out in the quinazoline field, Söderbaum and Widman, 1889; Gabriel and Stelzner, 1896).

Another approach to 3,4-dihydro-2-hydroxypteridine was planned, starting from the hydrogenated pyrimidine, (3b-XXVI) $\longrightarrow$ (3b-XXI). In hydrochloric acid 4,5-diamino-2-hydroxypyrimidine (3b-XXVI) absorbed one mole of hydrogen over palladium catalyst. The product, however, did not correspond to $C_4H_8N_4O.HCl$, 4,5-diamino-dihydro-2-hydroxypteridine (3b-XXVII), but analysed as $C_4H_7N_3O_2.HCl.\frac{1}{2}H_2O$. These figures show that one amino group of (3b-XXVII) was replaced by a hydroxyl group and the compound could therefore not be used as an intermediate for dihydro-2-hydroxypteridine (3b-XXI).

(3b-XXVI)   (3b-XXVII)

(3b-XXI)

Syntheses Directed Towards Hydrogenated 4-Hydroxypteridines

5,6,7,8-Tetrahydro-4-hydroxypteridine. An unambiguous route
to 5,6,7,8-tetrahydropteridines has been described by Brook
and Ramage (1955, 1957) (see p. 11). In using this method
it is essential to protect all groups (such as NH_2 or OH)
which have hydrogen atoms tautomerizable with the ring
nitrogen atoms. This protection, which could be afforded
by O-alkylation (-OMe) or N-benzylation (-NHCH$_2$Ph), is
required to prevent alternative ring closure to pyrimidino-
imidazoles (Ramage and Trappe, 1952; Brook and Ramage, 1955,
1957).

Failure to afford such protection to groups other
than those forming the pyrazine ring has, in practice, limited

the number of known 5,6,7,8-tetrahydropteridines to those
having a hydrogen-, methyl-, or chloro-group in the 2-, or
the 4-position.   The solitary exception is 5,6,7,8-
tetrahydro-2-hydroxy-4-methyl-8-benzylpteridine (1b-XXVI)
which was prepared by hydrolysis of the corresponding 2-
chloro derivative (see p. 12).

In the present work, this method was attempted for the
4-hydroxy-isomer but found unsuccessful, although, as will
be shown later, the desired substance was eventually
obtained by modification of the route:

(3b-XXVIII)   (3b-XXIX)   (3b-XXX)

(3b-XXXI)   (3b-XXXII)

4,6-Dichloro-5-nitropyrimidine (3b-XXVIII) was condensed with
β-benzylaminoethanol in chloroform to give (3b-XXIX) but
the product could not be isolated. The product was
hydrogenated over Raney-nickel and 5-amino-4-(benzyl-β-
hydroxyethylamino)-6-chloropyrimidine hydrochloride (3b-XXX)
was isolated. (This hydrochloride, $C_{13}H_{16}Cl_2N_4O$, was
isomerized when boiled in ethanol to an unidentified compound,
$C_{13}H_{16}Cl_2N_4O$, which did not cyclize on treatment with
phosphorus trichloride). The 5-aminopyrimidine hydrochloride
(3b-XXX) was cyclised directly with phosphorus trichloride to
8-benzyl-4-chloro-5,6,7,8-tetrahydropteridine (3b-XXXI) the
structure of which was confirmed by reduction with sodium in
liquid ammonia to the known 5,6,7,8-tetrahydropteridine
(3b-XXXII). However, the 4-chloro group could not be replaced
with a hydroxyl group by such treatment as refluxing for three
hours with (a) pH 5 buffer, (b) glacial acetic acid plus sodium
acetate, (c) 6N-hydrochloric acid, (d) 12N-hydrochloric acid,
(e) N-sodium hydroxide, or (f) methanolic sodium methoxide.
Heating in triethylene glycol at 120° with sodium hydroxide
decomposed the material.

Because of the difficulty of replacement of the
4-chloro group in the above tetrahydropteridine, it seems
reasonable to introduce other types of group into the 4-
position. It is well known, that the benzyloxy group can be
reduced to a hydroxy group by catalytic hydrogenolysis using
palladium on carbon. The following route was therefore

attempted.

(3b-XXVIII)   (3b-XXXIII)

(3b-XXXIV)

Attempts to isolate the product from each of the steps (1, and 2) were unsuccessful, but (3b-XXXIII) was finally isolated as the hydrochloride in low yield. Treatment of (3b-XXXIII) with phosphorus trichloride gave the pyrimidine (3b-XXXIV) instead of the desired tetrahydropteridine, and the method was therefore abandoned.

However, the facile hydrolysis of the 4-benzyloxy group suggested a new synthetic route in which ethyl replaced benzyl.

(3b-XXVIII)   (3b-XXXV)   (3b-XXXVI)

(3b-XXXVII)   (3b-XXXVIII)   (3b-XXXIX)

4-Chloro-6-ethoxy-5-nitropyrimidine (3b-XXXV) (Boon and Jones,
1951) was condensed with β-benzylaminoethanol and the
condensation product (3b-XXXVI) was hydrogenated over Raney-
nickel. The aminopyrimidine (3b-XXXVII) could not be
isolated, but was treated with phosphorus trichloride at room
temperature to cyclise it. Not only cyclisation but also
simultaneously slow hydrolysis of the 4-ethoxy group occurred.
Paper chromatography showed that the hydrolysis was complete
after two days at room temperature, and from the reaction
mixture 8-benzyl-5,6,7,8-tetrahydro-4-hydroxypteridine
(3b-XXXVIII) was isolated. Debenzylation of (3b-XXXVIII) was

84

accomplished with sodium in liquid ammonia, and 5,6,7,8-
tetrahydro-4-hydroxypteridine (3b-XXXIX) was obtained. By
comparison of their pKa values, ultraviolet and infrared
spectra, the 5,6,7,8-tetrahydro-4-hydroxypteridine was
shown to be identical with the product obtained by reduction
of 4-hydroxypteridine (see p.48).

5,6-Dihydro-4-hydroxypteridine (3b-XLII) was
synthesized by essentially the same method as was used in
the preparation of the 2-hydroxy-isomer (see p.74).

(3b-XL)

(3b-XLI)

(3b-XLII)

4,5-Diamino-6-hydroxypyrimidine (3b-XL), hydrogenated over
Raney-nickel in ethanol containing glyoxal monoacetal,
gave 4-amino-5-β-diethoxyethylamino-6-hydroxypyrimidine
(3b-XLI). This pyrimidine, when boiled with N-hydrochloric
acid for one minute, gave 5,6-dihydro-4-hydroxypteridine

(3b-XLII). The compound was not identical with the x,y-dihydro-4-hydroxypteridine, formed by reduction, which must therefore be an isomer.

	x,y-Dihydro-4-hydroxypteridine obtained by reduction	5,6-Dihydro-4-hydroxypteridine obtained by synthesis
colour	yellow	colourless
m.p.	263-265 (decomp.)	230 (decomp.)
pKa basic	0.32 ± 0.05	2.94 ± 0.04
acidic	12.13 ± 0.03	10.24 ± 0.1

7,8-Dihydro-4-hydroxypteridine (and 7,8-dihydro-4-hydroxy-6-methylpteridine). A method similar to the one used for the synthesis of 7,8-dihydro-2-hydroxypteridine (3b-VI) (see p.68) was attempted for the preparation of 7,8-dihydro-4-hydroxypteridine, but it failed to yield a 7,8-dihydro compound.

3,7-Dihydro-4-hydroxypteridine. No suitable method could be found to prepare 3,7-dihydro-4-hydroxypteridine. However, 3,7-dihydro-4-hydroxypteridine and its 7,8-dihydro-isomer have a common cation. If the 3,7-isomer is more stable than the 7,8-dihydro-isomer, this compound would be obtained by any syntheses suitable for the 7,8-dihydro-isomer. Unfortunately, the synthesis of 7,8-dihydro-4-hydroxypteridine was also unsuccessful.

Cl

O₂N

Cl

(3b-XXVIII)

Cl

O₂N

HN

CH₂CH OEt OEt

(3b-XLIII)

OH

O₂N

HN

CH₂CH OEt OEt

(3b-XLIV)

H₂/Ni
or Zn-AcOH

H⁺

OH

H₂N

HN

CH₂CH OEt OEt

(3b-XLV)

OH

O₂N

HN

CH₂CHO

(3b-XLVI)

4,6-Dichloro-5-nitropyrimidine (3b-XXVIII) was condensed with
aminoacetal and although the intermediate (3b-XLIII) could
not be isolated, the condensed product was hydrolysed by
heating with N-sodium hydroxide to give 4-β-diethoxyethylamino-
6-hydroxy-5-nitropyrimidine (3b-XLIV).   This absorbed five
moles of hydrogen (cf. three moles for a nitro group) over
Raney-nickel and none of the desired aminopyrimidine (3b-XLV)
could be isolated.   Reduction of (3b-XLIV) with zinc dust in
acetic acid also gave a mixture from which (3b-XLV) could not

be isolated. Hydrolysis of (3b-XLIV) with N-hydrochloric acid gave a product analysing for $C_{12}H_8N_8O_6 \cdot \frac{1}{2}H_2O$, and this compound absorbed ten moles of hydrogen over Raney-nickel (calculated on the above formula) and gave a dark resinous product. No 7,8-dihydro-4-hydroxypteridine was obtained by this method.

Because of the difficulty of synthesizing the 6-unsubstituted derivative, the synthesis of 7,8-dihydro-4-hydroxy-6-methylpteridine was attempted because it should have similar pKa values and spectra. The following route was used:

(3b-XXVIII)   (3b-XLVII)   (3b-XLVIII)

4,6-Dichloro-5-nitropyrimidine was condensed with aminoacetone by Boon's method (Boon and Jones, 1951), and the product (presumably 3b-XLVII) was hydrolyzed with aqueous ethanol to 4-acetonylamino-6-hydroxy-5-nitropyrimidine (3b-XLVIII). However, in the hydrogenation of the pyrimidine (3b-XLVIII) over Raney-nickel, a side-reaction took place similar to that

which happened in the reduction of the 4-β-diethoxyethylamino-isomer (3b-XLIV) (see p. 86). No 7,8-dihydro-4-hydroxy-6-methylpteridine was obtained.

1,2-Dihydro-4-hydroxypteridine. The 1,2-dihydro-structure is improbable for the reduction product of 4-hydroxy-pteridine, because it was found possible to reduce the x,y-dihydro-4-hydroxypteridine further with potassium borohydride or by hydrogenation over Raney-nickel catalyst to give 5,6,7,8-tetrahydro-4-hydroxypteridine.

No attempts have been previously made to prepare 1,2-dihydropteridines. An example of the synthesis of a fused 1,2-dihydropyrimidine ring is seen in the preparation of 3-phenyl-1,2-dihydro-4-quinazoline (3b-L) from o-aminobenzanilide (3b-XLIX) and formaldehyde (Feldman and Wagner, 1942).

(3b-XLIX)   (3b-L)

Because this reaction seemed to offer an easy opportunity to obtain a 1,2-dihydropteridine, 2-amino-3-carbamoylpyrazine (3b-LI) was warmed with formaldehyde but no reaction occurred under the described conditions.

(3b-LI)   (3b-LII)

Synthesis Directed Towards Hydrogenated 7-Hydroxypteridine

5,6-Dihydro-7-hydroxypteridine. As it seemed likely that

the reduction product of 7-hydroxypteridine had this

constitution, its synthesis was attempted by the following

three routes:

a) The reduction of a Schiff's base (3b-LXVI) of ethyl

glyoxylate hemiacetal and 4,5-diamino-6-hydroxypyrimidine gave

the corresponding 5-alkylaminopyrimidine (3b-LXVII) which

cyclized to 5,6-dihydro-4,7-dihydroxypteridine (see, p.95).

Unfortunately this promising method was not successful with

4,5-diaminopyrimidine (3b-LIII). Thus 4,5-diaminopyrimidine

(3b-LIII) showed no tendency to condense with ethyl glyoxylate

hemiacetal (3b-LIV) in ethanol, and although it did so in

aqueous ethanol, there followed spontaneous cyclization to

7-hydroxypteridine (3b-LVI) and no Schiff's base (3b-LV)

could be isolated.

(3b-LIII)

(3b-LIV)

(3b-LV)

(3b-LVI)

b) By analogy with a derivative of 5,6-dihydro-7-amino-pteridine (2d-V) which has been prepared through the 5-cyanomethylaminopyrimidine (2d-IV) (Blicke and Godt, 1954) (see p.40), 4,5-diaminopyrimidine (3b-LIII) was condensed with formaldehyde and hydrogen cyanide to 4-amino-5-cyanomethylaminopyrimidine (3b-LVII). However, this compound (3b-LVII) was quite unstable to acid and alkali (hydrolysis) and it decomposed to 4,5-diaminopyrimidine (3b-LVI) and hydrogen cyanide on attempted cyclization.

(3b-LVI)   (3b-LVII)

c) An attempted preparation of 5,6-dihydro-7-hydroxypteridine through a 4-substituted aminopyrimidine (see p.72) is shown below, but it was unsuccessful:

(3b-LVIII)

(3b-LIX)

(3b-LX)

Condensation of 4-amino-5-bromopyrimidine (3b-LVIII) with phthaloylglycyl chloride gave 5-bromo-4-phthaloylglycylamino-pyrimidine (3b-LIX). However, the amide linkage between

the phthaloylglycyl group and the 4-aminopyrimidine was so
labile that 2-amino-5-bromopyrimidine (3b-LVIII) was formed
by hydrolysis of (3b-LIX) with hydrazine hydrate or with acid,
and none of the desired (3b-LX) was obtained. These three
routes are therefore abandoned.

As synthetic methods were unsuccessful, conversion of
the ring opened product obtained by reduction of 7-hydroxy-
pteridine (believed to be[*] 4-amino-5-carboxymethylamino-
pyrimidine; 3b-LXI) to 4-amino-5-cyanomethylaminopyrimidine
(3b-LVII) was attempted. The methyl ester (3b-LXII) gave
x,y-dihydro-7-hydroxypteridine on treatment with aqueous or
methanolic ammonia. Heating the ammonium salt of the acid
(3b-LXI) gave the same x,y-dihydro-7-hydroxypteridine, but
ammonolysis of this (3b-LXIII) was unsuccessful.

---

[*]This constitution was later established, see p.111 .

HO$_2$CCH$_2$NH ⟶ CH$_3$O$_2$C-CH$_2$NH

(3b-LXI)   (3b-LXII)

H$_2$N.COCH$_2$NH

(3b-LXIV)   (3b-LXIII)

NC.CH$_2$NH

(3b-LVII)

Later, confirmation of the constitution of (3b-LXI) established
that of x,y-dihydro-7-hydroxypteridine as 5,6-dihydro-7-
hydroxypteridine.   Hence other attempts to synthesize
(3b-LXIII) were dropped.

Syntheses Directed Towards Hydrogenated 2,4-Dihydroxypteridine.

Because of the instability of tetrahydro-2,4-dihydroxy-
pteridine to oxidation (see p.51), a route through 7,8-
dihydro-2,4-dihydroxypteridine was sought. This involved
condensation of 2,4,6-trichloro-5-nitropyrimidine with

aminoacetal. A complex mixture of products resulted, but
none of the desired substance was isolated. This synthesis
was not further pursued as the constitution of the tetrahydro-
compound is not in doubt.

Syntheses Directed Towards Hydrogenated 2,6-Dihydroxypteridine.

7,8-Dihydro-2,6-dihydroxypteridine was synthesized
according to the method of Boon, Jones and Ramage (1951) (see
p. 8). The 7,8-dihydro-2,6-dihydroxypteridine was identical
with the sole product obtained by reduction of 2,6-dihydroxy-
pteridine (see p. 57).

Syntheses Directed Towards Hydrogenated 4,6-Dihydroxypteridine.

7,8-Dihydro-4,6-dihydroxypteridine was synthesized
according to the method of Boon, Jones and Ramage (1951) (see
p.8). The 7,8-dihydro-4,6-dihydroxypteridine was identical with
the sole product obtained by reduction of 4,6-dihydroxypteridine
(see p. 58).

Syntheses Directed Towards Hydrogenated 2,7-Dihydroxypteridine.

5,6-Dihydro-2,7-dihydroxypteridine. The synthesis of
this compound by the same method used for the preparation of
5,6-dihydro-4,7-dihydroxypteridine (see p.95), proved
unsuccessful. Because condensation of 4,5-diamino-2-hydroxy-
pyrimidine and ethyl glyoxylate hemiacetal gave 2,7-dihydroxy-
pteridine in place of the desired Schiff's base. Proceeding
by another route 4,5-diamino-2-hydroxypteridine did not give
a cyanomethyl-derivative as did 4,5-diaminopyrimidine.

Synthesis Directed Towards Hydrogenated 4,7-Dihydroxypteridine.

5,6-Dihydro-4,7-dihydroxypteridine (3b-LXVIII) was synthesized
by the following route (see also p.71), which is an entirely
new method:

(3b-LXV)   (3b-LXVI)

(3b-LXVII)   (3b-LXVIII)

The reduction of a Schiff's base is a well known
method of preparing a secondary amine (Emerson, 1948).
4-Amino-5-ethoxycarbonylmethylenamino-6-hydroxypyrimidine
(3b-LXVI) (Pfleiderer, 1959) absorbed one mole of hydrogen
over Raney-nickel and gave 4-amino-5-ethoxycarbonylamino-6-
hydroxypyrimidine (3b-LXVII).   On treatment with hydrochloric
acid, this pyrimidine gave 5,6-dihydro-4,7-dihydroxypteridine
(3b-LXVIII).   This substance was shown to be identical with
the dihydro-4,7-dihydroxypteridine obtained as sole product
by reduction of 4,7-dihydroxypteridine (see p.59).

Synthesis of 7,8-Dihydro-4,6-dimethylpteridine. The synthesis of unsubstituted 7,8-dihydropteridine was desired in order to lay a foundation for correlating the basic pK_a values of 7,8-dihydropteridines and of the corresponding pteridines. However, no suitable method was found to prepare 7,8-dihydropteridine. Fortunately, however, it was found possible to prepare a simple methyl derivative, 7,8-dihydro-4,6-dimethylpteridine, by the following route:

(3b-LXIX)

(3b-LXX)

(3b-LXXI)

(3b-LXXII)

2-Chloro-7,8-dihydro-4,6-dimethylpteridine (3b-LXXI) has been prepared by Lister and Ramage (1953) from 2,4-dichloro-6-methyl-5-nitropyrimidine (3b-LXIX) via 4-acetonylamino-2-chloro-

6-methyl-5-nitropyrimidine (3b-LXX). Replacement of a 2-chloro-group by hydrogen had not been attempted before. Reduction with hydriodic acid was unsuccessful in this case, as the dihydropteridine was unstable to such conditions. However, 7,8-dihydro-4,6-dimethylpteridine was obtained by catalytic hydrogenation of 2-chloro-7,8-dihydro-4,6-dimethylpteridine over palladium on carbon catalyst.

c. Ionization Constants[*].

Ionization constants are very useful to help in identification of substances which have no melting points and have been used several times for this purpose in the preceding pages (results summarized in Table 7). But apart from this, ionization constants yield two further types of information, both of them important.

First, an ionization constant can indicate which of the ionic species of the molecule is present in the solution at a particular pH. This information is essential when correlation of ultraviolet spectra and structure is attempted.

Second, information can be obtained from ionization constants which concerns directly the molecular structure. Although it is difficult to discuss the molecular structure of an isolated compound with only the information supplied by its ionization constants, one can do so when such information is available about a series of related compounds.   In such a case, a good deal of important information on the structure of a new compound in a series can be obtained from a study of the ionization constants of

[*]The ionization constants of several hydrogenated hydroxy-pteridines, obtained by synthesis and by reduction, are shown in Table 6 (p.104) and 7 .   They are expressed as pKa values; which are negative logarithms of the constants.   The higher the pKa value the stronger the base, and the weaker the acid.

the series.

In the present work, ionization constants of a number of (mainly hydrogenated) pteridines were determined for the above reasons, and the values are summarized in Table 6, p. 104.

The following paragraphs exemplify how knowledge of ionization constants was used in the present work to throw light on structures.

(a) When one looks at the structure of 5,6,7,8-tetrahydropteridine (3c-II), it is evident that this substance may be thought of as 4,5-diaminopyrimidine (3c-I), in which the two primary amino groups are alkylated by ethylene. Hence the two substances should have similar ionization constants. This turns out to be the case, for 4,5-diaminopyrimidine has pKa 6.03 and 5,6,7,8-tetrahydropteridine has pKa 6.63 (see Table 8).

(3c-I)

(3c-II)

The charge of the cation is shared between $N_{(1)}$, $N_{(3)}$ and the 4-amino group. The 5-amino group has almost no basic properties.

It is known that acylation of $N_{(8)}$ strikingly reduces the basic strength of this molecule.

In the present work, it was seen that 5,6,7,8-tetrahydro-4-hydroxypteridine (pK_a, 3.86, 10.13) is related in this way to 4,5-diamino-6-hydroxypyrimidine (pKa 3.57, 9.86). Hence the pKa of the tetrahydro-2-hydroxypteridine (obtained by reducing 7,8-dihydro-2-hydroxypteridine, and suspected to be the 5,6,7,8-tetrahydro derivative) was examined to see if it had a pKa similar to that of 4,5-diamino-2-hydroxypteridine. The tetrahydro-2-hydroxypteridine had pKa values (4.35 and 12.5) similar to those of 4,5-diamino-2-hydroxypyrimidine (4.37 and 11.45) and the structure was suggested to be 5,6,7,8-tetrahydro-2-hydroxypteridine.

(b) Usually, 7,8-dihydropteridine have much higher pKa values (both acidic and basic) than have the corresponding pteridines (Table 9, p. 107). This difference does not exist if <u>hydrated</u> forms of the non-hydrogenated pteridines are used for comparison (only 2-, and 6-, hydroxypteridines have stable hydrated forms). The hydrated form of 6-hydroxypteridine, which is actually 7,8-dihydro-6,7-dihydroxypteridine (3c-IV) (Brown and Mason, 1956) has a molecular structure similar to 7,8-dihydro-6-hydroxypteridine, and shows the same base-strengthening and acid-weakening effect (Table 9, p. 107), when compared with the anhydrous form of 6-hydroxypteridine. This base strengthening affect is considered to be due to resonance stabilization of the cations of the 7,8-dihydro structure, (3c-V) ⟷ (3c-VI), (R = H, or OH).

(3c-III)

(3c-IV)

(3c-V)

(3c-VI)

This kind of base strengthening effect has been shown
(Albert, Goldacre and Phillips, 1948) to be general in those
nitrogen heterocyclic compounds having a p-amino structure
which permits a resonance stabilization of the cation as
above (Table 10, p.108). The base strengthening effect due
to the o-amino structure is much less marked than that due to
the p-amino structure (Table 10, p.108), and m-amino groups
show only the expected small inductive effect.

The constitution of x,y-dihydro-2-hydroxypteridine is
also illuminated by comparison with the hydrated form of 2-
hydroxypteridine, neither of which has any basic pKa value
higher than 2, and both of which have very high acidic pK's
(12.6 and 11.1 respectively). It has been known that 2-
hydroxypteridine is hydrated at the 3,4-position (Brown and

Mason, 1956; see p. 44). Again, x,y-dihydro-2-hydroxy-6-methylpteridine has pKa values (both basic and acidic) somewhat similar to those of the hydrated 2-hydroxy-6-methyl-pteridine (Table 9, p. 107). For this reason, and because the ultraviolet spectra of the neutral molecules of hydrated 2-hydroxypteridines and their x,y-dihydro compounds are similar (see p.113), it is suggested that x,y-dihydro-2-hydroxy-pteridine has the 3,4-dihydro structure. (The close similarity of 2-hydroxypteridine and its 6-methyl derivative suggest that these two compounds are hydrated at the same positions). It is unfortunate that it proved impossible to synthesize 3,4-dihydro-2-hydroxypteridine (see p. 75, for attempts).

c) x,y-Dihydro-4-hydroxypteridine is not an appreciably stronger base than 4-hydroxypteridine (see Table 9, p.107). This may seem to support the 3,7-dihydro-structure (3c-V) for this compound, because it was found that 7,8-dihydro-pteridines are much stronger bases than the corresponding pteridines.

(3c-V)

However, the other two possible dihydro-4-hydroxypteridines would exist mainly in the lactam forms (3c-VI) and (3c-VII), and such structures can not take part in the above base strengthening resonance.

(3c-VI)   (3c-VII)

The acidic pKa of x,y-dihydro-4-hydroxypteridine is much
higher than that of 4-hydroxypteridine.   This acid
weakening effect might be expected from the above three
formulae but it does not help in the choice of any one of
these structures.

In conclusion, no effective information on the
structure of x,y-dihydro-4-hydroxypteridine can be obtained
from ionization constants at the present stage.

Table 6

Ionization constants of pteridines and hydrogenated pteridines
(obtained in the present work except where indicated) (20°)

Pteridines	basic	acidic
2-Hydroxy-6-methylpteridine		8.0 *(anhydrous)
	0.2	11.0 *(hydrated)
Dihydropteridines		
7,8-Dihydro-4,6-dimethylpteridine	6.00 ± 0.03	
7,8-Dihydro-2-hydroxypteridine	3.50 ± 0.02	***
3,4-Dihydro-2-hydroxypteridine	0	12.6
7,8-Dihydro-2-hydroxy-6-methyl-pteridine	3.42 ± 0.06	11.85 ± 0.02
3,4-Dihydro-2-hydroxy-6-methyl-pteridine	0.20 ± 0.06	13.05 ± 0.02
7,8-Dihydro-2-hydroxy-4,6-dimethyl-pteridine	3.99 ± 0.02	12.50 ± 0.04
5,6-Dihydro-4-hydroxypteridine	2.94 ± 0.04	10.24 ± 0.1
x,y-Dihydro-4-hydroxypteridine	0.32 ± 0.05	12.13 ± 0.03
7,8-Dihydro-6-hydroxypteridine	4.53 ± 0.03**	10.54 ± 0.02**
5,6-Dihydro-7-hydroxypteridine	3.36 ± 0.01**	9.94 ± 0.05**
7,8-Dihydro-2,6-dihydroxypteridine	2.80 ± 0.02	10.22 ± 0.01
x,y-Dihydro-2,7-dihydroxypteridine		5.84 ± 0.02
7,8-Dihydro-4,6-dihydroxypteridine		9.14 ± 0.02
5,6-Dihydro-4,7-dihydroxypteridine		8.55 ± 0.02
7,8-Dihydro-2,4,6-trihydroxypteridine		7.07 ± 0.03
Tetrahydropteridines		
5,6,7,8-Tetrahydro-2-hydroxypteridine	4.35 ± 0.05	12.5
5,6,7,8-Tetrahydro-4-hydroxypteridine	3.86 ± 0.02	10.13 ± 0.03

*Determined by Dr. D.D. Perrin using rapid titration method.

**Albert, Brown and Cheeseman, 1952.

***Because of its instability in strong alkali, no exact pK_a value
was obtained.

Table 7

Use of ionization constants to establish identity.

pK_a values of hydrogenated pteridines prepared by synthesis and by reduction.

	pK_a (20°)	
	(basic)	(acidic)
7,8-Dihydro-2,6-dihydroxypteridine (authentic)	2.82 ± 0.02	10.26 ± 0.03
Dihydro-2,6-dihydroxypteridine (by reduction)	2.80 ± 0.02	10.23 ± 0.02
7,8-Dihydro-4,6-dihydroxypteridine (authentic)		9.07 ± 0.05
Dihydro-4,6-dihydroxypteridine (by reduction)		9.07 ± 0.02
5,6-Dihydro-4,7-dihydroxypteridine (authentic)		8.45 ± 0.02
Dihydro-4,7-dihydroxypteridine (by reduction)		8.48 ± 0.05
5,6,7,8-Tetrahydro-4-hydroxypteridine (authentic)	3.87 ± 0.02	10.10 ± 0.03
Tetrahydro-4-hydroxypteridine (by reduction)	3.86 ± 0.02	10.13 ± 0.03

Table 8.

pK$_a$ values of tetrahydropteridines and the corresponding 4,5-diaminopyrimidines.

	pK$_a$ (20°)	
	basic	acidic
5,6,7,8-Tetrahydropteridine	6.63[*]	
4,5-Diaminopyrimidine	6.03[**]	
5,6,7,8-Tetrahydro-4-hydroxypteridine	3.86	10.13
4,5-Diamino-6-hydroxypyrimidine	3.57[**]	9.86[**]
5,6,7,8-Tetrahydro-2-hydroxypteridine	4.35	12.5
4,5-Diamino-2-hydroxypyrimidine	4.37[**]	11.45[**]

[*] Brook and Ramage, 1957.

[**] Mason , 1954.

Table 9

pK$_a$ values of hydroxypteridines and their dihydro derivatives.

	Pteridines				7,8-Dihydropteridines		x,y-Dihydropteridines	
	Anhydrous		Hydrated					
	(basic)	(acidic)	(basic)	(acidic)	(basic)	(acidic)	(basic)	(acidic)
4,6-Dimethylpteridine	_ [1]				6.00			
2-Hydroxypteridine		7.7[2]	2[4]	11.05[2]	3.50	12[5]	2	12.6
2-Hydroxy-6-methylpteridine		8.0[3]	-0.4	11.0 [3]	3.42	11.85	0.2	13.05
2-Hydroxy-4,6-dimethylpteridine		Substance unknown			3.99	12.50		
4-Hydroxypteridine	-0.17	7.89[6]	Does not hydrate				0.32	12.13
6-Hydroxypteridine		6.45[2]	3.67[4]	9.90[2]	4.78	10.54		
2,6-Dihydroxypteridine		5.99,9.66[2]		8.84,10.29[2]	2.80	10.22		
4,6-Dihydroxypteridine		6.05,9.51[2]		8.34,10.08[2]		9.14		

1) This compound is **not** known, but the pK$_a$ values of similar methyl derivatives (respectively 2.94 and 2.93 for 4-methyl- and 6,7-dimethyl-pteridines) suggest that the pK$_a$ value of this compound is about 3.

2) Perrin and Inoue, 1960.

3) Kindly measured by Dr. D.D. Perrin by a special rapid technique.

4) Albert, Brown and Cheeseman, 1951.

5) This compound has an acidic pK$_a$ near 12, but because of its instability in strong alkali a good value was not obtained.

6) Brown and Mason, 1956.

d. Spectra

i) Ultraviolet Absorption Spectra

Ultraviolet spectra are important in molecular structure determination, not only in identification of specimens prepared by different routes, but also for the fundamental information that they can contribute (see p. 31).

In the present work, ultraviolet spectra of hydrogenated pteridines were used for both reasons. The spectra were determined on each ionic species of the substances, carefully isolated from other species by using buffers whose pH values were indicated by knowledge of the appropriate pKa values. These spectra are summarized in Table 11, p. 116.

The following cases exemplify the use of ultraviolet spectra in determining the structure of hydrogenated pteridines. a) It has been reported that 5,6,7,8-tetrahydropteridines have ultraviolet absorptions similar to those of the corresponding 4,5-diaminopyrimidines, and that a 15-18 mμ bathochromic shift is observed in the spectra of tetrahydropteridines when compared to the corresponding 4,5-diaminopyrimidines (Lister and Ramage, 1953; Taylor and Sherman, 1959) (Table 12, p. 117).

In the present work the synthesis of 5,6,7,8-tetrahydro-2-hydroxypteridine involved the catalytic hydrogenation of 7,8-dihydro-2-hydroxypteridine (see p. 70). The result of this reaction is rather ambiguous due to the

possibility of migration of hydrogen atoms in the presence of a metal catalyst. Evidence for the 5,6,7,8-tetrahydro structure, however, was obtained by comparing the ultraviolet spectra of the substance (neutral molecule, cation and anion) with those of 4,5-diamino-2-hydroxypyrimidine (Table 13, p. 118, and Fig. 4,5 and 6). It will be noticed that each ionic species of tetrahydro-2-hydroxypteridine has an absorption curve closely similar to that of the corresponding species of 4,5-diamino-2-hydroxypyrimidine, but shifted to longer wavelengths by approximately 12-22 mμ. These facts are in accord with the results obtained by Lister and Ramage (1953), and by Taylor and Sherman (1959), and it may therefore be reasonably concluded that the hydrogen atoms in tetrahydro-2-hydroxypteridine occupy the 5-, 6-, 7-, and 8-, positions. Further, 5,6,7,8-tetrahydro-4-hydroxypteridine, prepared unambiguously, also has ultraviolet spectra (of neutral molecule, cation and anion) closely similar to those of the corresponding ionic species of 4,5-diamino-6-hydroxypyrimidine (Table 13, and Fig. 7,8 and 9).

b) As already stated (p.15) the product obtained by alkaline hydrolysis of dihydro-7-hydroxypteridine seemed to be 4-amino-5-carboxymethylaminopyrimidine (3d-I) on reasonable chemical evidence (Albert, Brown and Cheeseman, 1952). However, the possibility of its being 4-amino-5-

carboxymethylen*e*aminodihydropyrimidine (3d-II) was not completely excluded. The structure (3d-I) has a conjugated system similar to 4,5-diaminopyrimidine (3d-III), and therefore the ultraviolet spectra of (3d-I) should be similar to those of 4,5-diaminopyrimidine (3d-III). On the other hand, the conjugated system of the dihydropyrimidine (3d-II) is dissimilar to that of (3d-III). It would be possible to distinguish these two structures, 3d-I and 3d-II, by comparing their ultraviolet spectra with those of 4,5-diaminopyrimidine (3d-III).

(3d-I)

(3d-II)

(3d-III)

(3d-IV)

However, 4-amino-5-carboxymethylaminopyrimidine exists mainly as a zwitterion (3d-IV), as described before (p.32), and therefore care was taken to compare the ultraviolet spectrum of the acid's neutral molecule with the spectrum of the 4,5-diaminopyrimidine <u>cation</u>, and similarly the spectrum of the acid's anion with that of the neutral molecule of 4,5-diaminopyrimidine. The ultraviolet spectra of these two pairs have indeed a close similarity (Table 14, and Fig. 10, 11), and this eliminates the possibility of the dihydropyrimidine structure (3d-II), thus the product obtained by alkaline hydrolysis of dihydro-7-hydroxypteridine is 4-amino-5-carboxymethylaminopyrimidine (3d-I). Accordingly, the parent x,y-dihydro-7-hydroxypteridine is 5,6-dihydro-7-hydroxypteridine.

c) The structure of x,y-dihydro-2-hydroxypteridine could not be confirmed by synthesis, but it had pKa values somewhat similar to those of hydrated 2-hydroxypteridine (3d-V) (see p. 101). This hydrated 2-hydroxypteridine (3d-V) has the same conjugated system as had 3,4-dihydro-2-hydroxypteridine (3a-VI), thus the pair of the compounds would be expected to have similar ultraviolet spectra[*]. Marked similarity of ultraviolet

---

[*]As a basis for this expectation, correlations between the spectra of hydrated pteridines and hydrogenated pteridines which have the same conjugated systems have been observed in some 7,8-hydrated 6-hydroxypteridines (3d-VII) and the corresponding 7,8-dihydro derivatives (3d-VIII) (Fig.2,12,13).

spectra is seen between the x,y-dihydro-2-hydroxypteridine and hydrated 2-hydroxypteridine (Fig. 1). Since the structure of hydrated 2-hydroxypteridine has been established as 3,4-dihydro-2,4-dihydroxypteridine (3d-V) (Brown and Mason, 1956), the above spectroscopic evidence supports the 3,4-dihydro structure for x,y-dihydro-2-hydroxypteridine.

(3d-V)

(3d-VI)

(3d-VII)

(3d-VIII)

d) As described before (p. 48, 85 and 102) the x,y-dihydro-4-hydroxypteridine obtained by reduction of 4-hydroxypteridine with potassium borohydride could reasonably be 5,8-, 3,7- or 7,8-, dihydro-4-hydroxypteridine. The x,y-dihydro-4-hydroxypteridine shows a strong bathochromic shift (57 mμ) in

its ultraviolet absorption when compared with 4-hydroxy-pteridine (see Table 15, p. 120). Such a strong bathochromic shift has never been observed between pteridines and their 7,8-dihydro derivatives (Table 15, p. 120). However, an unusually strong bathochromic shift (54 mμ) was recently found between a pteridine and its 5,8-dihydro derivative (Pfleiderer and Taylor, 1960, see p. 45) who explained this shift by the stabilization, by the external ring formation, of a 5,8-dihydro structure. In the present case, two possible structures, 5,8-dihydro-, and 3,7-dihydro-, 4-hydroxypteridine remain. But no decision can be reached on the constitution of this minor product of the reduction of 4-hydroxypteridine.

ii) Infrared Absorption Spectra.

Because of the insolubility of hydrogenated pteridines in organic solvents, all infrared absorption spectra were determined in the solid state (potassium bromide disk method). This prevented an intensive discussion about the structure of the compounds as revealed by the infrared spectra, because solid state measurements present a bewildering variety of peaks arising from interactions between the molecules. For

this reason infrared spectra were used in the present work, mainly for testing identity.

iii) <u>Nuclear Magnetic Resonance Spectra</u>.

The nuclear magnetic resonance spectra of solids can only be determined in solution. For this reason, in spite of its great value in the determination of the position of hydrogen atoms in a molecule, this method could not be used in the present work. Several attempts to use the method are described (see p. 33), but in no case could a sufficiently concentrated solution be obtained to give clear signals.

Table 11.

Ultraviolet spectra of hydrogenated pteridines (obtained in the present work).

Values underlined refer to shoulders or inflexions.

ihydropteridines	pK_a	pH (measured)	species	λ max. (mμ)	log ε
,8-Dihydro-4,6-dimethylpteridine		8.2	o	218; 293	4.27; 3.73
	6.00 ± 0.04	3.0	+	218; 293	4.13; 3.91
,4-Dihydroxy-2-hydroxypteridine		7.0	o	248; 317	3.72; 3.89
	0	-2	+	254; 317	3.78; 3.85
	12.6	14.16	−	201; 343	3.90; 3.84
,8-Dihydro-2-hydroxypteridine		7.0	o	223; 290	4.35; 3.83
	3.50 ± 0.02	1.0	+	225; 282; 290; 310	3.85; 3.75; 3.79; 3.7
	a)	14.16	−	308	3.95
,4-Dihydro-2-hydroxy-6-methylpteridine		7.0	o	248; 321	3.83; 3.92
	0.20 ± 0.06	-2.03	+	257; 347	3.86; 3.83
	13.05 ± 0.04	14.16	−	281; 352	4.01; 3.84
,8-Dihydro-2-hydroxy-6-methylpteridine		7.0	o	220; 287	4.46; 3.99
	3.42 ± 0.06	2.0	+	279 + 287; 310	4.06 + 4.04, 3.82
	11.85 ± 0.04	14.16	−	300.5	4.08
,8-Dihydro-2-hydroxy-4,6-dimethyl-pteridine		7.0	o	222; 289	4.39; 4.04
	3.99 ± 0.02	2.0	+	283 + 288; 312	4.07 + 4.07; 3.90
	12.50 ± 0.04	14.0	−	223; 304	4.37; 4.10
,6-Dihydro-4-hydroxypteridine		7.0	o	257.5	3.74
	2.94 ± 0.04	0.0	+	286	3.70
	10.24 ± 0.1	12.3	−	278.5	3.82

Table 11 (continued)

x,y-Dihydro-4-hydroxypteridine		7.0	o	248; 357	3.86; 3.59
	0.32 ± 0.05	-2.0 b)	+	257; 374	3.87; 3.80
	12.13 ± 0.03	14.16	−	253; 364	3.97; 3.70
7,8-Dihydro-6-hydroxypteridine [1]		7.0	o	295	3.93
	4.53 ± 0.03	2.0	+	292	4.02
	10.54 ± 0.02	13.0	−	227; 308	4.09; 4.05
5,6-Dihydro-7-hydroxypteridine [1]		6.0	o	271; 319	3.59; 3.70
	3.36 ± 0.01	1.02	+	223; 284; 352	4.17; 3.74; 3.71
	9.94 ± 0.05				
7,8-Dihydro-2,6-dihydroxypteridine		6.0	o	237; 265; 290	4.11; 3.90; 3.46
	2.80 ± 0.02	0	+	257; 317	4.01; 3.86
	10.22 ± 0.01	12.3	−	279; 315	4.01; 3.70
7,8-Dihydro-4,6-dihydroxypteridine		6.5	o	274; 318	3.90; 3.69
	9.07 ± 0.05	12.0	−	273; 300	3.83; 3.57
x,y-Dihydro-2,7-dihydroxypteridine		3.52	o	252; 324	3.50; 3.97
	5.84 ± 0.02	7.98	−	250; 340	3.49; 4.01
5,6-Dihydro-4,7-dihydroxypteridine		5.0	o	217; 275; 323	4.23; 3.70; 3.71
	8.45 ± 0.02	10.90	−	254; 310	3.72; 3.59
7,8-Dihydro-2,4,6-trihydroxy-pteridine		4.78	o	267; 306	3.90; 4.09
	7.07 ± 0.03	9.14	−	222,5; 272; 305	4.34; 4.05; 3.89

Table 12

Ultraviolet spectra of 5,6,7,8-tetrahydropteridines and the corresponding 4,5-diaminopyrimidines (from literature). ("neutral molecule" for those done in alcohol, and "cation" for those done in acid[*].)

(N.B. The 4- and 6-positions in pyrimidine are equivalent).

5,6,7,8-Tetrahydropteridine	λ max.(mμ)	4,5-Diaminopyrimidine	λ max.(mμ)
Unsubstituted	208; 304 [1]	Unsubstituted	284 [2]
2,4-Dichloro-	318 [3]	2,6-Dichloro-	303 [3]
4,6-Dimethyl-	213; 306 [4]	6-Methyl-	288 [4]
2-Chloro-4,6-dimethyl-	221; 310 [4]	2-Chloro-6-methyl-	214; 292 [4]
2-Hydroxy-4,6-dimethyl-	230; 325 [4]	2-Hydroxy-6-methyl-	214; 293 [4]

1) cation ; Brook and Ramage, 1957.

2) cation ; Mason , 1954.

3) neutral molecule (in ethanol); Taylor and Sherman, 1959.

4) cation ; Lister and Ramage, 1953.

[*]Many of the above measurements were not made on isolated ionic species of the substance . However, the spectra which were determined in 0.1N-hydrochloric acid are considered to be largely those of cations and those determined in ethanol are considered to be largely those of neutral molecules.

Table 13.

Comparison of ultraviolet spectra of isolated species of
tetrahydropteridines and the corresponding 4,5-diaminopyrimidines.
(N.B. The 4- and 6-positions are equivalent in pyrimidine).

	ionic species[***]	λmax.(mμ)	log ε
5,6,7,8-Tetrahydro-2-hydroxypteridine[*]	0	306	3.70
	+	327	3.69
	−	315	3.79
4,5-Diamino-2-hydroxypyrimidine[**]	0	292	3.58
	+	305	3.70
	−	303	3.67
5,6,7,8-Tetrahydro-4-hydroxypteridine[*]	0	289	4.10
	+	259	4.06
	−	284	4.11
4,5-Diamino-6-hydroxypyrimidine[**]	0	278	3.95
	+	258	3.74
	−	272	3.87

[*] Present work.

[**] Mason , 1954.

[***] 0 : neutral molecule, + : cation, − : anion.

Table 14

Ultraviolet spectra of 4,5-diaminopyrimidine and of the product obtained by alkaline hydrolysis of dihydro-7-hydroxypteridine.

	ionic species	pH	λmax(mμ)	log ε
4,5-Diaminopyrimidine	neutral molecule	8.05	289	3.86[1]
	cation	3.25	284	3.94[1]
Alkaline hydrolysis product	cation	3.0	288	3.94[2]
of dihydro-7-hydroxypteridine	zwitterion	6.67	282	3.93[2]

[1] Mason , 1954.

[2] Albert, Brown and Cheeseman, 1952.

Table 15

Ultraviolet spectra of pteridines and their 7,8-dihydro-derivatives.
(Values underlined refer to shoulders or inflexions).

Aminopteridine [1) (both in 0.1N-HCl)		Pteridine λ max.(mμ)	7,8-Dihydro- λ max.(mμ)
2-Amino-6-methylpteridine		235; 305	290
2-Amino-6,7-diphenylpteridine		275; 335	232; 335
2-Diethylamino-6,7-diphenylpteridine		230; 273; 335	232; 280; 337
4-Amino-6,7-diphenylpteridine		278; 375	257; 370
4-Dimethylamino-6,7-diphenylpteridine		395	230; 265; 310; 385
Hydroxypteridine	ionic species		
2-Hydroxypteridine	0	230; 307	223; 290 *
	+	233; 308	290; 310 *
	−	260; 375	308 *
2-Hydroxy-6-methylpteridine	0	235; 315 *	220; 287 *
	+	240; 310; 335*	279; 310 *
	−	261; 377	308.5 *
2-Hydroxy-4,6-dimethylpteridine	0		222; 289 *
	+		283+288; 312 *
	−		222; 304 *
			x,y-Dihydro-
4-Hydroxypteridine	0	230; 310 2)	248; 367 *
	+	257; 303 2)	257; 374 *
	−	242; 333 2)	*

1) Boon and Jones ,1951.

2) Brown and Mason ,1956.

* Present work.

SECTION 4.

EXPERIMENTAL

Microanalyses were kindly carried out by Dr. J.E. Fildes and her staff in the Department of Medical Chemistry in this university. Samples submitted for analyses were dried at 106°/0.1 mm., unless otherwise indicated. In the experimental part, the analytical values between 0.07 and 0.13% are recorded as 0.1% and those between 0.14 and 0.16% as 0.15%.

All melting points recorded below were taken in soda glass capillaries and are uncorrected.

All paper chromatographic runs mentioned in this thesis were carried out by the "ascending front" method using Whatman No 1 or No 4 paper. Both (a) 3% aqueous ammonium chloride (NH_4Cl) and (b) n-butanol (7 volumes) + 5 N-acetic acid (3 volumes) (Bu/Ac) were used as solvents. The paper chromatograms were examined under ultraviolet light at two wavelengths, (a) principally 365 mμ, with a mercury vaper lamp and a Wood's glass filter, and (b) principally 254 mμ, with a mercury resonance lamp and a Chance Brother's OX7/19874 filter. The colours of observed fluorescences are recorded in the experimental part of this thesis as follows: Y = yellow, G = green, W = white, SB = sky blue, B = blue, V = violet. Two further symbols mean: D = dark (i.e. absorption occurs), X = neither absorption

nor fluorescence occurs. Thus 0.75 2D/3B indicated a dark
spot visible in the light of the 254 mμ lamp, and blue
fluorescence in the light of the 365 mμ lamp, and 0.75 is
the Rf value. Similarly 2/3B indicates a blue fluorescence
under both the 254 mμ and the 265 mμ lamps.

When two substances had to be compared for identity,
they were always run simultaneously.

All new compounds can be distinguished from previously
reported compounds by the convention of The Chemical Society,
namely that the ideal analytical figures for a new compound
are cited as ".......requires.......", and for a previously
known compound as ".......calc. for.......". The names of
new compounds are underlined at their first mention in the
experimental part. (As in the Journal of the Chemical Society,
names which are paragraph headings are also underlined but this
does not indicate that the compound is new).

a. Reduction.

Reduction of 2-hydroxypteridine.

i) with potassium borohydride. Potassium
borohydride (330 mg.) was added to a solution of 2-hydroxy-
pteridine monohydrate (1.0 g.) in 0.1N-sodium hydroxide
(100 ml.), and the mixture was kept under nitrogen overnight
at room temperature. Neutralization with phosphoric acid
gave a precipitate which on recrystallization from water
gave 3,4-dihydro-2-hydroxypteridine (610 mg., 55%), it

darkens at 250° (Found: C, 48.1; H, 4.1; N, 36.9. $C_6H_6N_4O$ requires C, 48.0; H, 4.0; N, 37.0%). From the filtrate of the reaction mixture, 5,6,7,8-tetrahydro-2-hydroxypteridine was detected by paper chromatography.

	NH$_4$Cl		Bu/Ac.	
3,4-dihydro-2-hydroxypteridine	0.69	2B/3V	0.50	2B/3V
the filtrate	0.74	2SB/3G	0.22	2/3G
5,6,7,8-tetrahydro-2-hydroxypteridine[*]	0.74	2SB/3G	0.22	2/3G

ii) **with sodium dithionite**. Sodium dithionite (4.8 g.) was added to a boiling solution of 2-hydroxypteridine monohydrate (1.0 g.) in N-sodium carbonate (30 ml.). After chilling overnight under carbon dioxide, the precipitate was extracted with hot water (20 + 20 ml.), the second extract was concentrated to 5 ml. and added to the first. Chilling gave 3,4-dihydro-2-hydroxypteridine (230 mg., 25%), decomposing at 250°C without melting (Found for material dried at 20°: C, 47.9; H, 4.05; N, 37.1. Calc. for $C_6H_6N_4O$: C, 48.0; H, 4.0; N, 37.3%). A product (65 mg.) insoluble in boiling water, remained on recrystallization.

General procedure for catalytic hydrogenation.

The hydrogenation of hydroxypteridines was carried out using a semimicro hydrogenation apparatus at room temperature (20-22°C) and atmospheric pressure (about 710-720 mm.). After absorption of hydrogen by the catalyst had

---

[*] Obtained by synthesis, see p. 152.

ceased, the sample was introduced and further absorption of hydrogen was recorded. The following is a typical example of the hydrogenation over palladium on carbon catalyst, and the results of all such hydrogenations are summarized in Table 11. Only exceptional cases are detailed in the experimental part.

Hydrogenation of 2-hydroxypteridine.

i) over palladium catalyst in 0.1N-sodium hydroxide solution. 2-Hydroxypteridine monohydrate (1.0 g., 0.6 m mole) in 0.1N-sodium hydroxide (100 ml.) was hydrogenated over palladium on carbon (10% Pd; 500 mg.), and 120 ml. of hydrogen (80% of theoretical for 2H) was absorbed in 20 min., when the rate of absorption fell sharply. After filtering off the catalyst, the filtrate was adjusted to pH 6, giving 3,4-dihydro-2-hydroxypteridine (600 mg., 67%), which was crystallized from water and identified by paper chromatography. Rf. 0.69 2B/3V (NH_4Cl), 0.50 2B/3V (Bu/Ac).

ii) over Raney-nickel. (a) 2-Hydroxypteridine (1.0 g., 6 m mole) in methanol (500 ml.) was hydrogenated over Raney-nickel, and the absorption of hydrogen stopped after 20 ml. was absorbed (13% of theoretical for 2H).

(b) 2-Hydroxypteridine (1.0 g., 6 m mole) in methanol (500 ml.) containing N-sodium hydroxide (6 ml.) was hydrogenated over Raney-nickel, and 170 ml. of hydrogen (120% of theoretical for 2H) was absorbed in 4 hr. After removal of the catalyst, the filtrate was evaporated to

dryness (in vacuo), and recrystallization of the residue
from water gave 3,4-dihydro-2-hydroxypteridine (311 mg. 42%),
it darkens at 250° (Found: C, 47.9; H, 4.1; N, 37.2.
Calc. for $C_6H_6N_4O$: C, 48.0; H, 4.0; N, 37.3%).

The filtrate from the recrystallization was taken to
dryness and extracted with water (1.5 ml.). The extract
was evaporated to dryness in a desiccator, and reextracted
with methanol. The methanol solution was examined by
paper chromatography and by ultraviolet spectra. It gave
Rf. values 0.74 2SB/3G (NH_4Cl), 0.22 2/3G. (Authentic
5,6,7,8-tetrahydro-2-hydroxypteridine gave 0.74 2SB/3G
(NH_4Cl), 0.22 2/3G), and λmax. 325 mμ at pH 1 , and 304 mμ
at pH 7[*] (authentic sample gives λmax. 327 mμ at pH 1.0, and
306 mμ at pH 7.16).

iii) over Adams' platinum oxide catalyst. (a) 2-
Hydroxypteridine in formic acid or in dimethylformamide
did not absorb hydrogen over Adams' catalyst.

(b) 2-Hydroxypteridine (166 mg., 1 m mole) in water
(300 ml.) over Adams' catalyst absorbed 100 ml. of hydrogen
(this corresponded to 8H). The solution was concentrated,
but neither absorption nor fluorescence was detected on
paper chromatography. The product is very soluble in water
and further investigation was abandoned because it was either
a fully hydrogenated product or its decomposition fragments.

---

[*]As there was not enough material to purify, the correct
extinction could not be determined.

Reduction of 3,4-dihydro-2-hydroxypteridine over
Adams' catalyst. When 3,4-dihydro-2-hydroxypteridine (150 mg.,
0.3 m mole) was hydrogenated in water (150 ml.), it absorbed
80 ml. of hydrogen (6 H) in 40 hr. As in the above case,
neither absorption nor fluorescence was detected in the
reduction mixture and no further investigation of the
product was undertaken.

Reduction of 4-hydroxypteridine.

i) with potassium borohydride. Potassium borohydride
(500 mg., 8 H) was added to a solution of 4-hydroxypteridine
(740 mg. 5 m mole) in N-potassium carbonate (10 ml.), and
kept overnight at room temperature. The mixture was
adjusted to pH 5 with hydrochloric acid to decompose the
excess of borohydride, and then adjusted to pH 10 with
potassium hydroxide. The solution was evaporated to dryness
in vacuo with "Hyflo-supercel" (2 g.) and extracted with
ethyl acetate using a Soxhlet extractor (for 40 hr.).
The extract gave a mixture of di- and tetra- hydro-4-
hydroxypteridine (224 mg.) whereas the unchanged 4-
hydroxypteridine remained in the thimble.   The mixture of
hydro-derivatives was extracted with warm ethanol (20 ml.),
and the residue, crystallized from water (2.5 ml.), gave
x,y-dihydro-4-hydroxypteridine as yellow needles (56 mg.,
7.5%), m.p. 263-265° (decomp.) (Found: C, 48.2; H, 4.05;
N, 36.95. $C_6H_6N_4O$ requires C, 48.0; H, 4.0; N, 37.3%).

The ethanol extract, on concentration and recrystallization from ethanol (2 ml.), gave <u>5,6,7,8-tetrahydro-4-hydroxy-pteridine</u> as buff prisms (66 mg., 8.8%), m.p. 230° (decomp.) Found: C, 47.35; H, 5.5. $C_6H_8N_4O$ requires C, 47.35; H, 5.3%). (See p. 48 for establishment of its identity with synthetic material; see below for material obtained by hydrogenation).

ii) <u>with sodium amalgam</u>. Sodium amalgam (4%, 4 g.) was added with stirring to a suspension of 4-hydroxy-pteridine (148 mg., 1 m mole). The mixture changed first to yellow, then brown and finally it became colourless. After removal of the mercury, the solution (on adjustment to pH 7) gave a white precipitate, which in air changed to a brown substance, Rf. 0.41 2/3W (NH_4Cl)1 0.05 2W/3Y. Paper chromatography of the filtrate detected 5,6,7,8-tetrahydro-4-hydroxypteridine, Rf. 0.68 2B/3V (NH_4Cl), 0.26 2B/3V (Bu/Ac).

<u>Hydrogenation of 4-Hydroxypteridine.</u>

i) <u>over Raney-nickel</u>. 4-Hydroxypteridine (2.25 g., 15 m mole) in ethanol (300 ml.) was hydrogenated over Raney-nickel (20 g.) and 470 ml. of hydrogen was absorbed in 40 min. The filtrate from the catalyst was concentrated to dryness and the residue crystallized from ethanol, giving 5,6,7,8-tetrahydro-4-hydroxypteridine as pale buff prisms

(1.38 g., 60%), m.p. 228-230° (Found C, 47.5; H, 5.45;
N, 36.95. Calc. for $C_6H_8N_4O$: C, 47.35; H, 5.3; N, 36.8%).

ii) over palladium on carbon. 4-Hydroxypteridine
(148 mg., 1 m mole) in 0.1N-potassium hydroxide (10 ml.)
was hydrogenated over palladium on carbon. Absorption of
hydrogen ceased after 40 min. and 32.2 ml. (60% for 4H)
of hydrogen was absorbed. No crystallizable substance was
isolated from the reaction mixture but an unstable product
(20 mg.) was obtained, which oxidized to a brown substance
in air. In the filtrate 5,6,7,8-tetrahydro-4-hydroxy-
pteridine was detected by paper chromatography, Rf. 0.68
2B/3V (NH_4Cl), 0.26 2B/3V (Bu/Ac), (5,6,7,8-tetrahydro-
4-hydroxypteridine gave Rf. 0.68 2B/3V (NH_4Cl), 0.26 2B/3V
(Bu/Ac)).

Reduction of 6-hydroxypteridine.

i) with potassium borohydride. Reduction of 6-hydroxy-
pteridine is one of the most typical examples of the
reduction of hydroxypteridines with potassium borohydride.
The results of all such reactions are summarized in Table
17, p.140 , and only exceptional cases are detailed in the
experimental part.

Potassium borohydride (55 mg.) was added to 6-hydroxy-
pteridine monohydrate (166 mg., 1 m mole) in 0.1N-potassium

hydroxide (10 ml.), and kept overnight at room temperature.
The mixture was adjusted to pH 6 with phosphoric acid.
The precipitate of 7,8-dihydro-6-hydroxypteridine (143 mg.,
86%), crystallized from water, decomposed at 310°
without melting (Found: C, 47.6; H, 4.0; N, 36.55. Calc.
for $C_6H_6N_4O$: C, 48.0; H, 4.0; N, 37.3%).

ii) with sodium dithionite. Sodium dithionite
(300 mg.) was added to a hot solution of 6-hydroxypteridine
monohydrate (200 mg., 1.2 m mole) in N-sodium carbonate
(6 ml.), boiled for one min., and cooled to room temperature.
Neutralization of the mixture with phosphoric acid gave a
crude product, which was boiled with N-hydrochloric acid
and then adjusted to pH 7 with sodium hydroxide.
Recrystallization of the precipitate from water gave 7,8-
dihydro-6-hydroxypteridine as colourless micro needles
(132 mg., 65.7%), decomposing at 310° without melting
(Found: C, 48.25; H, 4.2; N, 36.6. Calc. for $C_6H_6N_4O$
C, 48.0; H, 4.0; N, 37.3%).

Hydrogenation of 6-hydroxypteridine over palladium
on carbon. This gave 7,8-dihydro-6-hydroxypteridine in
63% yield (see Table 16, p.139).

Reduction of 7-hydroxypteridine.

i) with potassium borohydride. This gave 5,6-
dihydro-7-hydroxypteridine in 80% yield (see Table 17).

ii) <u>with potassium amalgam</u>. 4%-Potassium amalgam
(5 g., a 150% excess for 2 H) was added with stirring to
an ice cooled suspension of 7-hydroxypteridine (148 mg.,
1 m mole) in water (10 ml.).   After 10 min. the supernatant
solution was adjusted to pH 7 with hydrochloric acid,
recrystallization of the precipitate gave 5,6-dihydro-7-
hydroxypteridine as colourless needles (63 mg., 43%),
decomposing at 235° without melting (Found: C, 48.25;
H, 3.9; N, 36.86.   Calc. for $C_6H_6N_4O$: C, 48.00; H, 4.0;
N, 37.3%).

<u>Hydrogenation of 7-hydroxypteridine over palladium
catalyst.</u>   This gave 4-amino-5-carboxymethylaminopyrimidine
in 63% yield (see Table 16).

<u>Hydrogenation of 2,4-dihydroxypteridine.</u>

i) <u>over Adams' catalyst</u>.   When 2,4-dihydroxypteridine
(164 mg., 1 m mole) in formic acid (12 ml.) was hydrogenated
over Adams' catalyst, it absorbed 48 ml. (4 H) of hydrogen
and gave the same spot on paper chromatography as that
obtained by the reduction of 2,4-dihydroxypteridine with
sodium amalgam.

ii) <u>over palladium on carbon</u>. When 2,4-dihydroxy-
pteridine (164 mg. 0.1 mole) in 0.1N-sodium hydroxide was
hydrogenated over palladium on carbon, it absorbed 50 ml.
of hydrogen (4 H).   Paper chromatography indicated that the

product is the same 5,6,7,8-tetrahydro-2,4-dihydroxy-pteridine obtained by reduction of the pteridine with sodium amalgam.

Reduction of 2,4-dihydroxypteridine.

i) <u>with sodium amalgam.</u> (a) 2,4-Dihydroxypteridine (500 mg., 3 m mole) was reduced with 4%-sodium amalgam (9 g.) under a nitrogen atmosphere. 2,3-Dimercaptopropanol (1×10^{-3} M solution, 3 ml.) was added to the mixture as an antioxidant and then the mercury was separated by decantation. The solution was quickly adjusted to pH 5 with acetic acid and the precipitate centrifuged, washed with 1×10^{-4} M dimercaptopropanol solution (3 x 50 ml.), and dried at room temperature under nitrogen at 10^{-1} mm. This gave <u>5,6,7,8-tetrahydro-2,4-dihydroxypteridine</u> as a pale buff powder (317 mg., 63%). This sample quickly changed to a brown substance in air and no accurate decomposition point was determined. (Found for substance dried at 20°, 10^{-1} mm: C, 42.2; H, 4.1; N, 32.2, adjusted for presence of 5% sodium acetate[*] to C, 42.95; H, 4.2; N, 33.3 .

---

[*]As the substance precipitated as a slime, and had to be centrifuged, some sodium acetate remained inspite of repeated washing. This explains the trace of ash in the combusted sample. Further washing caused decomposition of the substance due to oxidation.

$C_6H_8O_2N_4$ requires C, 42.85; H, 4.8; N, 33.3%). It gave Rf. 0.69 2D/3B (NH$_4$Cl)[**].

(b) 2,4-Dihydroxypteridine (500 mg.) was reduced with sodium amalgam as above, and the solution was added to 10% acetic acid containing 1×10^{-3} mole dimercaptopropanol (20 ml.). The precipitate was centrifuged and dried under nitrogen at 10^{-1} mm. over P_2O_5. Formic acid (50 ml.) and acetic formic anhydride (5 ml.) were added to the product and kept at room temperature overnight. The small amount of precipitate was discarded and the filtrate was evaporated to dryness under reduced pressure. Crystallization of the residue from water gave N-formyl-5,6,7,8-tetrahydro-2,4-dihydroxypteridine (140 mg., 28%), m.p. ca 300° (decomp.) (Found: C, 40.55; H, 4.1; N, 27.2. $C_7H_8N_4O_3 \cdot \frac{1}{2}H_2O$ requires C, 41.0; H, 4.4; N, 27.05%).

(c) reoxidation. 2,4-Dihydroxypteridine (164 mg., 1 m mole) was reduced with sodium amalgam exactly as above, and the solution was reoxidized with air using a semimicro-hydrogenation apparatus, and 20 ml. of oxygen was absorbed (80% calc. for O_2).

ii) with sodium dithionite. Sodium dithionite (4.8 g.) was added to a hot solution of 2,4-dihydroxypteridine (1.64 g., 0.01 mole) in 0.1N-sodium hydroxide (100 ml.) and boiled

---

[*]All processes of paper chromatography for tetrahydro-2,4-dihydroxypteridine, i.e. spotting, development and drying, were undertaken under nitrogen.

for two min. The mixture was refrigerated overnight under
a nitrogen atmosphere and the white precipitate centrifuged.
The precipitate was washed with 30%, 45% and 60% ethanol and
when dried under nitrogen at 10^{-1} mm, gave a pale buff
powder (900 mg., 54%). This product changed to brown in air
as tetrahydro-2,4-dihydroxypteridine did, and gave the same
Rf. 0.69 2D/3B (NH_4Cl under nitrogen).

The supernatant solution from the centrifuge was
concentrated to about 50 ml. under reduced pressure at room
temperature and ethanol (50 ml.) was added. After removal of
the precipitate, the filtrate was concentrated to 30 ml. and
60 ml. ethanol was added, and the precipitate was
recrystallized from 30% ethanol, giving <u>sodium tetrahydro-
2,4-dihydroxypteridine sulphonate</u> as a white powder, slowly
decomposing at 80° (Found for substance dried at room
temperature 10^{-1} mm. C, 24.75; H, 3.1; N, 19.15; S, 10.65.
$C_6H_7N_4NaO_5S.H_2O$ requires C, 25.0; H, 3.15; N, 19.4; S, 11.1%).
<u>Reduction of 2,6-dihydroxypteridine.</u>

i) <u>with **potassium borohydride**.</u> This gave 7,8-dihydro-
2,6-dihydroxypteridine in 80% yield (see Table 17) (Found:
C, 43.3; H, 3.75; N, 33.7   Calc. for $C_6H_6N_4O_2$: C, 43.35;
H, 3.65; N, 33.7%).

ii) <u>with potassium amalgam.</u>   2,6-Dihydroxypteridine
monohydrate (182 mg., 1 m mole) was reduced with 3%-
potassium amalgam (5 g., 100% excess for 2 H). This method

gave no insoluble product and it was abandoned when it was found that potassium amalgam decomposed 7,8-dihydro-2,6-dihydropteridine to a similar compound.

Hydrogenation of 2,6-dihydroxypteridine.

i) over palladium on carbon. This gave 7,8-dihydro-2,6-dihydroxypteridine in 73% yield (see Table 16).

ii) over Adams' catalyst. When 2,6-dihydroxypteridine monohydrate (91 mg., 0.5 m mole) in 0.1N-potassium hydroxide (10 ml.) was hydrogenated over Adams' catalyst (10 mg.), 13 ml. of hydrogen (=2 H) was abosrbed in 7 hr. After removal of the catalyst the filtrate was dropped into boiling N-sodium acetate (50 ml.), giving 7,8-dihydro-2,6-dihydroxypteridine (71 mg., 85%).

Reduction of 4,6-dihydroxypteridine.

i) with potassium borohydride. This gave 7,8-dihydro-4,6-dihydroxypteridine in 96% yield (see Table 17) (Found: C, 43.15; H, 3.6; N, 33.5. Calc. for $C_6H_6N_4O_2$: C, 43.4; H, 3.65; N, 33.7%).

ii) with potassium amalgam. 4,6-Dihydroxypteridine (182 mg., 1 m mole) was reduced with 3% potassium amalgam (5 g. 4 H). The solution, on adjustment to pH 6 with hydrochloric acid, gave 7,8-dihydro-4,6-dihydroxypteridine, which was recrystallized from water (120 mg., 72%).

Hydrogenation of 4,6-dihydroxypteridine over palladium on carbon. This gave 7,8-dihydro-4,6-dihydroxypteridine in

79% yield (see Table 16).

Reduction of 2,7-dihydroxypteridine.

i) with potassium borohydride. This gave x,y-dihydro-2,7-dihydroxypteridine in 84% yield (see Table 17) (Found: C, 43.45; H, 3.75; N, 33.65. $C_6H_6N_4O_2$ requires C, 43.4; H, 3.65; N, 33.7%).

ii) with potassium amalgam. 3%-Potassium amalgam (5g., 4 H) was added to a suspension of 4,7-dihydroxypteridine monohydrate (182 mg., 1 m mole) in water (5 ml.). After removal of the mercury the solution was adjusted to pH 6 with acetic acid. Recrystallization of the precipitate from water gave x,y-dihydro-2,7-dihydroxypteridine as colourless needles (96 mg., 64%).

iii) with sodium dithionite. Sodium dithionite (600 mg.) was added to a hot solution of 2,7-dihydroxypteridine monohydrate (182 mg., 1 m mole) in 0.5 N-potassium hydroxide (6 ml.) and boiled for 1 min. The mixture was cooled to room temperature, adjusted to pH 0 with hydrochloric acid, and refrigerated overnight. This gave sodium tetrahydro-2,7-dihydroxypteridine sulphonate as yellow needles (160 mg., 60% calc. for $C_6H_7N_4NaO_5S$), which was reprecipitated from cold water (2 ml.) with hydrochloric acid (pH 0) as yellow needles, decomposing at 245° without melting (Found for material dried at 65°/10^{-1} mm.: C, 27.05; H, 2.7; S, 11.10; 10% ash. $C_6H_7N_4NaO_5S$ requires C, 26.7; H, 2.6; S, 11.85%).

Sodium dihydro-2,7-dihydroxypteridine sulphonate.

Sodium metabisulphite (600 mg. in 0.5 ml. water) was added to a
solution of 2,7-dihydroxypteridine (323 mg.) in N-sodium
hydroxide (1.5 ml.) and kept at room temperature for 5 hr.,
and refrigerated overnight. The product, recrystallized
from water, gave sodium dihydro-2,7-dihydroxypteridine
sulphonate as colourless needles (147 mg.), m.p. 310° (Found
after drying at 60°/10^{-1} mm.: C, 23.3; H, 2.4; N, 18.3; S, 10.9.
$C_6H_4N_4Na_2O_5S.H_2O$ requires C, 23.4; H, 2.0; N, 18.1; S, 10.4%).

Sodium dihydro-2-hydroxypteridine sulphonate. Sodium
metabisulphite (500 mg.) was added to a solution of 2-hydroxy-
pteridine monohydrate (164 mg.) in N-sodium hydroxide (1 ml.).
After refrigeration overnight the percipitate on
crystallization from water gave sodium dihydro-2-
hydroxypteridine sulphonate as colourless needles (90 mg.),
m.p. 310° (decomp.) (Found: C, 27.85; N, 2.4; N, 21.45;
S, 12.25. $C_6H_5N_4NaO_4S.\frac{1}{4}H_2O$ requires C, 27.6; H, 2.3; N, 21.45;
S, 12.3%).

Reduction of 4,7-dihydroxypteridine with potassium
borohydride. This gave 5,6-dihydro-4,7-dihydroxypteridine
in 85% yield, m.p. 300° (decomp.) (Found: C, 43.5;
H, 3.9; N, 33.4. $C_6H_6N_4O_2$ requires C, 43.4; H, 3.65;
N, 33.7%) (see table 17).

Hydrogenation of 4,7-dihydroxypteridine over palladium
on carbon. This gave 5,6-dihydro-4,7-dihydroxypteridine

in 67% yield (see Table 16).

Reduction of 2,4,6-trihydroxypteridine.

i) with potassium borohydride. This gave 7,8-dihydro-2,4,6-trihydroxypteridine in 77% yield (see Table 17).

ii) with potassium amalgam. 2,4,6-Trihydroxypteridine (198 mg., 1 m mole) was reduced with 3%-potassium amalgam (5 g., 4 H). The solution, on adjustment to pH 6 with hydrochloric acid, gave 7,8-dihydro-2,4,6-trihydroxypteridine, which was crystallized from water (1 l.) (120 mg., 65%).

Hydrogenation of 2,4,6,-trihydroxypteridine over palladium on carbon. This gave 7,8-dihydro-2,4,6-trihydroxypteridine in 75% yield (see Table 16).

Reduction of 2-amino-4,6-dihydroxypteridine (xanthopterin)

i) with potassium borohydride. This gave 2-amino-7,8-dihydro-4,6-dihydroxypteridine in 90% yield (see Table 17).

ii) with sodium amalgam. 2-Amino-4,6-dihydroxy-pteridine (1 g.) was reduced with 4%-sodium amalgam (10 g., 3.4 H) to 2-amino-7,8-dihydro-4,6-dihydroxypteridine (752 mg., 75%).

Reduction of 2-hydroxy-6-methylpteridine with potassium borohydride. 2-Hydroxy-6-methylpteridine (360 mg.) (see p.148) was reduced by the method used for 2-hydroxy-pteridine and gave 3,4-dihydro-2-hydroxy-6-methylpteridine (96 mg., 30%), darkening above 265° but unmelted even at 300° (Found: C, 51.3; H, 4.95; N, 34.0. $C_7H_8N_4O$ requires

C, 51.2; H, 4.9; N, 34.1%). Chromatography indicated that this product was not identical with 7,8-dihydro-2-hydroxy-6-methylpteridine prepared unambiguously. In the reduction mixture a trace of a product, possibly 5,6,7,8-tetrahydro-2-hydroxy-6-methylpteridine was detected by paper chromatography, Rf: 0.75 2SB/3G (NH_4Cl), 0.23 2/3 GB (Bu/Ac).

Table 16

Hydrogenation of hydroxypteridines over 10%-palladium on carbon

Pteridine	solvent	(ml.)	Reduction period (min.)	Absorption of hydrogen	Product	Yield (%)
2-Hydroxy-	0.1N-KOH	10	20	80% for 4H	3,4-Dihydro- + 5,6,7,8-Tetrahydro-	57 (3,4-dihydro-)
4-Hydroxy-	"	"	30	60% for 4H	5,6,7,8-Tetrahydro- + unstable substance	–
6-Hydroxy-	"	"	20	2H	7,8-Dihydro-[**]	63
7-Hydroxy-	"	"	40	2H	4-Amino-5-carboxymethylaminopyrimidine[***]	64
2,4-Dihydroxy-	"	20	40	4H	5,6,7,8-Tetrahydro-[****]	–
2,6-Dihydroxy-	"	"	10	2H	7,8-Dihydro-	73
4,6-Dihydroxy-	"	"	70	2H	7,8-Dihydro-	79
2,7-Dihydroxy-	"	"	70	2H	x,y-Dihydro-	92
4,7-Dihydroxy-	"	"	17 hr.	2H	5,6-Dihydro-	67
6,7-Dihydroxy-	"	"	–	0	–	
2,4,6-Trihydroxy-	0.2N-KOH	15	15	2H	7,8-Dihydro-	75
2,4,7-Trihydroxy-	"	"	–	0	–	
2,6,7-Trihydroxy-	"	"	–	0	–	
4,6,7-Trihydroxy-	"	"	–	0	–	
2,4,6,7-Tetrahydroxy-	0.5N-KOH	10	–	0	–	

[*] In all experiments 1 m. mole of hydroxypteridines were reduced over 10%-palladium on carbon catalyst (50 mg.)

[**] (Found: C, 48.4; H, 4.2; N, 37.0. Calc. for $C_6H_6ON_4$ C, 48.0; H, 4.0; N, 37.3%).

[**] (Found: C, 42.7; H, 4.8; N, 33.3. Calc. for $C_6H_8O_2N_4$ C, 42.85; H, 4.8; N, 33.3%).

[**] This product was detected by paper chromatography.

Table 17

Reduction of hydroxypteridines with potassium borohydride

Pteridines	Starting material (m.Mole)	Solution	(ml.)	KBH$_4$ (mg.)	Product	Yield (%)	Found: C	H	N		C	H	N
2-Hydroxy-	6	0.1N-KOH	100	330	3,4-Dihydro- 5,6,7,8-Tetrahydro-	55	48.1	4.1	36.9	C$_6$H$_6$N$_4$O	48.0	4.0	37.3
4-Hydroxy-	5	N-K$_2$CO$_3$	10	500	x,y-Dihydro-	7.5	48.2	4.05	36.95	C$_6$H$_6$N$_4$O	48.0	4.0	37.3
					5,6,7,8-Tetrahydro-	8.8	47.35	5.5		C$_6$H$_8$N$_4$O$_2$	47.35	5.5	
6-Hydroxy-	1	0.1N-KOH	10	55	7,8-Dihydro-	86	47.6	4.0	36.55	C$_6$H$_6$N$_4$O	48.0	4.0	37.3
7-Hydroxy-	1	0.5N-K$_2$CO$_3$	8	55	5,6-Dihydro-	80	47.5	4.1		C$_6$H$_6$N$_4$O	48.0	4.0	
2,4-Dihydroxy-	1	0.1N-KOH	20	100	No reduction	–							
2,6-Dihydroxy-	1	0.2N-KOH	10	54	7,8-Dihydro-	80	43.2	3.75	33.6	C$_6$H$_6$N$_4$O$_2$	43.4	3.65	33.7
4,6-Dihydroxy-	2	0.1N-KOH	20	108	7,8-Dihydro-	96	43.15	3.6	33.5	C$_6$H$_6$N$_4$O$_2$	43.4	3.65	33.7
2,7-Dihydroxy-	1	0.1N-KOH	10	54	x,y-Dihydro-	84	43.45	3.75	33.65	C$_6$H$_6$N$_4$O$_2$	43.4	3.65	33.7
4,7-Dihydroxy-	1	H$_2$O	20	2x100	5,6-Dihydro-	85	43.5	3.9	33.4	C$_6$H$_6$N$_4$O$_2$	43.4	3.65	33.7
6,7-Dihydroxy-	1	0.1N-KOH	20	100	No reduction								
2,4,6-Trihydroxy-	0.76	0.3N-KOH	10	54	7,8-Dihydro-	77	38.5	3.3	30.25	C$_6$H$_6$N$_4$O$_2$·3H$_2$O	38.6	3.5	30.0
2,4,7-Trihydroxy-	0.5	0.2N-KOH	10	54	No reduction								
2,6,7-Trihydroxy-	0.5	0.2N-KOH	10	54	No reduction								
4,6,7-Trihydroxy-	0.5	0.2N-KOH	10	50	No reduction								
2,4,6,7-Tetrahydroxy-	0.5	0.2N-KOH	20	50	No reduction								
2-Amino-4,6-dihydroxy-	1	H$_2$O	5	80	7,8-Dihydro-	90	39.6	4.0	38.65	C$_6$H$_7$N$_5$O$_2$	39.8	3.9	38.55

b. Synthesis of Starting Materials

1) Chloronitropyrimidines.

2,4-Dichloro-5-nitropyrimidine

2,4-Dihydroxypyrimidine (uracil) was prepared (89%
yield) from 4-hydroxy-2-mercaptopyrimidine (thiouracil)
according to Brown (1952). 2,4-Dihydroxy-5-nitropyrimidine
was prepared (85% yield) from 2,4-dihydroxypyrimidine by
nitration according to Brown (1952). 2,4-Dichloro-5-
nitropyrimidine was prepared (77% yield) from 2,4-
dihydroxy-5-nitropyrimidine according to Whittaker (1951).
It distilled at 130°/10 mm.(lit. 138-139°/14 mm.).

4,6-Dichloro-5-nitropyrimidine.

4,6-Dihydroxypyrimidine was prepared (61% yield)
from malondiamide and ethyl formate according to Hull
(1951). The product was identified by paper chromatography
with an authentic sample and it had m.p. > 300° (Hull gives
56% yield, m.p. > 300°). 4,6-Dihydroxy-5-nitropyrimidine
was prepared (93% yield) by nitration of 4,6-dihydroxy-
pyrimidine according to Boon, Jones and Ramage (1951). The
product was identified by paper chromatography with an
authentic sample. 4,6-Dichloro-5-nitropyrimidine was
prepared (77% yield) from 4,6-dihydroxy-5-nitropyrimidine
by the action of phosphorus oxychloride and diethylaniline
according to Boon, Jones and Ramage. It had m.p. 103° (no
m.p. in lit.).

2,4-Dichloro-6-methyl-5-nitropyrimidine was prepared (69%
yield) by chlorination of 2,4-dihydroxy-5-methyl-5-
nitropyrimidine according to Albert, Brown and Wood (1954).
It had m.p. 53° (lit. 53-54°).

2,4,6-Trichloro-5-nitropyrimidine.

2,4,6-Trihydroxypyrimidine (barbituric acid) was
prepared (66% yield) by condensation of urea and diethyl
malonate according to Dickey and Gray (1943). 5-Nitro-
2,4,6-trihydroxypyrimidine was prepared (85% yield) by
nitration of 2,4,6-trihydroxypyrimidine according to
Hartman and Sheppard (1943). It had m.p. 187° (decomp.)
(lit. 181-183° (decomp.)).   2,4,6-Trichloro-5-
nitropyrimidine was prepared (23% yield) by chlorination of
2,4,6-trihydroxy-5-nitropyrimidine according to Robins,
Dille and Christensen (1954). It had m.p. 57° (lit. m.p.
57-58°).

2) 4,5-Diaminopyrimidines

4,5-Diaminopyrimidine

4-Amino-2-chloro-5-nitropyrimidine was prepared
(79% yield) from 2,4-dihydroxy-5-nitropyrimidine by the
action of phosphorus oxychloride and then ammonia according
to Brown (1952). The product after two recrystallization
from ethanol had m.p. 216°. (lit. 215-217°). 4,5-Diamino-
2-mercaptopyrimidine was prepared (54% yield, lit. 42%)

from 4-amino-2-chloro-5-nitropyrimidine by the action of
sodium hydrogen sulphide according to Brown (1952). The
product gave the same Rf. values as the authentic sample.
4,5-Diaminopyrimidine was prepared (70% yield) from 4,5-
diamino-2-mercaptopyrimidine by the action of Raney-nickel
according to Brown (1952). The product had m.p. 203-204.5°
(lit. 65% yield and m.p. 201°).

4,5-Diamino-2-hydroxypyrimidine.

2,4-Dimercaptopyrimidine was prepared (65% yield) from
4-hydroxy-2-mercaptopyrimidine by the action of phosphorus
pentasulphide according to Brown (1950). The product
darkened at 240° and decomposed at 255°, and was used for
the next reaction without further purification as it gave
only one spot on paper chromatography (Rf: 0.50 2D/3Y
(NH$_4$Cl), 0.74 2D/3Y (Bu/Ac) (lit. m.p. 265-270° (decomp.)).
4-Amino-2-mercaptopyrimidine (thiocytosine) was prepared
(75% yield) from 2,4-dimercaptopyrimidine by the action of
ammonia, according to Brown (1950), it had m.p. 266°
(decomp.) (lit. 85% yield, m.p. 265°for crude and 273° for
pure material). The crude material was used for the next
synthesis without further purification. 4-Amino-2-
hydroxypyrimidine (cytosine) was prepared (95% yield) by
hydrolysis of 4-amino-2-mercaptopyrimidine according to
Brown (1950). It had m.p. 306° (decomp.) (lit. 75%

yield and m.p. 305-308° (decomp.)).   4-Amino-2-hydroxy-
5-nitropyrimidine was prepared (89% yield) by nitration
of 4-amino-2-hydroxypyrimidine according to Johns (1911).
The product was identified by paper chromatography with an
authentic sample.   4,5-Diamino-2-hydroxypyrimidine was
prepared (76% yield) by reduction of 4-amino-2-hydroxy-5-
nitropyrimidine according to Brown (1957), m.p. 270-275°
(decomp.) (Found: C, 38.3; H, 4.85; N, 44.35. Calc. for
$C_6H_6N_4O$: C, 38.1; H, 4.83; N, 44.4%).

4,5-Diamino-6-hydroxypyrimidine

4-Amino-6-hydroxy-2-mercaptopyrimidine was prepared
(79% yield) from urea and ethyl cyanoacetate according to
Traube (1904). 4,5-Diamino-6-hydroxy-2-mercaptopyrimidine
was prepared (89% yield) from 4-amino-6-hydroxy-2-mercapto-
pyrimidine by nitrosation and then reduction according to
Albert, Brown and Cheeseman (1951). The product was
identified with an authentic sample by paper chromatography.
4,5-Diamino-6-hydroxypyrimidine was prepared (46% yield) from
4,5-diamino-6-hydroxy-2-mercaptopyrimidine by the action of
Raney-nickel according to Albert, Brown and Cheeseman (1951).
It had m.p. 238° (decomp.) (lit. 239°).

4,5-Diamino-2,6-dihydroxypyrimidine.

4-Amino-2,6-dihydroxypyrimidine was prepared from urea
and ethyl cyanoacetate according to Cain, Mallette and Taylor
(1946). 4,5-Diamino-2,6-dihydroxypyrimidine was prepared
from 4-amino-2,6-dihydroxypyrimidine by nitrosation and

subsequent reduction with sodium dithionite according to Cain et al. (1946). The overall yield from ethyl cyanoacetate was 27%. The product was identified with an authentic sample by paper chromatography.

2,4,5-Triamino-6-hydroxypyrimidine bisulphite, was prepared (70% yield) from guanidine hydrochloride and ethyl cyanoacetate according to Cain, Mallette and Taylor (1946). The product was identified with an authentic sample by paper chromatography.

3) Pteridines.

All pteridines in Table 18 were prepared in one step by known methods from the 4,5-diaminopyrimidines described above. Most pteridines have no melting points and usually have no sharp decomposition points. Hence all such pteridines described in this experimental part were examined for their identity and purity by paper chromatography . These results are summarized in Table 18.

Table 18

Synthesis of hydroxypteridines

Pteridine	Ref.	Yield (%)	m.p.	Rf NH_4Cl	Bu/Ac
Unsubstituted	1	70	138–139	0.78 2DB/3D	0.71 2X/3B
2-Hydroxy-	1	87	240(d)[*]	0.74 2WB/3X	0.80 2W/3B
4-Hydroxy-	2	60	>300(d)	0.68 2D/3X	0.26 2D/3X
6-Hydroxy-	3	85	240(d)	0.66 2D/3X	
7-Hydroxy-	4	70	>300(d)	0.64 2B/3V	0.54 2X/3B
2,4-Dihydroxy-	1	51	250(d)	0.65 2D/3B	0.23 2W/3B
2,6-Dihydroxy-	4	61	>280(d)	0.67 2/3B	0.13 2/3B
2,7-Dihydroxy-	4	35	>320(d)	0.50 2DB/3V	0.16 2D/3V
4,6-Dihydroxy-	5	50	>300(d)	0.63 2/3B	0.32 2/3B
4,7-Dihydroxy-	6	20	>300(d)	0.61 2DB/3BV	**0.14** 2X/3B
6,7-Dihydroxy-	7	88	>300(d)	0.60 2B/3VB	0.25 2B/3V
2,4,6-Trihydroxy-	4	50	>300(d)	0.50 2/3SB	0.25 2/3SB
2,4,7-Trihydroxy-	8		>300(d)	0.43 2/3B	0.05 2B/3VB
2,6,7-Trihydroxy-	4	95	>300(d)	0.63 2/3B[**] / 0.55 2/3B	0.06 2WB/3B
4,6,7-Trihydroxy-	5	90	>300(d)	0.37 2WB/3B	0.04 2W/3X
2,4,6,7-Tetrahydroxy-	4	45	>300(d)	0.30 2WB/3B	0.02 2D/3X
2-Amino-4,6-dihydroxy-	9	45	>300(d)	0.36 2/3Y	0.15 2/3Y

1 Albert, Brown and Cheeseman, 1951
2 Albert, Brown and Wood,   1956
3 Albert,   1955
4 Albert, Lister and Pedersen, 1956
5 Albert and Brown,   1953
6 Pfleiderer,   1959
7 Albert, Brown and Cheeseman, 1952
8 Pfleiderer,   1957
9 Korte,   1954

[*] Decomposed without melting.

[**] In aqueous solution, this compound present as an equilibrium mixture of two species, Albert, Lister and Pedersen (1954).

c. <u>Syntheses of Hydrogenated Pteridines</u>.

<u>7,8-Dihydro-2-hydroxy-6-methylpteridine</u>.

<u>Phthalimidoacetone</u> was prepared as follows according to

Dr. F. Reich (personal communication): Bromoacetone (60 g.

0.48 mole) was added to potassium phthalimide (92 g. 0.5 mole)

in dimethylformamide at 60-70° and kept at this temperature

for 1 hr. Water (450 ml.) was added to the reaction mixture

and then extracted with chloroform (3 x 150 ml.). The

chloroform layer was washed with 0.5 N - sodium hydroxide and

with water. Removal of the chloroform gave a solid which

melted at 122° (Ellinger and Goldberg, 1949 give m.p. 111-120°).

Aminoacetone hydrochloride was prepared (74% yield) by

hydrolysis of phthalimidoacetone according to Ellinger and

Goldberg (1949). It had m.p. 81°. 4-Acetonylamino-2-chloro-

5-nitropyrimidine was prepared (62% yield) from 2,4-dichloro-

5-nitropyrimidine (see p.141) and aminoacetone hydrochloride

according to Boon and Jones (1951). It had m.p. 129-130°

(lit. 131°). The chloro-substituent was changed into a

hydroxy group as follows: 2-chloro-4-acetonylamino-5-

nitropyrimidine (6.9 g. 0.03 mole) and sodium acetate trihydrate

(6 g., 0.054 mole) in glacial acetic acid (100 ml.) were

refluxed for 80 min. Recrystallization of the product from

water gave <u>4-acetonylamino-2-hydroxy-5-nitropyrimidine</u> as

colourless prisms (2.3 g., 36%), m.p. 186° (decomp.) (Found:

C, 39.55; H, 3.9. $C_7H_8N_4O_4$ requires C, 39.6; H, 3.8%).

This product was reduced and cyclized simultaneously as follows:

After removal of the ammonia, 6 N - sodium hydroxide was added to the residue and the solution was continuously extracted with benzene. The extract, after drying over sodium sulphate, was fractionated, and the product distilled at 65°/17 mm (55.2 g., 75%). (Allen et al. give 32-39% yield). Woodward and Doering (1945) record 72.5% and b.p. 99-103°/100 mm., but such a high yield has not been obtained here by following their direction[s] which evidently lack some essential detail.

4-β-Diethoxyethylamino-2-hydroxy-5-nitropyrimidine.

Aminoacetal (135 g., 0.1 mole) in water (100 ml.) was adjusted to pH 7.5 with acetic acid and sodium bicarbonate (12 g.) was added. The solution was added dropwise, with shaking, to 2,4-dichloro-5-nitropyrimidine (20 g., 0.101 mole) in chloroform (100 ml.). Shaking was continued for a further 3 hr. until evolution of carbon dioxide had ceased. The chloroform layer was distilled with N - sodium hydroxide (500 ml.) on a steam bath while bubbling nitrogen through the solution for about 20 min. (During this time the 2-chloro-substituent was replaced by a hydroxy group). The mixture was extracted with benzene (3 x 30 ml.) and the aqueous solution, after adjustment to pH 6, was refrigerated overnight. The product crystallized from ethanol giving 4-β-diethoxyethylamino-2-hydroxy-5-nitropyrimidine as colourless leaflets (14.4 g., 53%), m.p. 157° (Found:

C, 44.15; H, 5.9. $C_{10}H_{16}N_4O_5$ requires C, 44.1; H, 5.9%).
The benzene extract was evaporated to dryness, and the
residue recrystallized from aqueous ethanol giving
2,4-bis-β-diethoxyethylamino-5-nitropyrimidine as colourless
needles, m.p. 99-100° (Found: C, 49.8; H, 7.3.
$C_{16}H_{29}N_5O_6$ requires C, 49.6; H, 7.55%).

5-Amino-4-β-diethoxyethylamino-2-hydroxypyrimidine.
4-β-Diethoxyethylamino-2-hydroxy-5-nitropyrimidine (2.53 g.)
in ethanol (300 ml.) was hydrogenated over Raney-nickel.
After the absorption had ceased (640 ml. of hydrogen, 89%
for 6 H) the catalyst was filtered off and the filtrate was
evaporated to dryness at room temperature in a nitrogen
atmosphere. The residue crystallized from ethanol-ethyl
acetate (1:9) to give 5-amino-4-β-diethoxyethylamino-2-
hydroxypyrimidine as a pale green powder (1.2 g., 53%), m.p.
174-175° (Found for substance dried at $20°/10^{-1}$ mm. :
C, 47.0; H, 7.9; N, 22.1. $C_{10}H_{18}N_4O_3 \cdot 3/4 H_2O$ requires
C, 46.95; H, 7.7; N, 21.95%).

Attempted cyclization of 5-amino-4-β-diethoxyethylamino-
2-hydroxypyrimidine (a) The 5-aminopyrimidine (154 mg.) in
0.1 N - hydrochloric acid was refluxed under nitrogen for
15 min., and adjusted to pH 6 with sodium hydroxide. The
precipitate was filtered off and reprecipitated from 0.1 N -
hydrochloric acid solution with N- sodium hydroxide giving a
pale buff powder (22 mg.) which decomposed at 220-230°

without melting (Found: C, 42.7; H, 4.65; N, 32.95.

Calc. for $C_6H_6N_4O.H_2O$: C, 42.85; H, 4.8; N, 33.3%).

Rf. 0.61 2/3B (NH_4Cl), 0.07 (Bu/Ac). (7,8-Dihydro-2-

hydroxypteridine prepared by a different method (see, p.152)

had Rf. 0.61 2/3 B (NH_4Cl)).

The filtrate was evaporated to dryness under nitrogen

and the residue was extracted with hot ethanol (6 ml.) and

evaporated to dryness. The residue was crystallized from

ethanol-ethyl acetate (1:1) giving a pale buff powder .(It

behaved like (3b-VII) see p. 69), m.p. 170-175° (decomp.)

(Found: C, 41.1; H, 5.65; N, 23.1. $C_8H_{14}N_4O_3.H_2O$ requires

C, 41.4; H, 6.9; N, 24.1%). Rf. 0.83 2/3 B (NH_4Cl), 0.35

2/3 B (Bu/Ac). Although paper chromatography showed that

it contained a small amount of the former compound (Rf.

0.61 2/3 B), further purification of this compound was

abandoned because during the purification it changed to

the former compound.

(b) The 5-amino-4-β-diethoxyethylaminopyrimidine, when

refluxed with N-hydrochloric acid for 45 min. under nitrogen,

gave a buff powder, Rf. 0.29 2D/3B (NH_4Cl), 0.08 2/3B

(Bu/Ac).   The same compound was also obtained from the above

two compounds by heating with N- hydrochloric acid.

4-Formylmethylamino-2-hydroxy-5-nitropyrimidine. 4-β-

Diethoxyethylamino-2-hydroxy-5-nitropyrimidine (14 g.) was

refluxed with N- hydrochloric acid (100 ml.) for 20 min.

Adjustment of the mixture to pH 4 with sodium bicarbonate gave 4-formylmethylamino-2-hydroxy-5-nitropyrimidine as colourless needles (8.4 g., 82%) which were recrystallized from water. It darkened at 220-225° without melting (Found: C, 36.5; H, 3.15. $C_6H_6N_4O_4$ requires C, 36.4; H, 3.05%).

7,8-Dihydro-2-hydroxypteridine. 4-Formylmethylamino-2-hydroxy-5-nitropyrimidine (1.98 g.) was hydrogenated over Raney-nickel. The catalyst was collected and extracted with boiling water (80 ml.) giving 7,8-dihydro-2-hydroxypteridine (352 mg., 23%) which recrystallized from water as micro-prisms, decomposing at 190° without melting (Found, after drying at 135°/10^{-1} mm.: C, 47.0; H, 4.1; N, 36.6. $C_6H_6N_4O.1/4 H_2O$ requires C, 46.6; H, 4.25; N, 36.2%). Rf. 0.61 2/3 B (NH_4Cl): in Bu/Ac it decomposed. The methanolic filtrate on concentration, gave more of the crude dihydro-compound which had the same Rf. values as above, but this did not satisfactorily recrystallize from water, probably due to impurity.

5,6,7,8-Tetrahydro-2-hydroxypteridine.

7,8-Dihydro-2-hydroxypteridine in water (100 ml.) was hydrogenated over Adams' catalyst. After removal of the catalyst the filtrate was evaporated to dryness. The residue, on crystallization from water (5 ml.), gave 5,6,7,8-tetrahydro-2-hydroxypteridine as pale buff needles,

decomposing at 220° without melting (Found, after drying at 106°/10⁻¹ mm.: C, 47.5; H, 5.9; N, 36.4. $C_6H_8ON_4$ requires C, 47.35; H, 5.3; N, 36.8%). The anhydrous material was unusually hygroscopic and absorbed one mole of water from air in 20 min.

5,6-Dihydro-2-hydroxypteridine

β-Chloropropionaldehyde acetal was prepared (19% yield) from acrolein by the action of ethanolic hydrogen chloride according to Witzemann, Evans, Hass and Schroeder (1943). It had b.p. 65-70°/15 mm. (lit. 58-62°/8 mm.). It was converted to acrolein acetal (in 78% yield) by the action of potassium hydroxide (same reference). It boiled at 120-121°/720 mm. (lit. 122-126°). Glyceraldehyde acetal was prepared (50% yield) from acrolein acetal by oxidation with potassium permanganate (same reference). It boiled at 79°/1 mm. (lit. 120-121°/8 mm.). Glyoxal monoacetal was prepared (46% yield) from glyceraldehyde acetal according to Fischer and Baer (1935). It boiled at 50-60°/18 mm. (lit. 42-43°/12-13 mm.).

4-Amino-5-β-diethoxyethylamino-2-hydroxypyrimidine.

4,5-Diamino-2-hydroxypyrimidine (630 mg., 5 m mole) and glyoxal monoacetal (850 mg., 5.2 m mole) in water (25 ml.) were heated for 10 min. on a steam bath. The mixture was evaporated to dryness under reduced pressure and the residue was triturated with acetone. The solid, in 97% ethanol (50 ml.),

was hydrogenated over Raney-nickel. Removal of the catalyst, and concentration of the filtrate gave 4-amino-5-β-diethoxyethylamino-2-hydroxypyrimidine (117 mg., 10%) as needles which crystallized from ethanol, m.p. 198-200° (Found: C, 49.15; H, 7.4; N, 22.7. $C_{10}H_{18}N_4O_3$ requires C, 49.6; H, 7.5; N, 23.1%).

Attempt to prepare 3,4-dihydro-2-hydroxypteridine.

2-Aminopyrazine-3-aldehyde oxime was prepared (54% yield) from pteridine by the action of hydroxylamine hydrochloride in 2N-sodium carbonate followed by heating with N-acetic acid according to Albert, Brown and Wood (1956). It had m.p. 200° (lit. 199-200°).

Reduction of 2-aminopyrazine-3-aldehyde oxime. Various conditions (see Table 19) were used for the reduction of the oxime, and hydrogenation over Adams' catalyst in N-acetic acid gave the best result. Although the reduction mixture exhibited one main spot on paper chromatography, 0.70 2/3 V (NH_4Cl) and 0.20 2/3 V (Bu/Ac), no pure compound could be isolated and it slowly changed in air to a dark resin. Treatment of the crude product with urea (190°, 45 min.), urethane (180°, 1 hr.) or ethyl chloroformate (reflux for 3 hr.) gave no product corresponding to 3,4-dihydro-2-hydroxypteridine.

Table 19

Reduction of 2-aminopyrazine-3-aldehyde oxime

Reductant	Result
$Na_2S_2O_4$	Many spots on paper chromatography.
Na–Hg	Ammonia evolved.
$LiAlH_4$	Many spots on paper chromatography.
H_2/PtO_2 in HCl	Went brown, half of theoretical H_2 abosrbed.
H_2/PtO_2 in aqueous NH_4OH	No reduction.
H_2/PtO_2 in 0.1N- acetic acid	5 H were absorbed (4 H for theoretical) and one main spot on paper chromatography.

Reduction of 2-amino-3-cyanopyrazine over Adams' catalyst gave results similar to the reduction of the oxime described above.

2-Amino-3-carboxypyrazine was prepared (79% yield) by heating the ammonium salt of 2,4-dihydroxypteridine with 2.5N-sodium hydroxide according to Weijlard, Tishler and Erickson (1945). It decomposed at 203° (lit. 201°).

2-Amino-3-methoxycarbonylpyrazine was prepared (70% yield) from 2-amino-3-carboxypyrazine by the action of methanolic sulphuric acid according to Ellingson, Henry and McDonald (1945). It had m.p. 172-173° (lit. 172°).

2-Amino-3-hydroxymethylpyrazine. Lithium aluminium hydride (80 mg.) was added to a solution of 2-amino-3-carboxymethyl-pyrazine (1.53 g.) in tetrahydrofuran (200 ml.) and kept at room temperature for 2 hr. The complex was decomposed with water (3 ml.) and the inorganic salt was filtered off. The filtrate was evaporated to dryness and extracted with ether. After removal of the ether, crystallization of the residue from amyl acetate gave 2-amino-3-hydroxymethylpyrazine as colourless needles (574 mg., 46%), m.p. 118-119.5° (Found, after drying at $65°/10^{-1}$mm.: C, 47.65; H, 5.7; N, 33.1. $C_5H_7N_3O$ requires C, 48.0; H, 5.65; N, 33.6%).

Attempts at the synthesis of 3,4-dihydro-2-hydroxypteridine from 2-amino-3-hydroxymethylpyrazine (a) The pyrazine (100 mg.) in hydrobromic acid (sp. gr. 1.48, 1 ml.) was kept overnight at room temperature. Only the starting material was detected by paper chromatography.

(b) The pyrazine (100 mg.) was refluxed with hydrobromic acid (sp. gr. 1.48, 2.5 ml.). Soon after boiling the mixture became a brown resin and no product was obtained from it.

(c) The pyrazine (100 mg.) was mixed with urea and heated at 170°C for 45 min. Paper chromatography of the product indicated that no reaction had occurred.

(d) The pyrazine (100 mg.) and urethane (0.5 g.) was heated at 190° for 1 hr. Paper chromatography of the product indicated

that no reaction had occurred.

(e) The pyrazine (63 mg.) and potassium cyanate (31 mg.)
in N-hydrochloric acid (6.5 ml.) were refluxed for 45 min.
Paper chromatography of the reaction mixture indicated that
no reaction had occurred.

Hydrogenation of 4,5-diamino-2-hydroxypyrimidine. When
4,5-diamino-2-hydroxypyrimidine (1.26 g., 10 m mole) in 0.5N-
hydrochloric acid (40 ml., 2 eq.) was hydrogenated over 10%
palladium on carbon, 250 ml. of hydrogen (2 H) was absorbed.
After removal of the catalyst, the filtrate was concentrated
to 3 ml. and the product was precipitated with methanol
(3 ml.). Recrystallization from 90% methanol (50 ml.)
gave the product as colourless needles, m.p. 242-248°
(decomp.) (Found, after drying at 62°/10^{-1} mm.: C, 27.7;
H, 5.2; N, 23.85. $C_4H_7N_3O_2 \cdot HCl \cdot \frac{1}{2}H_2O$ requires C, 27.5;
H, 5.15; N, 24.1%). The analysis and properties indicate
the product is an amino-dihydro-dihydroxy-pyrimidine
hydrochloride hemihydrate.

5,6,7,8-Tetrahydro-4-hydroxypteridine.

Benzylaminoethanol was prepared from benzylchloride
and ethanolamine according to Dr. D.J. Brown (personal
communication) with slight modification. Benzylchloride
(250 g., 2 mole) and ethanolamine (500 g., 8 mole) was
heated on a steam bath for 2 hr. with gentle stirring.

After cooling, 2N-sodium hydroxide (1 l.) was added to the mixture and extracted with ether. The extract was washed with water and dried over potassium carbonate. After removal of the ether, the residue was fractionated under vacuum, benzylaminoethanol distilled at 94-96°/0.02 mm. (121 g., 41%) (lit. 148-149/13 mm.).

5-Amino-4-(benzyl-β-hydroxyethylamino)-6-chloropyrimidine hydrochloride. A solution of benzylaminoethanol (15 g., 0.1 mole) in chloroform (40 ml.) was added dropwise with shaking to a mixture of 4,6-dichloro-5-nitropyrimidine (19.5 g., 0.1 mole) in chloroform (150 ml.) and sodium bicarbonate (8.4 g., 0.1 mole) in water (30 ml.). Shaking was continued until the evolution of carbon dioxide ceased. The chloroform layer was washed with water (50 ml.) dried over sodium sulphate, and evaporated under reduced pressure to give an oil (37 g.). The oil, on hydrogenation over Raney-nickel, absorbed 6.6 l. of hydrogen (6 H). After removal of the catalyst the filtrate was concentrated to 100 ml., adjusted to about pH 1 with ethanolic hydrogen chloride. Refrigeration of the solution gave 5-amino-4-(benzyl-β-hydroxyethylamino)-6-chloropyrimidine hydrochloride as colourless prisms (9.3 g., 34%). For analysis it was rapidly recrystallized from ethanol below 70° giving colourless prisms, m.p. 130° (Found, after drying at

$62^{\circ}/10^{-1}$ mm. : C, 49.6; H, 5.2; Cl, 22.5; N, 17.8.

$C_{13}H_{16}Cl_2N_4O$ requires C, 49.5; H, 5.1; Cl, 22.5; N, 17.8%).

Rf.: 0.62 2D/3X (NH_4Cl), 0.94 2D/3X (Bu/Ac). When boiled in

ethanol for 5 min. the above pyrimidine rearranged to an

isomer, m.p. 202-203° (Found, after drying at $62^{\circ}/10^{-1}$ mm.:

C, 49.65; H, 5.2; Cl, 22.6; N, 18.0. $C_{13}H_{16}Cl_2N_4O$ requires

C, 49.5; H, 5.1; Cl, 22.5; N, 17.8%). Rf.: 0.77 2D/3X

(NH_4Cl), 0.66 2D/3X (Bu/Ac). This compound on treatment with

phosphorus trichloride did not give a tetrahydropteridine.

8-Benzyl-4-chloro-5,6,7,8-tetrahydropteridine . 5-

Amino-4-(benzyl-β-hydroxyethylamino)-6-chloropyrimidine

(1.5 g.) was added at 10° C.to phosphorus trichloride and kept

at room temperature overnight. The excess of phosphorus

trichloride was distilled off at room temperature and the

residue was dissolved in water (30 ml.). The aqueous

solution was extracted with chloroform and then adjusted to

pH 7 with sodium bicarbonate. The solution was extracted

with chloroform. Removal of the chloroform gave 8-benzyl-

4-chloro-5,6,7,8-tetrahydropteridine (975 mg., 79%) which was

recrystallized from ethanol (4.5 ml.) as colourless needles,

m.p. 127-128° (Found, after drying at $74^{\circ}/10^{-1}$ mm.: C, 59.9;

H, 5.0; Cl, 13.95; N, 21.3. $C_{13}H_{13}ClN_4$ requires C, 59.9;

H, 5.0; Cl, 13.6; N, 21.45%).

5,6,7,8-Tetrahydropteridine. Metallic sodium was added in small portions to a solution of 8-benzyl-4-chloro-5,6,7,8-tetrahydropteridine in liquid ammonia (130 ml.) until a permanent blue colour remained, and the colour was retained for 50 min. by addition of sodium. Ammonium chloride was added until the blue colour disappeared and the ammonia was evaporated. Water (3 ml.) was added to the residue which was then extracted with chloroform (5 x 10 ml.). The chloroform extract was evaporated to dryness and the residue was purified by sublimation. 5,6,7,8-Tetrahydropteridine (66 mg., 14%) had m.p. 147° (Brook and Ramage (1957) give m.p. 146-7°).

Attempted hydrolysis of 8-benzyl-4-chloro-5,6,7,8-tetrahydropteridine. A typical method is shown below: 8-Benzyl-4-chloro-5,6,7,8-tetrahydropteridine (120 mg.) was refluxed with N-sodium hydroxide (50 ml.) and ethanol (10 ml.) under nitrogen for 3 hr. The mixture was adjusted to pH 7 and evaporated to dryness. The residue was dissolved in ethanol (50 ml.), and water (50 ml.) was added dropwise to the boiling ethanol solution. This gave colourless needles (100 mg., m.p. 126.5-127°) which had the same Rf. values as the starting material and showed no melting point depression with it. The results of the reactions under various conditions are summarized below.

Reaction conditions (refluxed for 3 hr.)	Starting material (mg.)	Recovery of the starting material (mg.)
Acetate buffer (pH 5) glacial acetic acid	95	86
+ sodium acetate	120	100
6N-HCl	120	95
12N-HCl	120	95
N-NaOH	120	100
2% sodium methoxide	120	96
4% sodium hydroxide in tri-(ethyleneglycol)	120	*

*No product was isolated. No spot corresponding to the 4-hydroxy derivative was detected.

5-Amino-4-(benzyl-β-hydroxyethylamino)-6-benzyloxy-pyrimidine .

4,6-Dichloro-5-nitropyrimidine (10 g.) and benzylaminoethanol (7.8 g.) was condensed by the method described before, and the chloroform layer was washed with water, dried over sodium sulphate, and the chloroform removed. Benzene (15 ml.) was added to the residual oil and then distilled off under vacuum at 30°C, this treatment was repeated to remove the water and chloroform completely. Sodium benzyloxide (sodium, 2.5 g. in benzylalcohol, 70 ml.) was added to the residue and heated on a steam bath for 10 min. Dry-ice was added to the cooled mixture to decompose the alcoholate and

then water (50 ml.) was added.   The mixture was adjusted to

pH 6 with acetic acid and then the benzyl alcohol was removed

by steam distillation (4 hr.).   The **residual** solution was

extracted with benzene, and the benzene layer was dried over

sodium sulphate.   After removal of the benzene a light brown

oil (21 g.) remained.   The oil (21 g.) in ethanol over Raney-

nickel absorbed 2.6 l. of hydrogen (this corresponds to 13.3 g.

of the product).   After removal of the catalyst, the filtrate

was concentrated to about 40 ml.   10%-Ethanolic hydrogen

chloride (10 ml.) was added to the concentrate and refrigerated

for two days, giving needles (604 mg., 3%).   The product after

crystallization from ethanol gave 5-amino-4-(benzyl-β-

hydroxyethylamino)-6-benzyloxypyrimidine as colourless needles,

m.p. 203° (Found: C, 62.5; H, 6.0; N, 14.35. $C_{20}H_{22}N_4O_2$.HCl

requires C, 62.1; H, 6.0; N, 14.5%).

Attempted cyclization of 5-amino-4-(benzyl-β-

hydroxyethylamino)-6-benzyloxypyrimidine.   5-Amino-6-

benzyloxy-4-(benzyl-β-hydroxyethylamino)-pyrimidine (600 mg.)

was added to phosphorus trichloride (10 ml.) and kept at room

temperature.overnight.   Excess phosphorus trichloride was

distilled off under reduced pressure at room temperature and

crushed ice (5 g.) was added to the residue.   The solution was

extracted with benzene and adjustment of the aqueous solution

to pH 6 gave <u>5-amino-4-(benzyl-β-hydroxyethylamino)-6-</u>
<u>hydroxypyrimidine hydrochloride</u> (218 mg., 48%) which was
recrystallized from water, m.p. 246-247° (decomp.). The
free base was obtained by recrystallizarion of the hydrochloride
at pH 9.7, m.p. 140-142° (Found: C, 59.7; H, 6.3; N, 21.0.
$C_{13}H_{16}N_4O_2$ requires C, 60.0; H, 6.2; N, 21.5%).

    <u>4-Chloro-6-ethoxy-5-nitropyrimidine</u> was prepared (88%)
from 4,6-dichloro-5-nitropyrimidine and sodium ethoxide according
to Boon and Jones (1951). The product had b.p. 74°/1 mm. and
m.p. 45.5-46.5° (lit. m.p. 42°).

    <u>8-Benzyl-5,6,7,8-tetrahydro-4-hydroxypteridine.</u>
Benzylaminoethanol (3.8 g. in 10 ml. methanol, 26 m. mole) was
added to 4-chloro-6-ethoxy-5-nitropyrimidine (2.47 g. in 15 ml.
methanol, 12 m mole) at 0°, and kept at room temperature over-
night. Excess methanol was removed and water (50 ml.) was
added to the residual oil. The mixture was extracted with
benzene (2 x 25 ml.) and the benzene layer was washed with
water (5 x 50 ml.) to remove benzylaminoethanol.

    After removal of the benzene under reduced pressure
the residual oil was hydrogenated in ethanol over Raney-nickel,
and 890 ml. of hydrogen was absorbed. After removal of the
catalyst, the filtrate was concentrated and the excess ethanol
was completely removed by distillation with benzene.

    Phosphorus trichloride (15 g. in 30 ml. benzene) was
added to the residual oil (in 30 ml. benzene) at 0°, and the

mixture kept at room temperature for 2.5 days. Paper chromatography indicated that cyclization and simultaneous hydrolysis occurred during this period. The benzene layer was discarded, and crushed ice (50 g.) was added to the residue. The mixture was extracted with benzene, and the aqueous solution was adjusted to pH 7 with sodium bicarbonate. Crystallization of the product from ethanol gave 8-benzyl-5,6,7,8-tetrahydro-4-hydroxypteridine as colourless needles (747 mg., 26%), m.p. 170-171° (Found: C, 64.15; H, 5.75; N, 23.1. $C_{13}H_{14}N_4O$ requires C, 64.45; H, 5.8; N, 23.1%).

5,6,7,8-Tetrahydro-4-hydroxypteridine. Finely grounded 8-benzyl-5,6,7,8-tetrahydro-4-hydroxypteridine (1.0 g.) was added to liquid ammonia (130 ml.) followed by sodium until the solution became deep blue, and this blue colour was retained for 30 min. by the addition of sodium (about 350 mg. was necessary). Ammonium chloride was added until the blue colour disappeared, and the excess of ammonia was evaporated under nitrogen. Water was added to the residue and the solution was adjusted to pH 6 with N-hydrochloric acid. The solution was extracted with chloroform and the aqueous layer was evaporated to dryness under reduced pressure. The residue was extracted with hot ethanol and the extract was evaporated to dryness. Crystallization of the residue from water gave 5,6,7,8-tetrahydro-4-hydroxypteridine as pale buff needles (348 mg., 54%), m.p. 234-238° (decomp.) (Found, after drying at $135°/10^{-1}$mm.:

C, 47.25; H, 5.6; N, 36.35 Calc. for $C_6H_8N_4O$: C, 47.35; H, 5.3; N, 36.8%).

5,6-Dihydro-4-hydroxypteridine

4-Amino-5-β-diethoxyethylamino-6-hydroxypyrimidine. 4,5-Diamino-6-hydroxypyrimidine (1.26 g., 10 m mole) and glyoxal monoacetal (1.7 g., 13 m mole) in 90% ethanol (200 ml.) were hydrogenated over Raney-nickel. After removal of the catalyst, the filtrate was evaporated to dryness. Crystallization of the residue from acetone gave 4-amino-5-β-diethoxyethylamino-6-hydroxypyrimidine (837 mg., 35%) as colourless needles. It decomposed at 142° (Found, after drying at 65°/10^{-1} mm.: C, 49.1; H, 7.6; N, 23.15. $C_{10}H_{18}N_4O_3$ requires C, 49.55; H, 7.5; N, 23.15%).

5,6-Dihydro-4-hydroxypteridine. 4-Amino-5-β-diethoxyethylamino-6-hydroxypyrimidine (839 mg.) was boiled with 0.5N-hydrochloric acid (10 ml.) for 1 min. and cooled immediately. The solution was adjusted to pH 5 with sodium bicarbonate and refrigerated overnight. The precipitate on crystallization from water gave 5,6-dihydro-4-hydroxypteridine as colourless needles 486 mg., 88%. It decomposed at 230° (Found, after drying at 20°/10^{-1} mm.: C, 46.4; H, 4.35; N, 36.5. $C_6H_6ON_4 \cdot 1/4\ H_2O$ requires C, 46.6; H, 4.25; N, 36.2%). Although the product retained 1/4 molecule of water when dried at 20°/10^{-1} mm., no isolated carbonyl group could be detected by an infrared spectrum. This indicates that the product has entirely the ring-closed structure.

Attempted syntheses for 7,8-dihydro-4-hydroxypteridine.

4-β-Diethoxyethylamino-6-hydroxy-5-nitropyrimidine.

Amino acetal (5.4 g.) in water (50 ml.) was adjusted to pH 8 with acetic acid and then sodium bicarbonate (6.0 g.) was added to the solution. The solution was added dropwise with shaking to a cold solution of 4,6-dichloro-5-nitropyrimidine (7.9 g.) in chloroform (50 ml.). Shaking was continued for a further 2 hr. at room temperature. The chloroform layer was distilled with N-sodium hydroxide (200 ml.) on a steam bath while bubbling nitrogen through the solution for about 20 min. (During this time the 4-chloro-substituent was replaced by a hydroxy group). The residual solution was extracted with benzene and the aqueous solution was adjusted to pH 6 with acetic acid. The precipitate on crystallization from ethanol gave 4-β-diethoxyethylamino-6-hydroxy-5-nitropyrimidine (2.99 g., 27%), m.p. 118-120°. (Found: C, 42.35; H, 6.1. $C_{10}H_{16}N_4O_5 \cdot \frac{1}{2}H_2O$ requires C, 42.75; H, 6.1%).

Reduction of 4-β-diethoxyethylamino-6-hydroxy-5-nitropyrimidine (a) When 4-β-diethoxyethylamino-6-hydroxy-5-nitropyrimidine (140 mg., 0.5 m mole) was hydrogenated over Raney-nickel, 120 ml. of hydrogen (=10 H, 6 H for NO_2 group) was absorbed, and the reduction mixture turned brown. Concentration of the filtrate gave a brown oil which on heating with 0.1 N-hydrochloric acid for 15 min. gave a dark resin, and no product could be isolated. (b) The nitropyrimidine (700 mg.) in acetic acid was reduced with zinc

dust (2.1 g.). After removal of the excess zinc the filtrate
was concentrated to dryness, and the residue extracted with
methanol. The extract gave a spot similar to the above
reduction product (a) on paper chromatography, but no product
could be isolated.

Hydrolysis of 4-β-diethoxyethylamino-6-hydroxy-5-
nitropyrimidine. 4-β-Diethoxyethylamino-6-hydroxy-5-
nitropyrimidine (1.5 g., 5 m mole) in N-hydrochloric acid
(25 ml.) was refluxed for 10 min. The crystals were
filtered off and recrystallized from water giving colourless
needles (967 mg., 89%). The substance decomposed slowly at
230° without melting (Found: C, 39.25; H, 2.6.
$C_{12}H_8N_8O_6 \cdot \frac{1}{2}H_2O$ requires C, 39.05; H, 2.45%). The product
absorbed 5 molecules of hydrogen over Raney-nickel and gave
a dark resinous product.

Attempted syntheses for 7,8-dihydro-4-hydroxy-6-methylpteridine.

4-Acetonylamino-6-chloro-5-nitropyrimidine was prepared
(47% yield) from 4,6-dichloro-5-nitropyrimidine and aminoacetone
hydrochloride according to Boon and Jones (1951). It had
m.p. 84° (lit. 86°).

4-Acetonylamino-6-hydroxy-5-nitropyrimidine. 4-
Acetonylamino-6-chloro-5-nitropyrimidine (3.6 g.) was dissolved
in 50% aqueous ethanol and kept at room temperature overnight.
The precipitate, crystallized from ethanol, gave 4-
acetonylamino-6-hydroxy-5-nitropyrimidine as needles, m.p.

207° (decomp.) (Found: C, 39.1; H, 4.3. $C_7H_8N_4O_4$ requires
C, 39.6, H, 3.8%). Repeated crystallization of the product
caused loss of one molecule of water from the molecule and
gave a product which decomposed at 230° without melting
(Found: C, 43.2; H, 3.5. $C_7H_6N_4O_3$ requires C, 43.4;
H, 3.1%).

Hydrogenation of 4-acetonylamino-6-hydroxy-5-
nitropyrimidine. The nitropyrimidine absorbed 3 mole of
hydrogen over Raney-nickel, but the reduction mixture turned
brown. No pure product could be isolated from the mixture, and
no spot similar to that of x,y-dihydro-4-hydroxypteridine was
detected on paper chromatography.

Attempted synthesis for 1,2-dihydro-4-hydroxypteridine
(a) 2-Amino-3-carbamoylpyrazine (30 mg.) in (5 ml.) water was
heated with 30% formaldehyde (0.2 ml.) on a steam bath for 20
min. No product other than the starting material was detected
in the reaction mixture. (b) The pyrazine (50 mg.) in ethanol
(10 ml.) was refluxed for 45 min. with 30% formaldehyde (0.1 ml.).
No product other than the starting material was detected by
paper chromatography.

Attempted syntheses of 5,6-dihydro-7-hydroxypteridine.

Attempted preparation of the Schiff's base of 4,5-
diaminopyrimidine and ethyl glyoxylate. (a) Ethyl glyoxylate
hemiacetal (Rigby, 1950) (145 mg., 1 m mole) was added to a
solution of 4,5-diaminopyrimidine (110 mg., 1 m mole) and

kept at room temperature for 10 min. Only 7-hydroxypteridine was detected in the reaction mixture, and no spot corresponding to the Schiff's base was detected. (b) Ethyl glyoxylate hemiacetal (15 mg., 0.1 m mole) was added to 4,5-diamino-pyrimidine (10 mg., 0.1 m mole) in methanol (10 ml.). The solution had the same ultraviolet spectrum as 4,5-diamino-pyrimidine. When the solution was diluted with water, it gave the same ultraviolet spectrum as 7-hydroxypteridine, and no Schiff's base formation was detected.

4-Amino-5-cyanomethylaminopyrimidine. Potassium cyanide (70 mg., in 2 ml. water) was added to 4,5-diaminopyrimidine (1.1 g.) in methanol (10 ml.) and the mixture was adjusted to pH 7.5 with hydrochloric acid. 30%-Formaldehyde solution (0.9 ml.) was added to the solution and the mixture was kept at 40-45° for 45 min. The crystals were filtered off and washed with cold water. The 4-amino-5-cyanomethylamino-pyrimidine decomposed at 223° (Found[*], after drying at $20°/10^{-1}$ mm.: C, 47.05; H, 5.4; N, 46.85. $C_5H_7N_5$ requires C 48.3; H, 4.7; N, 46.95%). This compound gave 4,5-diaminopyrimidine on hydrolysis in acidic or alkaline condition.

Phthaloylglycine was prepared (87% yield) by heating a mixture of glycine and phthalic anhydride at 200° for 20 min.

_____

[*]This compound was unstable to hydrolysis and partially decomposed on recrystallization from water; hence the poor analytical figures.

It had m.p. 189-193° (Reese (1887) gives m.p. 192°).

Phthaloylglycyl chloride was prepared (80% yield) from phthaloyl glycine by the action of thionyl chloride. It boiled at 145-150°/2 - 3 mm. and had m.p. 85-86° (Gabriel (1907) gives m.p. 84-85°).

5-Bromo-4-hydroxypyrimidine was prepared (80% yield) by bromination of 4-hydroxypteridine according to Chesterfield, McOmie and Sayer (1955). It had m.p. 198-200° (lit. 199-200°). 4-Amino-5-bromopyrimidine was prepared (57% yield) from 5-bromo-4-hydroxypyrimidine by the action of phosphorus oxychloride and then ammonia according to Chesterfield, McOmie and Sayer (1955). It had m.p. 209-211° (lit. 208-210°).

5-Bromo-4-phthaloylglycylaminopyrimidine. 4-Amino-5-bromopyrimidine (1.0 g.) and phthaloylglycyl chloride (1.3 g.) in pyridine (5 ml.) was refluxed for 1 hr. After removal of the pyridine, water (20 ml.) was added to the residue. The precipitate was triturated with sodium bicarbonate solution (1 g. $NaHCO_3$ in 10 ml. water) and then crystallized from ethanol giving 5-bromo-4-phthaloylglycylaminopyrimidine as colourless needles, m.p. 223-225° (Found: C, 46.2; H, 2.6; N, 15.3. $C_{14}H_9BrN_4O_3$ requires C, 46.55; H, 2.5; N, 15.5%).

Hydrazinolysis of 5-bromo-4-phthaloylglycylaminopyrimidine. Hydrazine hydrate (0.12 ml.) was added to 5-bromo-4-phthaloylglycylaminopyrimidine (723 mg.) in methanol (30 ml.), and the solution was kept at room temperature overnight. After

removal of the crystals[*] (224 mg.), the filtrate was evaporated to dryness and the residue recrystallized from 50% ethanol. The colourless needles (252 mg., 73%), m.p. 212-213°, were identified as 4-amino-5-bromopyrimidine from the Rf. value (0.56 2D/3X), and mixed melting point with an authentic sample.

4-Amino-5-methoxycarbonylmethylaminopyrimidine was prepared from 4-amino-5-carboxymethylaminopyrimidine (see p.130) by the action of methanolic hydrogen chloride according to Albert, Brown and Cheeseman (1952). It decomposed at 188-189° (Found: N, 21.8; Cl, 27.5. Calc. for $C_7H_{10}N_4O_2.2HCl$: N, 21.95; Cl, 27.8%).

Attempts at syntheses for 4-amino-5-carbamoylmethylamino-pyrimidine (a) 4-Amino-5-methoxycarbonylmethylaminopyrimidine dihydrochloride (100 mg.) was added to methanolic ammonia (5%, 2 ml.) and kept at room temperature overnight. Only 5,6-dihydro-7-hydroxypteridine was detected in the reaction mixture by paper chromatography. (b) 4-Amino-5-carboxymethyl-aminopyrimidine (168 mg.) was dissolved in aqueous ammonia and evaporated to dryness. The residual ammonium salt was heated at 170° for 10 min. The product was identified as 5,6-dihydro-7-hydroxypteridine and none of the desired amide was produced.

---

[*]This compound had a low nitrogen content (6.9%) and corresponds to o-carboxybenzoylglycine ($C_{10}H_9O_5N$; N, 6.3%).

Attempted synthesis of 7,8-dihydro-2,4-dihydroxy-

pteridine.   2,4,6-Trichloro-5-nitropyrimidine was condensed with

aminoacetal by the same method as described before (see p.149).

Paper chromatography of the reaction mixture showed many spots,

and no product was isolated from the reaction mixture after

hydrolysis with N-sodium hydroxide.

7,8-Dihydro-2,6-dihydroxypteridine.

2-Chloro-4-ethoxycarbonylmethylamino-5-nitropyrimidine

was prepared (78% yield) from 2,4-dichloro-5-nitropyrimidine

and ethyl aminoacetate hydrochloride according to Boon, Jones

and Ramage (1951).   It had m.p. 101-103° (lit. 101-102°).

4-Ethoxycarbonylmethylamino-2-hydroxy-5-nitropyrimidine was

prepared (67% yield) by hydrolysis of 2-chloro-4-ethoxy-

carbonylmethylamino-5-nitropyrimidine according to Boon, Jones

and Ramage (1951).   It decomposed at 232° (lit. 230-232°).

7,8-Dihydro-2,6-dihydroxypteridine was prepared (61% yield) from

4-ethoxycarbonylamino-2-hydroxy-5-nitropyrimidine by reduction

followed by hydrolysis according to Boon, Jones and Ramage,

(1951).   It had m.p. >300°   (Found: C, 43.0; H, 3.85; N, 33.55.

Calc. for $C_6H_6N_4O_2$: C, 43.35; H, 3.65; N, 33.7%).

7,8-Dihydro-4,6-dihydroxypteridine.

6-Chloro-4-ethoxycarbonylmethylamino-5-nitropyrimidine

was prepared (62% yield) from 4,6-dichloro-5-nitropyrimidine

and ethyl aminoacetate hydrochloride according to Boon, Jones

and Ramage (1951).   It had m.p. 90-92° (lit. 93-94°).

4-Ethoxycarbonylmethylamino-6-hydroxy-5-nitropyrimidine was
prepared (41% yield) by hydrolysis of 6-chloro-4-ethoxy-
carbonylmethylamino-5-nitropyrimidine according to Boon,
Jones and Ramage (1951). It had m.p. 213-214° (lit. 214°).
7,8-Dihydro-4,6-dihydroxypteridine was prepared from 4-
ethoxycarbonyl-6-hydroxy-5-nitropyrimidine by reduction
followed by hydrolysis according to Boon, Jones and Ramage
(1951). It decomposed $>300°$ without melting (Found: C, 43.3;
H, 3.8; N, 33.6. Calc. for $C_6H_6N_4O_2$: C, 43.4; H, 3.65;
N, 33.7%).

Attempted syntheses for 5,6-dihydro-2,7-dihydroxypteridine.
(a) Ethyl glyoxylate hemiacetal (2.2 g.) was added to 4,5-
diamino-2-hydroxypteridine in water (20 ml.) and the solution
was kept at room temperature for 1 hr. and then refrigerated.
The precipitate crystallized from ethanol as leaflets (2.2 g.,
90%) which gave the same Rf. values as 2,7-dihydroxypteridine
on paper chromatography. (b) Ethyl glyoxylate hemiacetal
(140 mg.) was added to 4,5-diamino-2-hydroxypteridine in
ethanol (10 ml.) and the mixture was examined spectroscopically.
No reaction took place under anhydrous condition. When water
(10 ml.) was added to the mixture, 2,7-dihydroxypteridine was
produced, but no evidence of Schiff's base formation was
obtained. (c) 4,5-Diamino-2-hydroxypteridine (631 mg.) was
dissolved in N-hydrochloric acid (10 ml.) and then adjusted to
pH 7.5 with N-sodium hydroxide (5 ml.). Potassium cyanide

(350 mg.) and 37% formaldehyde solution (0.45 ml.) was added
to the solution and the solution was kept at room temperature
for 2 hr. and refrigerated. The crystals (252 mg.) had the
same Rf. values as 4,5-diamino-2-hydroxypyrimidine. Only
4,5-diamino-2-hydroxypyrimidine was detected by paper
chromatography in the filtrate.

5,6-Dihydro-4,7-dihydroxypteridine.

4-Amino-5-ethoxycarbonylmethyleneamino-6-hydroxy-
pyrimidine was prepared (68% yield) from 4,5-diamino-6-
hydroxypyrimidine and ethyl glyoxylate hemiacetal according
to Pfleiderer (1959). It decomposed at 195-196° (lit. m.p.
196°).

4-Amino-5-ethoxycarbonylmethylamino-6-hydroxypyrimidine.
4-Amino-5-ethoxycarbonylmethyleneamino-6-hydroxypyrimidine
(1.05 g. 5 m mole) in ethanol (250 ml.) was hydrogenated over
Raney-nickel, and 130 ml. of hydrogen (2H) was absorbed
during 70 min. After removal of the catalyst the filtrate was
concentrated to dryness. The residue, crystallized from
ethanol and gave 4-amino-5-ethoxycarbonylmethylamino-6-
hydroxypyrimidine as colourless needles (555 mg. 52%). It
decomposed at 138-139° (Found, after drying at $65°/10^{-1}$ mm:
C, 45.2; H, 5.8; N, 26.35. $C_8H_{12}N_4O_3$ requires C, 45.3; H, 5.7;
N, 26.4%).

5,6-Dihydro-4,7-dihydroxypteridine.   4-Amino-5-
ethoxycarbonylmethylamino-6-hydroxypyrimidine (307 mg.) in

N-hydrochloric acid (4 ml.) was heated on a steam bath for 1 hr. under nitrogen. The starting material dissolved, and then colourless needles separated. The product on recrystallization from water gave 5,6-dihydro-4,7-dihydroxypteridine as pale yellow needles (192 mg., 80%), m.p. > 300° (Found: C, 43.2; H, 3.7; N, 33.7. Calc. for $C_6H_6N_4O_2$: C, 43.4; H, 3.65; N, 33.7%).

7,8-Dihydro-4,6-dimethylpteridine.

4-Acetonylamino-2-chloro-6-methyl-5-nitropyrimidine was prepared (43% yield) from 2,4-dichloro-6-methyl-5-nitropyrimidine and aminoacetone hydrochloride according to Boon and Jones (1951). It had m.p. 106-108° (lit. 108°). 2-Chloro-7,8-dihydro-4,6-dimethylpteridine was prepared (59%) by reduction of 4-acetonylamino-2-chloro-6-methyl-5-nitropyrimidine according to Lister and Ramage (1953). It decomposed at 195° (lit. 215°) (Found: C, 48.4; H, 4.75; N, 28.05 calc. for $C_8H_9ClN_4$: C, 48.85; H, 4.6; N, 28.5%).

7,8-Dihydro-4,6-dimethylpteridine .

(a) 2-Chloro-7,8-dihydro-4,6-dimethylpteridine and red phosphorus (100 mg.) was refluxed with hydriodic acid (d 1.7, 2 ml.) for 1 hr. After removal of the red phosphorus, the filtrate was evaporated to dryness in a vacuum desiccator over potassium hydroxide. The residual oil was dissolved in water, adjusted to pH 10 with N-potassium hydroxide and extracted with chloroform. No product was obtained from the chloroform extract.

(b)   2-Chloro-7,8-dihydro-4,6-dimethylpteridine (920 mg.)
was hydrogenated in 50% ethanol over palladium on carbon
catalyst, in the presence of magnesium oxide (800 mg.);
and 125 ml. of hydrogen (122 ml., 2 H) was absorbed. After
removal of the catalyst the filtrate was evaporated to
dryness. The residue was dissolved in water (15 ml.) and
extracted with chloroform (15 x 8 ml.). The chloroform
layer, after drying over calcium chloride, was evaporated
to dryness. The crystalline residue (681 mg., 90%) was
recrystallized twice from benzene and then sublimed at
90-100°/10^{-1} mm. The 7,8-dihydro-4,6-dimethylpteridine
had m.p. 135-140° (Found, for substance purified by
sublimation: C, 59.2; H, 6.15; N, 34.0. $C_8H_{10}N_4$ requires
C, 59.25; H, 6.2; N, 34.55%).

c. Ionization Constants.

Two good general methods are available for the determination of ionization constants, one is by potentiometric titration and the other is by the spectroscopic method (Albert and Phillips, 1956). Potentiometric titration is far less laborious than the latter, but has two limitations: (a) the solubility of the substance should be higher than 10^{-3}M, because 1×10^{-3}M is usually the lower limit of accuracy. (b) The pK_a values of the substance should lie between 2.7 and 11 (at least in the present work where a 0.005 M solution had mostly to be used because of poor solubility) because potentiometry is inaccurate when the pK_a is less than the logarithm of the dilution; also it is not very accurate in the high alkaline region). The spectroscopic method can be used when the solubility of the substance is less than 10^{-3} M, or the pK_a values were lower than 2.7 or higher than 11. Howeverin this method any small errors, in determining the extinction values of each pure species, can cause a large effect on the pK_a values. This method can only be used for a substance whose two species have different ultraviolet absorption spectra. Both methods need special apparatus and techniques if they have to be used for a substance which has an unstable species.

i) Potentiometric Titration.

The dried specimen (0.00005 mole) was dissolved in CO_2-free water (10 ml., the concentration of this solution was M/200)

and titrated under nitrogen. A Cambridge Bench pH Meter was used with glass and calomel electrodes (standardized to pH 4.00 with 0.05 M-potassium hydrogen phthalate and 9.23 with 0.05 M-borax at 20°). Only when agreement on restandardization was within ± 0.02 pH unit, without further adjustment, this instrument was considered ready for titration. After the solution was titrated, the meter was checked against that one of the two buffers whose pH was nearer to the pK. Failure to agree within ± 0.02 pH unit, made it necessary to reject the titration. 0.9 Equivalent of 0.1 N-hydrochloric acid (or carbon dioxide-free 0.1 N-potassium hydroxide) was added in nine equal portions and the pH was recorded after each addition. The nine pK_a values, one for each pH reading, were calculated from the formula (1) when a base was titrated.

$$pK_a = pH - \log \left([B] + [H^+] \,/\, [BH^+] - [H^+] \right) \qquad (1)$$

where $[BH^+]$ and $[B]$ are the stoicheiometric concentrations of the cation and neutral molecule respectively. When an acid was titrated, formula (2) was used for the calculation of pK_a values.

$$pK_a = pH + \log \left([AH] + [OH^-] \,/\, [A^-] - [OH^-] \right) \qquad (2)$$

where $[AH]$ and $[A^-]$ are the stoicheiometric concentrations of the neutral molecule and anion respectively. The results are negative logarthms of <u>concentration</u> ionization constants (pK_a (conc.)) and are valid for the concentration and temperature given. At the concentration used, they would

differ little from the thermodynamic ionization constants (pK_a (therm.)). The two constants are related, approximately by equations (3) and (4):

$$pK_a \text{ (therm.)} = pK_a \text{ (conc.)} + 0.5 \sqrt{I} \text{ (for acids)}, \qquad (3)$$

$$pK_a \text{ (therm.)} = pK_a \text{ (conc.)} - 0.5 \sqrt{I} \text{ (for bases)}, \qquad (4)$$

where I is the ionic strength at half-neutralization. For example at 0.005 M, the values of pK_a (conc.) would be only 0.02 too high for bases and 0.02 too low for acids compared to pK_a (therm.). In the present Thesis all ionization constants were recorded as pK_a (conc.). For a few substances having unstable species, the pK_a values were determined by a rapid titration method using a self-recorder in which the whole titration was carried out within 3 min.

ii) Spectroscopic Determinations of pK_a.

Solutions were made in a series of buffers, standardized with a glass electrode. This series was decreased in pH down to values where the change in spectrum, corresponding to the step of ionization under study, ceased; and conversely it was increased towards the alkaline direction, until the change in spectrum ceased. The buffers (0.01 M) used were of low ultra-violet absorption: glycine (pH 2.1 - 2.7), formate (pH 3 - 4.2), acetate (pH 4.2 - 5.7), phosphate (pH 6.0 - 7.9), borate (pH 8.3 - 10.2), and ethylamine (pH 10.2 - 11.0). For the low

pH region, the acidity function solutions (sulphuric acid of various strengths) of Hammett (1940) and Bascombe and Bell (1959) were used. For the high pH region, potassium hydroxide solutions of known concentration were used. Measurements were made in the Hilger "Uvispec" Quartz Spectrophotometer using 1 or 4 cm. cells. Buffer solutions of the same strengths were used in the compensating cell. The wavelength was chosen where a marked difference in spectra were observed between the two species. Extinction coefficients at the selected wavelength were then determined for different pH values corresponding to the range from 15 to 85% protonation in 8 equal steps. The pK_a values were determined from formula (5):

$$pK_a = pH - \log [(\varepsilon_C - \varepsilon) / (\varepsilon - \varepsilon_M)] \qquad (5)$$

where ε_M and ε_C are the extinction coefficients of the pure neutral molecule and of the pure cation respectively. ε is the extinction coefficient of the sum of the two species at the pH value where measurement was carried out. A similar method and formula (6) was used for the equilibrium involving the neutral molecule and anion:

$$pK_a = pH - \log [(\varepsilon_M - \varepsilon) / (\varepsilon - \varepsilon_A)] \qquad (6)$$

where ε_M, ε_A and ε are extinction coefficients of the neutral molecule, the anion and of the equilibrium mixture of the two species respectively. No hydrolysis correction for $[H^+]$ or

[OH⁻] is required in this method. The pK_a values obtained from the above formulae, (5) and (6), are pK_a (conc.) values, because, although no corrections for ionic strength of the substance is necessary at the low dilutions, some correction would be required for the 0.01 M buffer solutions if pK_a (therm.) were required. The nature of these corrections would be to make both acid and bases about 0.03 pK_a unit weaker.

Approximate pK_a values of substances very unstable to air oxidation (_i.e._ tetrahydro-2,4-dihydroxypteridine) were determined as follows: 2,4-Dihydroxypteridine (164 mg., 1 m mole) was hydrogenated in 0.1 N-sodium hydroxide (10 ml.) over Pd-catalyst as described before (p. 130). 2,3-Dimercapto-propanol solution (M/1000; 1 ml.) was added to the reduction mixture and the catalyst filtered off. The filtrate was adjusted to pH 4 and diluted to 100 ml. in a measuring flask with M/10000 - 2,3-dimercaptopropanol. The absorption coefficients of the solutions, buffered for 3.0, 4.2, 5.0 and 7.6, were determined at wavelength 300 mμ. From these values, the cationic pK_a value was calculated by formula (5).

d. Spectra

1) Ultraviolet absorption spectra of the various species were obtained using the self-recording Perkin Elmer "Spectracord" 4000A and the extinction coefficients at the maximum wavelength were rechecked manually on a Hilger "Uvispek" Quartz Spectrophotometer. The solutions were buffered (with the same series of buffers as used in spectrophotometric determinations of pK_a), and at least 2 pH units away from the previously determined pK_a value, thus ensuring that at least 99% of the required species (and that no more than 1% of any unwanted species) were present.

2) Infrared absorption spectra of the various specimens were determined by the Perkin Elmer Model 21 instrument fitted with a NaCl prism. As all hydroxypteridines are insoluble in most organic solvents, the potassium bromide disc method had to be used for the determination of these spectra. Of the dried sample, 1 mg. was ground well, mixed with potassium bromide (200 mg.) and pressed to make a disc.

APPENDIX

Fig.1.　———— x,y-Dihydro-2-hydroxypteridine (neutral molecule)
　　　　 - - - - - 2-Hydroxypteridine (hydrated neutral molecule)

Fig.2.　———— 7,8-Dihydro-6-hydroxypteridine (neutral molecule)
　　　　 - - - - - 6-Hydroxypteridine (hydratedneutral molecule)

Fig.3.

absorption of oxygen by tetrahydro-2,4-dihydroxypteridine

Fig.4.   neutral   molecule

——————— Tetrahydro-2-hydroxypteridine
- - - - - - - - 4,5-Diamino-2-hydroxypyrimidine

Fig.5   cation

——————— Tetrahydro-2-hydroxypteridine
- - - - - - - - 4,5-Diamino-2-hydroxypyrimidine

Fig.6. anion

———— Tetrahydro-2-hydroxypteridine
-------- 4.5-Diamino-2-hydroxypyrimidine

Fig.7. neutral molecule

———— 5,6,7,8-Tetrahydro-4-hydroxypteridine
-------- 4,5-Diamino-6-hydroxypyrimidine

Fig.8. cation

———————— 5,6,7,8-Tetrahydro-4-hydroxypteridine

- - - - - - - 4,5-Diamino-6-hydroxypteridine

Fig.9. anion

———————— 5,6,7,8-Tetrahydro-4-hydroxypteridine

- - - - - - - 4,5-Diamino-6-hydroxypyrimidine

Fig.10. ———— Hydrolysis-product of dihydro-7-hydroxyptridine
with alkali (neutral molecule)

-------- 4,5-Diaminopyrimidine (cation)

Fig.11. ———— Hydrolysis-product of dihydro-7-hydroxypteridine
with alkali (anion)

-------- 4.5-Diaminopyrimidine   (neutral molecule)

Fig.12. —— 7,8-Dihydro-2,6-dihydroxypteridine (neutral molecule)
- - - - - - 2,6-Dihydroxypteridine (hydrated neutral molecule)

Fig.13. —— 7,8-Dihydro-4,6-dihydroxypteridine (neutral molecule)
- - - - - - 4,6-Dihydroxypteridine (hydrated neutral molecule)

Fig.14. 2-Hydroxy-6-methylpteridine

neutral molecule

.... cation

-------- anion

Fig.15.   7,8-Dihydro-4,6-dimethylpteridine

———— neutral molecule

············ cation

Fig.16.   3,4-Dihydro-2-hydroxypteridine

———— neutral molecule

············ cation

- - - - - - - anion

Fig.17.   7,8-Dihydro-2-hydroxypteridine

—————— neutral molecule

················ cation

――――― anion

Fig.18.   3,4-Dihydro-2-hydroxy-6-methylpteridine

—————— neutral molecule

················ cation

――――― anion

Fig.19.   7,8-Dihydro-2-hydroxy-6-methylpteridine

——————— neutral molecule

············ cation

– – – – – anion

Fig.20.   5,6-Dihydro-4-hydroxypteridine

——————— neutral molecule

············· cation

– – – – – – anion

Fig.21.   x,y-Dihydro-4-hydroxypteridine

——— neutral molecule

·········· catiom

------- anion

Wavelength (mμ)

log ε

Fig.22.   7.8-Dihydro-6-hydroxypteridine

————— neutral molecule

············· cation

- - - - - - anion

Fig.23.   5,6-Dihydro-7-hydroxypteridine

————— neutral molecule

············· cation

- - - - - - anion

Fig. 24.   7, 8-Dihydro-2,6-dihydroxypteridine

———— neutral molecule

·············· cation

- - - - - - anion

Fig. 25.   x, y-Dihydro-2,7-dihydroxypteridine

———— neutral molecule

- - - - - - anion

Fig.26.   7,8-Dihydro-4,6-dihydroxypteridine

———— neutral molecule

-------- anion

Fig.27.   5,6-Dihydro-4,7-dihydroxypteridine

———— neutral molecule

-------- anion

Fig.28.   7,8-Dihydro-2,4,6-trihydroxypteridine

———— neutral molecule

-------- anion

Fig.29.   5,6,7,8-Tetrahydro-2-hydroxypteridine

———— neutral molecule

.... cation

-------- anion

202

Fig.30.   5,6,7,8-Tetrahydro-4-hydroxypteridine

——————— neutral molecule
················ cation
- - - - - - - anion

Fig.31.   4,5-Diaminopyrimidine

——————— neutral molecule
················ cation

Fig.32.   4-Amino-5-carboxymethylaminopyrimidine

————— neutral molecule

------- anion

Fig.33.   4,5-Diamino-2-hydroxypyrimidine

————— neutral molecule

·············· cation

---------· anion

Fig.34. 4,5-Diamino-6-hydroxypyrimidine

————— neutral molecule

·············· cation

—————— anion

205

Fig. 35. 5,6,7,8-Tetrahydro-4-hydroxypteridine obtained by synthesis

Fig. 36. Tetrahydro-4-hydroxypteridine obtained by reduction

Fig.37. *5,6-Dihydro-4-hydroxypteridine*


Fig.38. *x,y-Dihydro-4-hydroxypteridine*

WAVELENGTH (MICRONS)

TRANSMITTANCE (PERCENT)

FREQUENCY (CM.⁻¹)

Fig.39. 7,8-Dihydro-2,6-dihydroxypteridine obtained by synthesis

WAVELENGTH (MICRONS)

TRANSMITTANCE (PERCENT)

FREQUENCY (CM.⁻¹)

*Fig.40.* Dihydro-2,6-dihydroxypteridine obtained by reduction

Fig. 41. 7,8-Dihydro-4,6-dihydroxypteridine obtained by synthesis

Fig. 42. Dihydro-4,6-dihydroxypteridine obtained by reduction

Fig. 43. 5.6-Dihydro-4,7-dihydroxypteridine obtained by syntesis


Fig. 44. Dihydro-4,7-dihydroxypteridine obtained by reduction

BIBLIOGRAPHY.

Albert, Goldacre and Phillips (1948), J. Chem. Soc., p. 2240.

Albert, Brown and Cheeseman (1951), J. Chem. Soc., p. 474.

Albert (1952), Quart. Rev., 6, 197.

Albert, Brown and Cheeseman (1952), J. Chem. Soc., p. 1620.

Albert and Brown (1953), J. Chem. Soc., p. 74.

Albert, Brown and Wood (1954), J. Chem. Soc., p. 3832.

Albert (1955), J. Chem. Soc., p. 2690.

Albert, Brown and Wood (1956), J. Chem. Soc., p. 2066.

Albert, Lister and Pedersen (1956), J. Chem. Soc., p. 4621.

Albert and Phillips (1956), J. Chem. Soc., p. 1294.

Allen and Clark (1944), Org. Synth., 24, 3.

Angier, Boothe, Hutchings, Mowat, Semb, Stokstad, SubbaRow,
        Waller, Cosulich, Fahrenbach, Hultquist, Kuh, Northey,
        Seeger, Sickels and Smith (1945), Science, 102, 227.

Angier, Boothe, Hutchings, Mowat, Semb, Stokstad, SubbaRow,
        Waller, Cosulich, Fahrenbach, Hultquist, Kuh, Northey,
        Seeger, Sickels and Smith (1946), Science, 103, 667.

Baker (1952), "Hyperconjugation" Oxford, p. 90.

Baker, Schaub and Joseph (1954), J. Org. Chem., 19, 638.

Baalen and Forrest (1959), J. Amer. Chem. Soc., 81, 1770.

Bascombe and Bell (1959), J. Chem. Soc., p. 1096.

Blakley (1959), Biochem. J., 72, 707.

Blakley (1960), Nature, 188, 231.

Blicke and Godt (1954), J. Amer. Chem. Soc., 76, 2798.

Boon, Jones (1950), Brit. Pat., 635,582.

Boon, Jones and Ramage (1951), J. Chem. Soc., p. 96.

Boon and Jones (1951), J. Chem. Soc., p. 591.

Boon and Leigh (1951), J. Chem. Soc., p. 1497.

Boon and Leigh (1952), Brit. Pat., 677,342.

Brook and Ramage (1955), J. Chem. Soc., p. 896.

Brook and Ramage (1957), J. Chem. Soc., p. 1.

Brown (1950), J. Soc. Chem. Ind., 69, 353.

Brown (1952), J. Appl. Chem., 2, 239.

Brown and Mason (1956), J. Chem. Soc., p. 3443.

Brown (1957), J. Appl. Chem., 7, 109.

Cain, Mallette and Taylor (1946), J. Amer. Chem. Soc., 68, 1996.

Chesterfield, McOmie and Sayer (1955), J. Chem. Soc., p. 3478.

Conant and Cutter (1922), J. Amer. Chem. Soc., 44, 2651.

Dickey and Gray (1943), Org. Synth., Coll. Vol. II, Wiley,
        New York, p. 60.

Dubb, Saunders and Wang (1958), J. Amer. Chem. Soc., 80, 1767.

Elderfield, Williamson, Gensler and Kremer (1947), J. Org. Chem.,
        12, 405.

Ellinger and Goldberg (1949), J. Chem. Soc., p. 263.

Ellingson, Henry and McDonald (1945), J. Amer. Chem. Soc., 67,
        1711.

Emerson (1948), "Organic Reactions" vol 4, Wiley, New York,
        p. 174.

Feldman and Wagner (1942), J. Org. Chem., 7, 31.

Fidler and Wood (1957), J. Chem. Soc., p. 4157.

Fischer and Baer (1935), Helv. Chim. Acta, 18, 514.

Futterman (1957), J. Biol. Chem., 228, 1031.

Forrest, Hull, Rodda and Todd (1951), J. Chem. Soc., p. 3.

Forrest, Baalen, Viscontini and Piraux (1960), Helv. Chim. Acta,
        43, 1005.

Gabriel and Jansen (1890), Ber., 23, 2807.

Gabriel and Stelzner (1896), Ber., 29, 1300.

Gabriel (1907), Ber., 40, 2647.

Hartman and Shepard (1943), Org. Synth., Coll. Vol. II, Wiley,
        New York, p. 440.

Hammett (1940), "Physical Organic Chemistry" McGraw-Hill,
        New York, p. 268.

Hull (1951), J. Chem. Soc., p. 2214.

Hutton and Westheimer (1958), Tetrahedron, 3, 73.

Ingold (1953), "Structure and Mechanism in Organic Chemistry"
        Cornell, New York, p. 700.

Johns (1911), Amer. Chem. J., 45, 79.

Jones (1948), Nature, 162, 524.

Korte (1954), Ber., 87, 1062.

Koshara (1936), Z. physiol. Chem., 240, 127.

Koshara (1937), Z. physiol. Chem., 250, 161.

Kuhn and Cook (1937), Ber., 70, 761.

Kuss and Karrer (1957), Helv. Chim. Acta, 40, 740.

Laidler (1951), J. Phys. Colloid., 55, 1067.

Lister and Ramage (1953), J. Chem. Soc., p. 2234.

Lister, Ramage and Coates (1954), J. Chem. Soc., p. 4109.

Marr and Bogert (1935), J. Amer. Chem. Soc., 27, 729.

Mason (1954), J. Chem. Soc., p. 2071.

O'Dell, Vandenbelt, Bloom and Pfiffner (1947), J. Amer. Chem. Soc., 69, 250.

Osborn and Huennekens (1958), J. Biol. Chem., 233, 969.

Overberger, Kogon and Einstman (1954), J. Amer. Chem. Soc., 76, 1953.

Perrin and Inoue (1960), Proc. Chem. Soc., p. 342.

Pesson (1948), Bull. Soc. chim. France, 15, 963.

Pfiffner, Bloom, Brown, Bird, Emmett, Hogan and O'Dell (1943), Science, 97, 404.

Pfiffner, Binkley, Bloom and O'Dell (1947), J. Amer. Chem. Soc., 69, 1476.

Pfleiderer (1957), Ber., 90, 2604.

Pfleiderer (1959), Ber., 92, 3190.

Pfleiderer and Taylor (1960), J. Amer. Chem. Soc., 82, 3765.

Polonovsky and Jérôme (1950), Compt. rend., 230, 392.

Polonovsky, Pesson and Puister (1950), Compt. rend., 230, 2205.

Pullman, San Pietro and Colowick (1954), J. Biol. Chem., 206, 129.

Purrmann (1940a), Annalen, 546, 98.

Purrmann (1940b), Annalen, 544, 182.

Purrmann (1941), Annalen, 548, 284.

Ramage and Trappe (1952), J. Chem. Soc., p. 4410.

Reese (1887), Annalen, 242, 1.

Rigby (1950), J. Chem. Soc., p. 1907.

Robins, Dille and Christensen (1954), J. Org. Chem., 19, 930.

Schöpf, Reichert and Riefstahl (1941), Annalen, 548, 82.

Shirakawa (1953), J. Pharm. Soc. Japan, 73, 643.

Sims (1958), Proc. Chem. Soc., p. 282.

Söderbaum and Widman (1889), Ber., 22, 1665.

Stokstad (1943), J. Biol. Chem., 149, 573.

Stokstad, Hutchings and SabbaRow (1948), J. Amer. Chem. Soc.,
        70, 3.

Taylor, Carbon and Hoff (1953), J. Amer. Chem. Soc., 75, 1904.

Taylor and Sherman (1959), J. Amer. Chem. Soc., 81, 2464.

Totter (1944), J. Biol. Chem., 154, 105.

Traube (1904), Annalen, 331, 64.

Traube and Nithak (1906), Ber., 39, 227.

Tschesche and Korte (1951), Ber., 84, 801.

Viscontini and Weilenmann (1959), Helv. Chim. Acta, 42, 1854.

Weijlard, Tishler and Erickson (1945), J. Amer. Chem. Soc.,
        67, 802.

Whittaker (1951), _J. Chem. Soc._, p. 1565.

Wieland and Schöpf (1925), _Ber._, _58B_, 2178.

Wieland, Tartter and Purrmann (1940), _Annalen_, _545_, 209.

Wieland and Liebig (1944), _Annalen_, _555_, 146.

Witzemann, Evans, Hass and Schroeder (1943), _Org. Synth._,
    Coll. Vol. II p. 17, 137 & 307.

Woodward and Doering (1945), _J. Amer. Chem. Soc._, _67_, 860.

Yarmolinsky and Colowick (1956), _Biochim. Biophys. Acta_,
    _20_, 177.